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ABSTRACT  
 
Lower urinary tract symptoms (LUTS) are very prevalent worldwide, both in men 
and women. They cause a significantly negative impact on quality of life in both 
patients and their relatives. Due to multifactorial origin, the diagnosis of the 
underlying condition is difficult to obtain and treatment options are insufficient. 
Purinergic signalling pathways are now considered to play an important role in 
regulating urinary bladder function. However, most of the data concerning 
purinergic signalling in the lower urinary tract comes from studies in animal 
models and little is known about this pathway in humans, particularly in those with 
lower urinary tract dysfunctions (LUTD). The present work was designed to fill 
the gaps in our knowledge regarding the role of adenosine triphosphate (ATP) 
and adenosine (ADO) on afferent and efferent paths of the micturition reflex. 
Results indicate that the detrusor of patients with benign prostatic hyperplasia 
(BPH) obtained during open prostatectomy release significantly more ATP and 
acetylcholine (ACh) when stimulated electrically than control samples collected 
from organ donors. The increase in the purinergic tone is favoured by an 
impairment in ATP hydrolysis and, subsequent, ADO formation due to deficient 
activity of ecto-nucleoside triphosphate diphosphohydrolase-1 (E-NTPDase-
1/CD39) and ecto-5’nucleotidase (5’NTase/CD73) in these patients. The higher 
ATP bioavailability and deficient ADO formation end-up by favouring ACh 
release, because ATP facilitates whereas ADO inhibits ACh release through the 
activation of prejunctional P2X3 and A1 receptors, respectively. Comparing the 
rate of ATP hydrolysis in the luminal with the abluminal sides of the human 
urothelium, we concluded that it was faster in the suburothelium, which may in 
part be due to surplus activity of the E-NTPDase2 that is a preferential 
triphosphatase resulting in significant ADP accumulation. Excessive urothelial 
ATP release and accumulation in the lumen of the bladder may concur to 
increase the urinary concentrations of the nucleotide in patients with lower urinary 
tract dysfunctions (LUTD), which might be of clinical relevance. As a matter of 
fact, we show here that female patients with overactive bladder (OAB), as well as 
men with bladder outlet obstruction (BOO) due to BPH, have significantly higher 
urinary ATP than healthy controls. Urinary ATP concentrations correlated with 
the voided volume, suggesting that bladder distension promotes the release of 
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ATP from the urothelium, which is in keeping with in vitro experiments. We also 
show here for the first time that urinary ATP correlates inversely with flow rate, 
suggesting that ATP release may be related to the degree of obstruction. This 
raises the possibility that urinary ATP amounts might be the first non-invasive 
pressure-transducer biomarker in the diagnosis of LUTD. Usefulness of urinary 
ATP as a dynamic biomarker in LUTD was further strengthen since its levels 
decreased significantly after intravesical botulinium toxin-A injections used to 
improve OAB symptoms. 
In conclusion, the results presented in this thesis add compelling information to 
understand the pathophysiological mechanisms responsible for the increase in 
the bladder purinergic tone verified both in the mucosa and detrusor of patients 
with LUTD and foresee the clinical application of urinary ATP as a dynamic 
biomarker of LUTD. Moreover, we anticipate that drugs targeting purinergic 
signalling pathways placed in evidence in the present study, may be useful novel 
candidates for therapeutic intervention in LUTS. 
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RESUMO 
 
Os sintomas do aparelho urinário baixo são muito prevalentes em homens e 
mulheres de todo o mundo e têm um impacto negativo muito significativo na 
qualidade de vida dos pacientes e das suas famílias. A abordagem clínica destes 
sintomas é difícil pela sua natureza multifatorial e as soluções terapêuticas 
disponíveis atualmente são insuficientes. O sistema purinérgico tem 
reconhecidamente um papel regulador em vários mecanismos envolvidos no 
funcionamento da bexiga. No entanto, a maior parte do conhecimento adquirido 
sobre este assunto resulta de estudos em modelos animais, sendo escassos os 
estudos em humanos, particularmente em doentes com disfunções do aparelho 
urinário inferior. Este trabalho foi delineado para preencher algumas lacunas no 
conhecimento do papel sinalizador do ATP e da adenosina no componente 
aferente e eferente do reflexo miccional. Os resultados mostram que a 
estimulação elétrica do detrusor de doentes com hiperplasia benigna da próstata 
(HBP) isolado durante prostatectomia aberta liberta mais ATP e acetilcolina 
(ACh) do que o detrusor de indivíduos controlo (dadores cadavéricos de órgãos). 
O aumento do tónus purinérgico é potenciado pela redução da velocidade de 
hidrólise do ATP e, subsequente, redução da formação de adenosina devidos à 
menor atividade da E-NTPDase-1/CD39 e da ecto-5´NTase/CD73 nos pacientes. 
O desequilíbrio entre a metabolização do ATP e a formação de adenosina em 
favor da acumulação do primeiro favorece a libertação de ACh através da 
ativação de recetores pré-sinápticos excitatórios do tipo P2X3 e da perda do 
tónus inibitório mediado pelos recetores A1 da adenosina. Comparando a 
cinética do catabolismo extracelular do ATP do lado luminal e abluminal do 
urotélio verificámos que a mesma era mais rápida na região suburotelial levando 
a acumulação de ADP mercê da presença da E-NTPDase2, que é uma 
trifosfatase responsável pela metabolização preferencial de ATP com menor 
afinidade para o ADP. A libertação de ATP pelo urotélio e a sua acumulação 
excessiva no lúmen da bexiga favorece o aumento dos níveis urinários deste 
nucleótido em doentes com disfunções do trato urinário inferior, fato que pode 
ter relevância clínica. Com efeito, os resultados mostram que as concentrações 
urinárias de ATP são mais elevadas em mulheres com bexiga hiperativa, assim 
como em homens com obstrução infravesical por HBP, do que as verificadas em 
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controlos saudáveis. Os níveis de ATP urinário correlacionam-se com o volume 
urinado confirmando resultados “in vitro” onde se demonstrou que a distensão 
da bexiga promove a libertação do nucleótido pelo urotélio. Também verificámos 
neste trabalho pela primeira vez a existência de uma correlação positiva entre 
os níveis de ATP urinário e (1) a gravidade dos sintomas urinários em mulheres 
com bexiga hiperativa e (2) com a severidade da obstrução infravesical nos 
homens com HBP avaliada em condições isovolumétricas. Estes últimos 
resultados mostram que o ATP urinário pode ser considerado o primeiro 
biomarcador não-invasivo de pressão intravesical com utilidade nas disfunções 
do aparelho urinário inferior. A utilidade clínica do doseamento dos níveis de ATP 
urinário como biomarcador dinâmico nas disfunções do aparelho urinário inferior 
foi comprovada já que os seus níveis baixaram significativamente após injeções 
intravesicais de toxina botulinica-A destinadas à melhoria sintomática da 
hiperatividade vesical. 
 Em conclusão, os resultados apresentados nesta tese ajudam a 
compreender melhor os mecanismos responsáveis pelo aumento do tónus 
purinérgico na bexiga (mucosa e detrusor) de doentes com disfunções do trato 
urinário inferior e antevê possíveis aplicações clínicas do ATP urinário como 
biomarcador não-invasivo nas disfunções miccionais. Mais ainda, os resultados 
demonstram que a manipulação da sinalização purinérgica em várias vertentes, 
locais de libertação, enzimas e recetores, pode constituir uma nova estratégia 
para o tratamento dos sintomas do aparelho urinário inferior.
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CHAPTER 1 
 
INTRODUCTION 
 
 
 
 
 
 
 
 
“The prostate should be exonerated 
from always being the first suspect for 
crimes against the micturition” 
 
 Vicenzo Mirone 
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1.1 LOWER URINARY TRACT SYMPTOMS 
 
 The main function of the lower urinary tract is the storage and periodic 
elimination of urine. It requires the coordinated activity of two functional units: a 
reservoir (the urinary bladder) and an outlet consisting of the bladder neck, the 
urethra, and the urethral sphincter. Coordination between these organs is 
mediated by a complex neural control system located in the brain, spinal cord, 
and peripheral ganglia. Thus, urine storage and release are highly dependent on 
central nervous system pathways in addition to local circuitry. This distinguishes 
the lower urinary tract from other visceral systems (e.g., the gastrointestinal tract 
and cardiovascular). Another particular feature of the lower urinary tract is that 
we consciously control de autonomic nervous responses. This may explain why 
controlling lower urinary tract function occurs so later in infancy, usually after 
walking and speaking. Taken together with anatomical and functional changes 
induced by age, this accounts for the high prevalence of lower urinary tract 
symptoms (LUTS) in both genders all over the world (Irwin et al., 2011). 
 LUTS are associated with great emotional burden to individuals (Engstrom 
et al., 2005) and substantial economic costs to society (Hu et al., 2003). As their 
prevalence increases with life expectancy, they are expected to be a major 
concern to physicians in the near future (Irwin et al., 2009). LUTS are generally 
divided into three groups: storage, voiding and postmicturition symptoms. 
Storage symptoms include increased urinary frequency, nocturia, urinary 
urgency, and urinary incontinence. Voiding symptoms include slow/weak stream, 
hesitancy, intermittency, straining and terminal dribble, whereas postmicturition 
symptoms consist of incomplete emptying and postmicturition dribble (Abrams et 
al., 2002). 
 According to the EPIC study, more than 62.5% of adult men and 66.6% of 
adult women report at least one urinary symptom throughout life (Irwin et al., 
2006). Storage symptoms are the most prevalent and are more common in 
women (59.2% vs 51.3%) whereas voiding symptoms are more common in men 
(25.7% vs 19.5%)(Irwin et al., 2006). Storage symptoms have also higher impact 
on quality of life (Coyne et al., 2008; Peters et al., 1997) and are a more frequent 
cause of healthcare seeking behaviour (Apostolidis et al., 2012). 
CHAPTER 1 | INTRODUCTION 
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Figure 1. Central and peripheral mechanisms involved in the development of 
bladder dysfunctions. 
 
 
1. 2 LOWER URINARY TRACT DYSFUNCTIONS- FOCUS ON 
THE BLADDER 
  
The cause of LUTS is multifactorial but bladder dysfunction seems to be 
pivotal in its pathogenesis. Normal bladder function requires adequate control of 
the cerebral cortex, pons and spinal cord; intact autonomic and somatic nerves; 
and a normal lower urinary tract. Disorders in any of these structures my result in 
bladder dysfunction. Figure 1 portrays possible mechanisms that affect bladder 
activity and cause storage LUTS.  
 It is accepted that the bladder is capable of only a limited range of 
behaviours in response to disease and, for that reason, diverse pathologic 
CHAPTER 1 | INTRODUCTION 
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mechanisms may manifest as the same urodynamic abnormality. Furthermore 
several bladder dysfunctions may co-exist, for instance a patient with blader 
outlet obstruction (BOO) can exhibit either detrusor overactivity and detrusor 
underactivity (DU). For practical reasons, bladder dysfunctions will be further 
described according to the underlying urodynamic abnormality. 
 
1.2.1 BLADDER OUTLET OBSTRUCTION 
 BOO is an urodynamic concept, characterised by increased detrusor 
pressure and low flow rate during voiding. BOO can be caused by a wide array 
of conditions, such as urethral strictures, urethral valves, female pelvic organ 
prolapse and urinary sphincter dysfunction. Yet, more commonly it is caused by 
benign prostatic hyperplasia (BPH). Traditionally BOO has been thought to be 
the cause of symptoms in patients with BPH and the relief of obstruction is the 
aim of most therapies designed to treat patients with BPH. In fact, BPH is a 
histological condition that causes benign prostatic enlargement that in some 
patients produce BOO by causing a physical compression of the urethra. 
However, the relation between LUTS, BOO and BPH is by far more complex. 
Firstly, the prostatic volume does not correlate linearly with the severity of BOO 
and LUTS (Eckhardt et al., 2001; Rosier & de la Rosette, 1995); and secondly, 
BOO can cause bladder dysfunction that clearly exacerbates the severity and 
nature of LUTS. This is a significant problem since around 30% of men older than 
50 have moderate to severe LUTS (Boyle et al., 2003; Rosen et al., 2003), and it 
is estimated that roughly 50% of men with LUTS and BPH are indeed obstructed 
(Oelke et al., 2007). 
 In recent years increasing evidences place the bladder as the central 
organ in the pathogenesis of LUTS in BPH patients. BOO can induce two basic 
types of bladder dysfunction. On one hand, it can lead to detrusor overactivity 
and reduced bladder compliance that is associated with frequency and urgency 
symptoms. On the other hand, detrusor underactivity may occur later on in the 
course of the disease (Mirone et al., 2007), which cause further worsening of the 
voiding symptoms (see below). 
At the tissue level, BOO produces several modifications in the bladder 
mucosa, detrusor smooth muscle and nerves as compensatory responses to 
overcome the high urethral resistance. One noticeable feature is bladder 
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hypertrophy; this is a constant finding both in animals and men with BOO (Michel 
& Barendrecht, 2008). In patients with BPH, bladder wall thickness measured by 
ultrasound correlates well with the severity of LUTS and obstruction (Oelke et al., 
2007). Bladder hypertrophy results both from smooth muscle cells enlargement 
and extracellular matrix deposition. It has been shown that the obstructed 
detrusor has a higher collagen content (Inui et al., 1999; Mirone et al., 2004) and 
there seems to be a relation between collagen content and symptoms severity 
(Mirone et al., 2004).  
 Obstruction also leads to substantial changes in the neural control of the 
bladder. Several studies have shown significant bladder denervation in BOO 
patients comparing to controls (Chapple et al., 1992; Gosling, 1997). Since 
nerves are very sensitive to hypoxic damage, it has been hypothesized that 
postganglionic parasympathetic neurons could be damaged by the transient wall 
ischemia that occurs during voiding in obstructed bladders (Geloso & Levin, 
1998). There is also evidence of a sensory dysfunction involving afferent C-fibers 
in BOO patients that could lead to detrusor overactivity. It has been shown in 
animal models that BOO induces an enlargement of afferent nerves in dorsal root 
ganglia (Steers et al., 1991) and an increase in the NGF content on the bladder 
tissue (Steers et al., 1991). It has also been reported that 71% of patients with 
BPH and BOO have a positive ice-water test suggesting a C-fiber hyperactivity 
usually inactive in normal adults (Chai et al., 1998). Accordingly, C-fiber 
desensitization with resiniferatoxin induced an improvement of storage LUTS in 
BPH patients (Dinis et al., 2004). 
 Bladder urothelium also changes with obstruction. Bladder epithelium from 
obstructed patients has been shown to have increased permeability to sodium 
and release higher amounts of adenosine triphosphate (ATP) (Araki et al., 2004; 
Silva et al., 2015). There have also been reported changes in the suburothelial 
interstitial cell network. In rat models of BOO, the population of these cells is 
increased and exhibit higher P2X3 receptor function (Kim et al., 2011; Li et al., 
2013). 
 At present, current knowledge on the mechanisms underlying detrusor 
dysfunction after BOO is scant, and new ways to diagnose, predict, prevent and 
treat this condition are deemly needed. 
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1.2.2 DETRUSOR OVERACTIVITY 
 Detrusor overactivity is assumed to be the cause underlying the symptoms 
of overactive bladder (OAB). The International Continence Society defines OAB 
as a clinical syndrome based on the symptom of urinary urgency, with or without 
urinary incontinence and usually accompanied by frequency and nocturia, in the 
absence of infection or other obvious pathology (Abrams et al., 2002). It is 
estimated that 11-16% of men and 13-17% of women are affected (Irwin et al., 
2006; Stewart et al., 2003). The impact of OAB on quality of life is significant, 
patients are predisposed to depression, sleep disturbance and falls, mainly in 
women with urge urinary incontinence (Brown et al., 2000; DuBeau et al., 1999; 
Dugan et al., 2000). 
 Detrusor overactivity is an urodynamic concept characterized by 
involuntary detrusor contractions during the filling phase. Detrusor overactivity 
may be further qualified according to cause, into neurogenic if there is a relevant 
neurologic condition or idiopathic when there is no defined cause. It is also 
possible to link detrusor overactivity to BOO. Indeed detrusor overactivity is 
present in about half to two thirds of patients with benign prostatic obstruction 
and disappears in almost two thirds of the patients after relief of obstruction by 
surgery (Abrams et al., 1979; de Nunzio et al., 2003). Similarly women with BOO 
have a significantly higher prevalence of detrusor overactivity compared to other 
women with LUTS but without BOO (Silva-Ramos et al., 2013a). However the 
exact mechanism by which obstruction induces detrusor overactivity is mostly 
unknown. 
 As shown in Figure 1 the pathogenesis of detrusor overactivity is 
multifactorial and poorly understood. For the sake of clarity, we can organize it 
into three different mechanisms:  
• Urothelial-suburothelial mechanisms. Urothelium is more than a barrier. It 
has an higher metabolic activity and receptor density than the detrusor, 
allowing for an important neuromodulatory role (Hypolite et al., 1993). 
Modification on urothelial receptor function and release of signaling 
molecules impacts on the suburothelial interstitial cellular networking, 
which can originate involuntary detrusor contractions (Birder, 2006).  
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• Myogenic mechanisms. Changes in smooth muscle cells coupling and 
patchy denervation seen in obstructed detrusor samples can cause 
spontaneous contractions and enhanced propagation of excitatory signals 
between muscle cells.  
• Neurogenic mechanisms. Detrusor overactivity may arise from several 
neurogenic mechanims. It can be originated via widespread nerve-
mediated excitation of the detrusor muscle owed to the reduction of central 
inhibition. This mechanism promotes the intensification of spinal bladder 
reflexes and involuntary detrusor contractions. On the other hand, 
sensitization of C-fiber bladder afferent neurons can also trigger detrusor 
overactivity. 
 The relationship between OAB symptoms and the presence of detrusor 
overactivity in urodynamic studies is far from being perfect (Hashim & Abrams, 
2006). Ultimately this may be due to two reasons: 
• Symptoms are subjective and urgency patients report may not be due to 
detrusor overactivity. 
• The sensitivity of urodynamic tests to diagnose detrusor overactivity is 
low. In fact, urodynamic studies test vesico-urethral function in very 
specific conditions and in a very limited time frame, which often does not 
mimic real life situations.  
 This renders the evaluation of patients’ reported symptoms particularly 
challenging, hence the aphorism “the bladder is an unreliable witness” (Bates et 
al., 1970) 
 
1.2.3 DETRUSOR UNDERACTIVITY 
 The International Continence Society defines detrusor underactivity (DU) 
as “a contraction of reduced strength and/or duration resulting in prolonged 
bladder emptying and/or a failure to achieve complete bladder emptying within a 
normal time span” (Abrams et al., 2002). Besides the somewhat ambiguous 
definition, clinical diagnose of DU is troubled with the need of a pressure flow 
study. This might partially explain why it is under-diagnosed, insufficiently 
investigated and poorly understood. In fact, we may be facing another “urologic 
iceberg”. Prevalence estimates show that this is a fairly common urodynamic 
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finding, ranging from 9% to 23% in men under 50 years old (Osman et al., 2014) 
and increasing to 48% in men over 70 years old (Abarbanel & Marcus, 2007). In 
women prevalence is somewhat lower than in men, and ranges between 12% 
and 45% in elderly women (Osman et al., 2014). However, the diagnosis of 
underactive bladder is not so common in clinical practice.  
 There are few clues about the pathogenesis of DU, but it is accepted that 
is more than just a smooth muscle contractile dysfunction, both myogenic and 
neurogenic (afferent, central nervous system and efferent) factors may be 
involved. Multiple disorders and diseases may cause DU. These include, ageing, 
BOO, diabetes, spinal cord and cauda equina injuries, several neurologic 
disorders, amyloidosis and pelvic surgery (Juszczak & Drewa, 2016). 
 Clinically it is difficult to distinguish DU from other lower urinary tract 
dysfunctions. Voiding symptoms are quite prevalent in patients with DU, but these 
are indistinguishable from those associated with BOO, although symptoms of 
straining to void and decreased bladder sensation are more specific of DU 
(Gammie et al., 2015). Patients with chronic urinary retention due to DU, can also 
report storage symptoms such as frequency, incontinence and enuresis, being 
difficult to tell apart from patients with OAB. Furthermore, DU can coexist with 
BOO and detrusor overactivity rendering both diagnosis and treatment of these 
patients very challenging. 
 Therapeutic options for DU are limited. Theoretically, it is possible to 
envisage pharmacological targets to increase detrusor contractility. The 
approach may rely on enhancing both cholinergic and/or purinergic tonus in the 
detrusor. 
 
1.3 THE PURINERGIC SYSTEM 
 
 In the 1970s when Burnstock formulated the purinergic neurotransmission 
hypothesis (Burnstock et al., 1972), the idea was received with tremendous 
scepticism, but it is now accepted that certain nerves use purine nucleotides as 
neurotransmitters. It is also recognised that ATP is not only released by nerves 
but also by non-neuronal cell types including the urothelial and interstitial cells. It 
mediates several biological processes such as synaptic transmission, 
nociception, ion transport, apoptosis, secretion and muscle contraction 
CHAPTER 1 | INTRODUCTION 
 
32  Role of endogenous purines in lower urinary tract dysfunctions	
 
Ph
D
 T
he
si
s:
 M
ig
ue
l S
ilv
a 
R
am
os
 
(Burnstock, 2006). It is also implicit in the purinergic transmission hypothesis the 
presence of purinergic receptors. They were first divided in P1 receptors that 
respond to adenosine and P2 receptors for ATP, ADP and pyrimidine nucleotides 
(UTP and UDP). P2 receptors are further divided in two families: the P2X (P2X1-
P2X7) ligand-gated ionotropic channel family and the P2Y (P2Y1, P2Y2, P2Y4, 
P2Y6, P2Y11, P2Y12, P2Y13, P2Y14) metabotropic G-protein coupled receptor 
family (Alexander et al., 2013a; Alexander et al., 2013b). P2X receptors are 
activated exclusively by ATP and respond more rapidly than P2Y receptors; the 
former act via ion channels and are more liable to desensitization (Burnstock, 
2000; Ralevic & Burnstock, 1998). P1 receptors are also further divided into A1, 
A2A, A2B and A3, all of which are G protein-coupled receptors (Fredholm et al., 
2011). The A1 and A3 receptors interact preferentially with members of the Gi 
protein family resulting in inhibition of adenylate cyclase and in the reduction of 
cyclic AMP (cAMP) production, whereas A2A and A2B receptors are coupled to Gs 
proteins and stimulate intracellular cAMP accumulation. All four receptors may 
also activate phospholipase C (PLC), resulting in inositol 1,4,5-trisphosphate 
(IP3) production and increased intracellular Ca2+ mobilization (Klinger et al., 
2002). Adenosine receptors can also stimulate mitogen-activated protein kinase 
cascades (Schulte & Fredholm, 2003). 
 One particularity of the purinergic system is that the extracellular 
metabolites of triphosphate nucleotides are also biologically active and can 
activate different receptors from the parent compound, which often counteract 
the initial signal. This gives the metabolic pathway a special importance. 
Extracellular nucleotides are hydrolyzed in a stepwise fashion into nucleosides 
by four main families of ectonucleotidases, both soluble and membrane-bound: 
ectonucleoside triphosphate diphosphohydrolases (NTPDases), nucleotide 
pyrophosphatase/phosphodiesterases (NPPs), alkaline phosphatases and ecto-
5’-nucleotidase. Taking into consideration differences in the affinity of the ecto-
enzymes for nucleotide substrates, the purinergic cascade is usually initiated by 
a ecto-nucleoside triphosphate diphosphohydrolase (ENTPDase;EC3.6.1.5) and 
is terminated by the ecto-5’-nucleotidase (CD73;EC3.1.3.5), which 
dephosphorylates nucleoside monophosphates into nucleosides. Adenosine is 
further converted to inosine by adenosine deaminase (ADA; EC3.5.4.4). As a 
result, extracellular adenosine concentrations are regulated by both ecto-5’ 
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nucleotidase and ADA, acting together with a relatively efficient nucleoside 
uptake system (Figure 2). 
 Eight different NTPDases have been described. Four of these are typically 
cell-surface enzymes with an extracellular catalytic domain (NTPDase1,2,3,8). 
These enzymes differ in their substrate affinity and product formation. NTPDase 
1 hydrolyses ATP and ADP equally well, NTPDases 3 and 8 have higher affinity 
for ATP, whereas NTPDase 2 is a preferential triphosphatase metabolizing 
almost exclusively nucleoside triphosphates. 
 
Figure 2. Extracellular catalytic cascade of nucleotides and potencial receptor 
activation. 
 
 Regarding product formation, NTPDase1 hydrolyzes ATP directly into 
AMP with transient production of minor quantities of ADP, thus bypassing P2Y 
receptors that are activated by nucleoside diphosphates. In contrast, the 
presence of NTPDase 2 results in the accumulation of ADP which is slowly 
dephosphorylated to AMP, thus promoting the activation of ADP-sensitive P2Y 
receptors (P2Y1, 12, 13). NTPDases 3 and 8 exhibit an intermediate pattern of 
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product formation, leading to the transient formation of diphosphonucleosides 
with the simultaneous presence of triphosphonucleosides (Robson et al., 2006) 
 Only a single gene has been identified for ecto-5’-nucleotidase. This 
enzyme is responsible for most of adenosine formation from released adenine 
nucleotides (Zimmermann, 2000). Once produced, adenosine may undergo 
bidirectional translocation between cytoplasm and the extracellular fluid (through 
equilibrative or concentrative nucleoside transporters), deamination into inosine 
by adenosine deaminase (ADA, EC 3.5.4.4), and phosphorylation by intracellular 
adenosine kinase (EC 2.7.1.20) to generate AMP.  
 As for NPP1 and NPP3, they release nucleoside 5’-monophosphate from 
a variety of nucleotides, but intriguingly, their phosphorylated product (e.g. AMP) 
bind to NPPs with a higher affinity than substrates do, and thus inhibit catalysis 
(Stefan et al., 2005). Finally, the alkaline phosphatases are a family of abundant 
enzymes with broad range specificity, including dephosphorylation of ATP, ADP 
as well as AMP. The overall role of this family in purinergic signaling is, however, 
not that well investigated (Zimmermann, 2000).  
 
1.3.1 ATP AND BLADDER  
 
The content of this section was adapted from the review chapter: 
 
Silva-Ramos M, Silva I, Ferreirinha F, Faria M, and Correia-de-Sá P (2016) Overactive 
Bladder (OAB): Is There a Place for Drugs Targeting the Purinergic Cascade? In: 
Overactive Bladder (OAB): Prevalence, Risk Factors and Management. Hauppauge NY; 
Nova Science Publishers, 2016. 
 
  
 Evidence for the role of ATP in bladder physiology, comes right from the 
beginning of the purinergic hypothesis formulated by Geoffrey Burnstock in the 
seventies. Indeed non-adrenergic and non-cholinergic (NANC) 
neurotransmission were first studied in the gut and in the urinary bladder 
(Burnstock, 1972; Burnstock et al., 1972). Since then, the knowledge of 
purinergic signalling in the lower urinary tract has expanded considerably. 
Purines are important regulators of normal bladder function, but also changes in 
purinergic signalling are associated with bladder dysfunction, particularly the 
overactivebladder. Although OAB is symptomatically complex, often idiopathic, it 
can be originated from multiple aetiologies. Mounting evidences indicate that 
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BOO and neurologic disorders are common causes of OAB and this is why much 
fundamental research on OAB comes from studying obstructed and neurogenic 
bladders.  
 
PURINERGIC EFFERENT MECHANISMS 
 Pioneering evidences that NANC contractions are caused by ATP came 
from similarities between NANC and ATP-induced contractile activity and from 
the depression of NANC responses owed to tachyphylaxis produced by previous 
application of high ATP concentrations (Burnstock et al., 1972). In agreement 
with this, it was demonstrated that desensitization of P2 purinoceptors with the 
enzymatically stable ATP analogue, α,β-methyleneadenosine 5′-triphosphate 
(a,b-meATP), abolished nerve-induced NANC contractions of the urinary bladder 
(Brading & Williams, 1990). Direct evidences came later on, by measuring the 
release of ATP during stimulation of NANC nerves using the luciferin-luciferase 
bioluminescence assay (Burnstock et al., 1978b). In vivo experiments in rats 
demonstrated that electrical stimulation of the spinal cord triggered increases in 
intravesical pressure, which were antagonized by pre-treatment with a,b-meATP 
or pyridoxalphosphate-6-azophenyl-2’,4’-disulphonic acid (PPADS, a non-
selective P2 receptor antagonist) (Hegde et al., 1998). Furthermore, cystometry 
experiments using non-anaesthetized rats showed that intra-arterial 
administration of ATP or a,b-meATP close to the bladder produced a dose 
dependent increase in bladder pressure (Igawa et al., 1993). Despite all these 
evidences, the study of the pos-junctional effect of ATP in the detrusor has been 
hampered by its metabolism into other biologically-active nucleotides with 
opposing effects and by P2 purinoceptors desensitization. Notwithstanding this, 
it is generally accepted that ATP released from efferent nerves cause bladder 
contractions in rodents via the activation of a,b-meATP-sensitive ionotropic P2X 
receptors, both in vitro and in vivo (Hegde et al., 1998; Lukacsko & Krell, 1982).  
 A slightly different scenario is observed in humans, where normal bladder 
contractions are mediated predominantly through the activation of muscarinic 
cholinergic receptors located in the detrusor smooth muscle with a very limited 
participation of ATP-sensitive P2 receptors. Human detrusor smooth muscle 
expresses muscarinic receptors of M2 and M3 subtypes, with the M2 receptor 
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(66%) exceeding the M3 receptor (33%) in number, but the latter being more 
active to cause smooth muscle contraction and voiding command under normal 
circumstances. The role of the M2 receptor is still a matter of debate, even though 
it may contribute to bladder contraction in certain disease conditions (e.g. 
denervated bladder, neurogenic bladder dysfunction). Atropine-resistant 
contractions have been reported in the normal human detrusor, but these do not 
substantially contribute to bladder emptying under physiological conditions in 
contrast to that occurring in small laboratory animals (Ruggieri, 2006). The 
atropine-resistant purinergic component of the human bladder contraction may 
increase up to 40% in pathological conditions, such as OAB secondary to 
prostatic obstruction, interstitial cystitis, neurogenic bladders and aged bladders 
(reviewed in Burnstock, 2014). Under these circumstances, which resemble the 
normal function of the bladder in laboratory animals (See Figure 3), atropine-
resistant contractions are attributed to ATP and may be due to (i) increased ATP 
release from nerves, (ii) impaired catabolism of ATP, and/or (iii) higher sensitivity 
of the detrusor smooth muscle to the nucleotide.  
 
 
Figure 3. Scheme of nerve-mediated contraction magnitude, cholinergic and non-
cholinergic components and residual direct muscle contraction. The contraction 
magnitude is indicated by the height of each bar. 
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Evidence for the first hypothesis is lacking; although there is evidence of 
increased ATP release with age, there are no reports of increased neuronal ATP 
release associated with specific urologic conditions (Yoshida et al., 2004).There 
is some support for the impaired catabolism option. In fact, it has been shown a 
decrease in ecto-ATPase activity in a mixed group of patients with detrusor 
overactivity and bladder outlet obstruction, thereby increasing tonic activation of 
P2 purinoceptors by endogenously produced ATP (Harvey et al., 2002). 
Concerning the sensitivity of the detrusor to ATP, there are conflicting results in 
the literature. In isolated detrusor myocytes, ATP evoked a similar increase in 
intracellular Ca2+ in both normal and overactive detrusor (Wu et al., 1999). On the 
other hand, ATP evokes more potent contractions in isolated detrusor samples 
from overactive or obstructed bladders compared with that from normal bladders 
(Harvey et al., 2002). Surprisingly the increase in ATP potency was not followed 
by its stable analogue, a,b-meATP, which evoked contractions with a similar 
magnitude in both groups (Harvey et al., 2002). The latter observations are 
consistent with the higher ATP bioavailability hypothesis due to deficient 
nucleotide catabolism. Notwithstanding this, a different sensitivity of the detrusor 
to ATP in diseased samples cannot be discarded since fast receptor 
desensitization induced by a,b-meATP might limit full detrusor contractions in 
overactive or obstructed bladder samples. 
 The recent availability of P2X receptor antagonists with subtype selectivity 
and of knockout mice allowed confirmation of the involvement of the P2X1 
receptor in atropine-resistant contractions. In anesthetized rats the P2X1 receptor 
antagonist, RO116-6446, caused a significant attenuation of phasic isovolumetric 
contractions, without affecting volume and pressure thresholds (King et al., 
2004). Moreover, ATP-induced contractions are completely absent in P2X1 
receptor knockout mice (Vial & Evans, 2000). The P2X1 receptor has also been 
shown to be the dominant P2X receptor in the human detrusor using quantitative 
reverse transcription polymerase chain reaction (RT-PCR) (O'Reilly et al., 2001). 
Furthermore, immunohistochemistry studies showed that P2X1 receptor subunits 
are localized in the periphery of detrusor smooth muscle fibres (Elneil et al., 
2001). Alltogether these data strongly suggest that the dominant receptor 
mediating purinergic contractions in the detrusor smooth muscle is the P2X1 
receptor. Despite this, evidences for the role of the P2X1 receptor in the 
CHAPTER 1 | INTRODUCTION 
 
38  Role of endogenous purines in lower urinary tract dysfunctions	
 
Ph
D
 T
he
si
s:
 M
ig
ue
l S
ilv
a 
R
am
os
 
pathophysiology of bladder syndromes are conflicting. Using RT-PCR, some 
authors reported no differences in P2X1 receptor transcripts among normal and 
obstructed bladder samples (Chua et al., 2007), while others showed increased 
amounts of these transcripts in obstructed samples (O'Reilly et al., 2001). Post-
translational protein modifications may affect the amount of functional receptors 
in the plasma membrane and not always reflect gene transcription particularly 
under pathological conditions. These conflicting results were recently dismissed 
since we showed an increase in the P2X1 receptor protein immunoreactivity on 
detrusor smooth muscle cells from obstructed patients compared to control 
individuals, which fully supports the higher ATP potency detected in myographic 
recordings using bladder strips from these patients (Silva-Ramos et al., 2016a).  
 P2Y receptors may also have a role in mediating detrusor response to ATP 
stimulation. At least in laboratory animals, pharmacological studies show that 
P2Y may be involved in relaxation of pre-contracted detrusor (McMurray et al., 
1998). On the other hand P2Y agonists like ADP and adenosine 5′-[β-
thio]diphosphate(ADPbS) are capable of inducing detrusor smooth muscle 
contractions (Aronsson et al., 2010; McMurray et al., 1998; Palea et al., 1994; 
Suzuki & Kokubun, 1994; Yu et al., 2011). This effect was recently attributed to 
activation of the P2Y12 receptor because it was blocked by the selective P2Y12 
receptor antagonist, PSB0739, but was unaffected by antagonists displaying 
affinity for other ADP-sensitive P2Y receptors, like P2Y1 and P2Y13 (Yu et al., 
2011). However, the identified P2Y12 receptor mediating ADP-induced bladder 
contractions has unique pharmacological properties because its effect on 
detrusor smooth muscle is temporally regulated by ectonucleotidases, both 
NTPDase1 and ecto-5’-nucleotidase, and by adenosine signalling. The crosstalk 
between P2Y12 and adenosine receptors may be at the second messenger level 
since inhibition of the adenylate cyclase via Gai provided by the P2Y12 receptor 
activation may counteract the smooth muscle relaxation attributed to A2A/A2B 
receptors positively coupled to activation of this enzyme by Gas proteins. The 
therapeutic significance of P2Y12 in hemostasis and thrombosis has long been 
recognized due to the potent anti-thrombotic effects of thienopyridine compounds 
like ticlopidine and clopidogrel, which selectively inhibit P2Y12 receptors in 
platelets. Given the recent data implicating the expression and function of P2Y12 
CHAPTER 1 | INTRODUCTION 
Role of endogenous purines in lower urinary tract dysfunctions 39 
 
receptors in the detrusor smooth muscle contraction, these receptors may open 
new therapeutic avenues for the use of thienopyridine compounds in human 
bladder disorders and LUTS.  
 P2Y1 receptor transcripts have been found in cells from the detrusor, 
although ADP-induced detrusor contractions were not inhibited by MRS2179. On 
the other hand, electrophysiological recordings in platelet-derived growth factor 
receptor-α-positive (PDGFRα+) interstitial cells in the detrusor muscle showed 
that ATP elicited large amplitude outward currents and hyperpolarization 
mediated by small conductance Ca2+-activated K+ (SK) channels sensitive to 
apamin. The P2Y1 receptor agonist, MRS2365, mimicked the effect of ATP, and 
a P2Y1 antagonist, MRS2500, inhibited ATP-activated SK currents (Lee et al., 
2014). Localization of purinergic inhibitory effects in PDGFRα+ cells may provide 
the basis for a novel neural regulatory mechanism for the stabilization of bladder 
excitability during the filling phase. These authors observed that during extended 
neural stimulation of bladder muscles, the sustained component of contraction is 
significantly reduced by P2Y1-mediated purinergic regulation. Thus, adenine 
nucleotides released from autonomic neurons may have dual, temporally-
distinctive, actions in micturition: activation of detrusor contraction via P2X1-
receptors in smooth muscle cells during voiding and stabilization of membrane 
potential and excitability during bladder filling through the activation of P2Y1 
receptors in PDGFRα+ cells. The purinergic inhibitory input mediated by P2Y1 
receptors may potentiate detrusor relaxation during urine storage caused by 
activation of adrenergic β3 receptors (Afeli et al., 2012; Brown et al., 2008). This 
synergism may be pathophysiologically relevant considering that discrete 
inhibitory neurons are extremely rare in the bladder (Lee et al., 2014). 
 In contrast to the compelling evidence for the extracellular signaling role of 
ATP and related adenine nucleotides, the hypothesis that uracil nucleotides exert 
autocrine/paracrine roles has only recently gained experimental support. Uridine 
diphosphate (UDP) sensitive P2Y6 receptors have been involved in the 
generation of large spontaneous contractions and propagating waves of 
intracellular Ca2+ and membrane depolarization originating in suburothelial 
myofibroblasts and spreading to the detrusor smooth muscle in rats submitted to 
spinal cord transaction (Fry et al., 2012). Furthermore, using myographic 
recordings it has been demonstrated that UDP, acting on P2Y6 receptors, 
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interplays with P2X1 receptors in a synergistic manner to increase bladder 
smooth muscle tone (Yu et al., 2013). We confirmed that UDP increased the 
frequency and the amplitude of spontaneous detrusor contractions in the isolated 
rat bladder when the nucleotide was applied in high concentrations (300 µM) 
outside the bladder wall, but not when it was infused into the bladder lumen 
(Carneiro et al., 2014). However, increments of spontaneous bladder twitching 
caused by UDP (300 µM) were minimal (<10%) when compared to muscarinic 
and P2X1 receptors activation, respectively with oxotremorine (30 µM) and a,b-
meATP (30 µM). A significant discrepancy was also observed between the lack 
of effect of intraluminal UDP in the isolated bladder and the increase in the voiding 
frequency when the nucleotide was infused into the bladder lumen in 
anaesthetized rats. Overall, these results indicate that direct activation of smooth 
muscle via co-expressed P2Y6 and P2X1 receptors might represent a minor 
component of the urodynamic response to UDP that is mediated predominantly 
by the sequential activation of urothelial P2Y6 receptors and ATP release 
resulting in stimulation of urothelial/sub-urothelial P2X3 receptors in the rat 
(Carneiro et al., 2014; Timóteo et al., 2014) and in humans (Silva et al., 2015). In 
addition, to the well-characterized post-junctional effect of ATP, the nucleotide 
released at the synaptic cleft, can act on prejunctional P2 receptors, modulating 
other transmitters release (Duarte-Araújo et al., 2009; Sperlágh & Vizi, 1991). 
This effect has been shown in rat and porcine detrusor; where, ATP was able to 
enhance parasympathethic motor drive through pre-synaptic P2X3 receptors 
(D'Agostino et al., 2012; King et al., 1997). Conceivably, this prejunctional 
modulatory effect of ATP also exists in the human bladder, although evidence 
has been lacking till now. 
 
PURINERGIC SIGNALING DURING BLADDER FILLING  
 Most afferent nerves conveying sensitive information from the urinary 
bladder to the spinal cord originate in dorsal root ganglia. In the dorsal horn of 
the spinal cord, information received enters (1) via ascending nerve afferents, 
giving rise to conscious perception of bladder sensations, or (2) via interneurons, 
affecting motor pathways. At the bladder wall, C-fibre axons possess endings in 
the suburothelial layer and may also penetrate the urothelium (Birder et al., 
2010). As the urothelium responds to mechanical and chemical stimuli, and 
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transmits information to underlying nervous and muscular systems, it can be 
regarded as a functional transduction unit playing a pivotal role in generating 
afferent signals to bladder intrinsic relay circuits and to control centres in the CNS. 
 The urothelium is a transitional epithelium composed of three to five cell 
layers: a basal layer attached to the basement membrane, an apical layer with 
large umbrella cells and an intermediate layer. The suburothelium is composed 
of nerves, interstitial cells, blood vessels and connective tissue; it closely interacts 
with the urothelial layer above, the detrusor layer below and acts as a functional 
unit. The umbrella cell layer has the ability to incorporate additional membrane 
into the luminal surface as it is stretched, increasing the surface area during 
bladder filling. This is done by fusion and exocytosis of a subapical pool of 
discoidal/fusiform-shaped vesicles (Truschel et al., 2002). Upon voiding, the 
mucosa refolds, and the membrane added to the apical surface of the umbrella 
cells is thought to be recovered by endocytosis. Besides changes in membrane 
capacity, pressure-induced membrane traffic in apical urothelial cells can 
dramatically change drugs targeting to membrane-bound receptors and their 
coupling to downstream signalling cascades. This leads to dynamic modifications 
of urothelial signals in a moment-to-moment basis in order to accommodate urine 
storage and/or trigger bladder emptying. However, little is known about the 
events underlying these changes in both physiological and pathological 
conditions. 
 ATP was the first transmitter shown to be released directly by the 
urothelium (Ferguson et al., 1997). The release of the nucleotide can be triggered 
both by chemical stimuli and by stretching the uroepithelium during bladder filling. 
Non-neuronal release of ATP plays an important role as an autocrine and/or 
paracrine signalling molecule. Once in the suburothelial layer, ATP may act on 
vimentin-positive interstitial cells and on afferent nerve fibres conveying sensory 
information to the CNS through the activation of P2X2 and P2X3 receptors, 
respectively (Silva et al., 2015). Immunohistochemistry experiments have shown 
immunoreactivity against the P2X3 receptor on nerve fibres in the lamina propria, 
urothelium and detrusor muscle (Ford & Cockayne, 2011). Mice lacking P2X3 
receptor exhibited reduced inflammatory pain, prolonged voiding intervals and 
higher voided volumes (Cockayne et al., 2000). Experiments using an in vitro 
bladder-pelvic nerve preparation, show that prolonged exposure to a 
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desensitizing dose of α,β-meATP significantly reduces the activity of 
mechanosensitive pelvic nerve afferents in response to bladder distension 
(Namasivayam et al., 1999). Likewise, intravesical applications of ATP induce 
rapid excitation of bladder afferents, which was counteracted by PPADS and 
2′,3′-O-(2,4,6-trinitrophenyl)-ATP (TNP-ATP) (Vlaskovska et al., 2001). Similarly, 
P2X3 knockout mice exhibited a diminished response to bladder distension and 
to instillation of P2X receptor agonists manifested by delayed bladder emptying 
and increased threshold of activation of sensory afferents when compared to 
wild-type mice (Vlaskovska et al., 2001). A sensory role for the P2X2 receptor 
subtype has also been revealed using P2X2 and P2X2/P2X3 knockout mice 
(Cockayne et al., 2005).  
 The mechanisms underlying ATP release from urothelial cells is a matter 
of debate in the literature (Sui et al., 2014). ATP can be released from both 
surfaces of isolated uroepithelium through multiple mechanisms, including 
vesicular excocytosis, conductance of ATP through ABC or nucleoside 
transporters or translocation across hemichannels containing either connexins or 
pannexins. ATP released from the uroepithelium or surrounding tissue may act 
as a trigger for discoidal/fusiform vesicle exocytosis and membrane recovery 
through signal at uroepithelial P2 receptors (Wang et al., 2005). Several studies 
using RT-PCR, Western blotting and immunocytochemistry techniques have 
demonstrated that the urothelium expresses almost all purinoceptor subtypes. 
These include all ionotropic P2X receptor subunits and metabotropic P2Y1, P2Y2, 
P2Y4 and P2Y6 receptors (Carneiro et al., 2014; Chopra et al., 2008; Elneil et al., 
2001; Lee et al., 2000; Shabir et al., 2013; Vial & Evans, 2000). Cooperation 
between metabotropic P2Y6 and ionotropic P2X3 and/or P2X2/3 receptor 
subunits contributes to promote ATP and ACh release from non-neuronal 
sources in healthy human urothelium, but the positive feedback mechanism 
operated by released ATP through fast desensitizing P2X3 and/or P2X2/3 
receptors is impaired in obstructed patients, without much affecting the P2Y6 
mediated facilitation (Silva et al., 2015). Our group has previously shown that 
activation of the P2Y6 receptor increases the voiding frequency in anesthetized 
rats indirectly by releasing ATP from the urothelium via pannexin-1 hemichannels 
(Timóteo et al., 2014) and subsequent activation of P2X3 receptors on 
suburothelial nerve afferents. These results suggest that down-modulation of the 
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release of signalling molecules, such as ATP and ACh, from the bladder 
uroepithelium with selective P2Y6 receptor antagonists may constitute a novel 
strategy to control hyperactivity of sensory nerves and persistent storage 
symptoms in patients with BOO. 
 Once released from the urothelium, ATP is rapidly dephosphorylated by 
membrane-bound ectonucleotidases. The four members of the NTPDase family, 
as well as 5′-nucleotidase, are expressed in the mouse bladder, as demonstrated 
by RT-PCR. However, immunolocalization studies failed to detect NTPDase1,2 
and 5’-nucleotidase on rat urothelium (Yu et al., 2011). Notwithstanding this, 
adenosine has been shown to negatively modulate stretch-induced ATP release 
from apical umbrella cells through the activation of A1 receptors (Dunning-Davies 
et al., 2013). Taking into consideration that adenosine levels at the luminal site 
of the urothelium are 10-fold below those found beneath the basal layer, one may 
hypothesize that adenosine A1 receptor-mediated inhibition of ATP release plays 
a minor (if any) role in physiological conditions. Besides mechanical, chemical 
and purinergic stimulation, other compounds can elicit ATP release from 
urothelial cells. Notably, ACh has an important role in modulating this process. 
All 5 muscarinic receptors are present in urothelial cells. Stimulation of these 
receptors can trigger ATP release from urothelial cells in culture (Kullmann et al., 
2008). Likewise, intravesical infusion of high doses of the muscarinic agonist 
oxotremorine increased the voiding frequency in anesthetized rats, an effect that 
was blunted by blocking P2X receptors with PPADS applied into to bladder lumen 
(Kullmann et al., 2008). Carbachol and oxotremorine also favored the release of 
ATP from the human urothelium and the effects of these drugs were abolished 
by the muscarinic M2 receptor antagonist, methoctramine (Sui et al., 2014). 
These results suggest that activation of muscarinic receptors located near the 
luminal surface of the bladder affects the voiding function by mechanisms 
involving ATP release, thus strengthening the concepts that antimuscarinic drugs 
used to treat OAB syndromes exert their effect at least in part through actions in 
the urothelium.  
 In the suburothelial layer, the recently discovered interstitial cells have 
become an exciting focus of research (Wiseman et al., 2003). These cells form a 
syncytium through extensive coupling via connexin 43-containing gap junctions 
in a similar manner to that described in the gastrointestinal tract. Through this 
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arrangement signals initiated in a group of interstitial cells can travel considerable 
distances in the suburotelium and its information conveyed above to the 
urothelium and below to the detrusor smooth muscle layer. These cells are in 
close proximity to afferent nerves and elicit excitatory responses mediated by 
both purines and pyrimidines, such as ATP, ADP, UTP and UDP, via several P2Y 
receptor subtypes (Fry et al., 2007), including the most expressed P2Y6 receptor 
(Sui et al., 2006).  
 
ATP-MEDIATED SIGNALS IN PATIENTS WITH BLADDER DYSFUNCTION 
 Changes observed in the bladder of patients with BOO are very similar to 
those observed in OAB patients. For that reason they are described together in 
the following section. 
 Most OAB patients, excluding some neurogenic cases, report an increase 
in bladder sensation. Whether this is a cause or a consequence of OAB remains 
to be elucidated. Anyway, there is a considerable amount of evidence showing 
that afferent inputs are increased in these patients. 
 The urothelium from patients with neurogenic or idiopathic detrusor 
overactivity, as well as with BOO, release more ATP than urothelial strips from 
control individuals (Kumar et al., 2010; Silva et al., 2015; Sun et al., 2002). 
Although the basal release of ATP from both neurogenic and control bladders 
was similar, it reached values that were 20-fold higher the control amounts in 
bladders from patients with idiopathic OAB, indicating different 
pathophysiological mechanisms underlying the two disease conditions (Kumar et 
al., 2010). While in neurogenic OAB the defect is predominantly in the central 
control of the micturition, in idiopathic OAB the urothelium may play a dominant 
role in its pathogenesis. Likewise, in patients with BOO, both stretch and electric 
field stimulation (EFS) can trigger the release of ATP from the urothelium (Silva 
et al., 2015; Sun et al., 2002). EFS-induced ATP release from the urothelium was 
5-fold higher in BOO patients compared to control; this difference can be 
attributed, at least partially, to an increase in the half-degradation time of ATP by 
ectonucleotidases confirming that these patients exhibit enhanced purinergic 
tone. 
 Moreover, patients with neurogenic detrusor overactivity possess higher 
P2X3 receptor amounts in suburothelial afferent sensory neurons compared to 
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control individuals (Brady et al., 2004). It was also observed that the number of 
suburothelial sensory nerves is increased in patients with idiopathic detrusor 
overactivity (Moore et al., 1992; Smet et al., 1997). Notably, it was demonstrated 
that responders to the transient receptor potential cation channel subfamily V 
member 1 (TRPV1) activator, resiniferatoxin, exhibit reduced expression of the 
P2X3 receptor after treatment, but this change was not observed in non-
responders (Brady et al., 2004). The same group studied the effects of botulinum 
toxin A injection on P2X3 and TRPV1 receptors expression in patients with 
neurogenic and idiopathic detrusor overactivity; they found a decrease in the 
expression of both receptors in suburothelial nerve fibers after injection of the 
toxin (Apostolidis et al., 2005). Taken together these data indicate a role for 
ionotropic P2X3 receptors in the pathophysiology of detrusor overactivity. 
 Interestingly, the population of suburothelial interstitial cells is also 
increased in OAB patients (Roosen et al., 2009) and this is accompanied by 
increased expression of P2X2 receptor subunits demonstrated by 
immunofluorescence and Western blot analysis in female patients with OAB 
compared to controls (Meng et al., 2015). However, the same was not observed 
in male patients with BOO due to BPH (Silva et al., 2015). The immunoreactivity 
against P2X2 and P2X3 ionotropic receptor subunits localized respectively in 
vimentin-positive interstitial cells and suburothelial nerve afferents, as well as in 
the urothelium, almost disappeared in BPH patients submitted to surgery to relief 
BOO. Disappearance of the P2X2 immunostaining was not detected in 
suburothelial blood vessels from BPH patients. In contrast to the partial loss of 
ionotropic P2X receptors staining, immunoreactivity against the metabotropic 
P2Y6 receptor was conserved in the urothelium of BPH patients compared to 
healthy controls. This receptor is abundantly expressed throughout the urothelial 
layer (including the more superficial umbrella cells), in suburothelial interstitial 
cells and in the detrusor smooth muscle; interestingly, the P2Y6 staining 
accompanied the increase in the population of suburothelial interstitial cells 
observed in patients with BOO due BPH (Silva et al., 2015). These findings 
denote different purinoceptor arrangements depending on the underlying 
pathophysiological mechanism of OAB.  
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Figure 4. Mechanisms underlying enhanced purinergic tone in OAB. (1) The 
urothelium of OAB patients releases higher amounts of ATP; involvement of P2Y6 
receptors activation and ATP-induced ATP release operated by P2X3 and/or P2X2/3 
receptors; (2) Surplus ATP released from the uroepithelium activates suburothelial P2X3 
receptors on sensory nerve afferents and P2X2 receptors on interstitial cells leading to 
increased sensation during bladder filling.(3) Atropine-resistant purinergic contractile 
responses are also potentiated in the detrusor of OAB patients, which may be due to 
overexpression of P2X1 receptors and/or deficient ATP catabolism. 
 
 
PURINERGIC CONTROL OF CENTRAL BLADDER REFLEXES 
 Several disorders of the CNS are known to cause OAB. CNS disease 
conditions are associated with detrusor overactivity , for instance, cortical lesions 
secondary to cerebral vascular accidents, multiple sclerosis lesions in the pons 
and traumatic spinal cord injuries. There is, however, a gap in our knowledge 
about the role of purines in bladder overactivity secondary to CNS diseases. 
Nowadays, the role of ATP as a fast synaptic neurotransmitter is by far best 
characterized at peripheral neuro-effector junctions than in the CNS (Khakh & 
North, 2012). Nonetheless, activation of P2 receptors on two important CNS 
areas controlling micturition reflexes (peri-aqueductal grey matter and Barrington 
nucleus) triggered increases in bladder pressure and efferent pelvic nerve 
activity, suggesting a role in modulating parasympathetic bladder innervation 
(Rocha et al., 2001).  
 At the spinal cord level, there is also evidence of ATP signaling mediating 
bladder reflexes. ATP mediated responses may be partially responsible for 
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detrusor overactivity induced by acetic acid, acrolein or cyclosphophamide in the 
rat (Masuda H et al., 2005). Involvement of ionotropic P2X3 and P2X2/3 receptor 
subunits have been claimed, since intrathecal administration of the potent and 
selective antagonist of these receptors, AF-792, produced long lasting inhibition 
of micturition reflex contractions (Khakh & North, 2012). These data support a 
role for presynaptic P2X3 and P2X2/3 receptors in facilitating the micturition 
reflex at the spinal cord level. Following spinal cord injury, the amount of ATP 
released in the damaged tissue increases dramatically (Peng et al., 2009), as 
well as the expression of P2X2 and P2X3 receptor subunits increase in the 
bladder (Brady et al., 2004; Pannek et al., 2009). 
 
 
RELEVANCE OF ATP IN CLINICAL PRACTICE 
 In the clinical setting diagnosing OAB is not always an easy task. 
Symptoms are subjective, patients do not always mean what they say and 
clinicians do not always get what patients mean. Therefore, there is a clinical 
need for a simple non-invasive test that could help diagnosis of OAB. In the last 
few years several urinary biomarkers for OAB have been investigated and 
proposed (Antunes-Lopes et al., 2011). Since these patients exhibit an higher 
purinergic tone, identifying this may help diagnosis and better characterize these 
patients. 
 Targeting the purinergic system also seems a reasonable option for the 
treatment of several lower urinary tract dysfunctions. In fact, antimuscarinic drugs 
frequently used as a first-line therapeutic option for OAB lose efficacy with the 
time of treatment (Sears et al., 2010). Long-term exposure to anticholinergics is 
associated with downregulation of the postjunctional response to carbachol and 
with an upregulation of purinergic responses to ATP in experimental rats (Uvin et 
al., 2013), leading us to hypothesize that association with P2 receptor antagonists 
might be appropriate.  
 Novel, potent and orally-active P2X3 antagonists have been developed 
and tested in lower urinary tract dysfunctions (Gever et al., 2010). The selective 
P2X3 antagonist, A317491, improved bladder function parameters in a rat model 
of spinal cord injury and in cyclophosphamide-induced cystitis; this drug 
effectively inhibited non-micturition contractions, increased inter-contraction 
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intervals and bladder capacity (Ito et al., 2008; Lu et al., 2007). Likewise, AF-353 
diminished the frequency of non-voiding contractions in spinal cord injured rats 
(Munoz et al., 2012). P2X3 antagonists, like AF-219, are being tested in clinical 
trials for chronic cough and interstitial cystitis/bladder pain syndrome (Abdulqawi 
et al., 2015; Moldwin R et al., 2015). A phase 2 study recently presented, showed 
that AF-219 improved pain and related symptoms in patients with interstitial 
cystitis/bladder pain syndrome compared to placebo, with minor adverse events 
(Moldwin R et al., 2015). Figure 4 shows the rationale for using selective P2X3 
(or P2X2/3) antagonists in OAB syndromes, which may derive from their relevant 
role in urothelium-mediated pressure transducer signaling pathway, involving 
excessive ATP-induced ATP release from uroepithelial cells and activation of 
suburothelial nerve afferents and interstitial cells by non-neuronal released ATP.  
 Another interesting finding from our group suggests that UDP-sensitive 
P2Y6 receptors activation triggers the release of ATP from urothelial cells via 
pannexin-1 hemichannels (Carneiro et al., 2014; Timóteo et al., 2014), which 
results in increased release of the nucleotide in BOO patients (Silva et al., 2015). 
Thus, blocking the P2Y6 receptor in the urothelium may constitute a novel 
therapeutic approach to control bladder overactivity and persistent storage 
symptoms in patients with BOO. 
 Botulinum toxin A (BoNT-A) is clinically used to treat both neurogenic and 
idiopathic bladder overactivity when anti-muscarinic drugs fail (Cruz et al., 2011; 
Pinto et al., 2010). The actions of BoNT-A are not restricted to suppression of 
ACh and norepinephrine release from autonomic nerves in the rat bladder, but, 
interestingly, it also diminishes the release of ATP (Khera et al., 2004; Smith et 
al., 2003). Reduction of ATP release by BoNT-A may decrease the activation of 
sensory nerve afferents induced by bladder irritation with acetic acid (Chuang et 
al., 2004). Therefore, it appears that the clinical efficacy of BoNT-A relies not only 
on the blockade of transmitter release from efferent nerves, but also on its action 
on urothelial sensory mechanisms.  
 All together, these data support a crucial role of ATP and its derivatives in 
the pathophysiology of OAB and foresee future drugs targeting the purinergic 
cascade, including ATP release sites, ectonuleotidases, and purinoceptors, for 
the treatment of OAB syndromes. 
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1.3.2 ADENOSINE AND BLADDER 
 
The content of this section was adapted from the review chapter: 
 
Silva-Ramos M, Silva I, Faria M, Magalhães-Cardoso MT, Correia-de-Sá P: 
Urinary bladder disorders: Is adenosine friend or foe? In: Adenosine receptors. 
Pharmacology, functions and therapeutic aspects. Hauppauge NY; Nova Science 
Publishers, 2014. 
 
 In the previous section we highlighted findings demonstrating that ATP (1) 
is a co-transmitter with acetylcholine (ACh) in parasympathetic nerves regulating 
bladder contraction (Burnstock et al., 1972), (2) activates afferent nerves during 
bladder filling transmitting both normal and abnormal sensations like urgency and 
pain (Birder & Andersson, 2013; Ferguson et al., 1997; Wang et al., 2005), and 
(3) participates in the control of bladder reflexes at the CNS (Rocha et al., 2001). 
However, the effects of the ATP metabolite, adenosine, has been less studied. 
Initial reports on the effect of adenosine in the lower urinary tract are from the 
nineteen seventies and coincided with Burnstock’s group attempt to prove that 
ATP was the non-cholinergic non-adrenergic neurotransmitter released from 
nerves supplying the urinary bladder (Burnstock et al., 1978b; Burnstock et al., 
1972). They managed to show that the breakdown product of ATP, adenosine, 
caused a decrease in both the tone and the spontaneous activity of the urinary 
bladder (Burnstock et al., 1978a).  
 Adenosine is a ubiquitously produced nucleoside that participates in the 
normal function of the cardiovascular, respiratory, renal, gastrointestinal, 
neuronal, musculoskeletal and immune systems where it regulates diverse 
phenomena including neuronal excitability, vasodilation, smooth muscle 
relaxation, protection against ischemic and inflammatory insults, and the release 
of vasoactive and neuroactive substances. Adenosine is generated within cells 
from the hydrolysis of S-adenosyl-L-homocysteine in parallel to its formation from 
the catabolism of adenine nucleotides, ATP, ADP, AMP or cAMP, via 
nucleotidases, which exist both at the intracellular and the extracellular space 
(Fredholm et al., 2001; Jackson & Raghvendra, 2004). Once produced, 
adenosine may undergo bidirectional translocation between cytoplasm and the 
extracellular fluid (through equilibrative or concentrative nucleoside transporters), 
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deamination into inosine by ADA (EC 3.5.4.4), and phosphorylation by 
intracellular adenosine kinase (EC 2.7.1.20) to generate AMP. The way 
adenosine builds its influence to control cells communication depends on the 
extracellular concentration of the nucleoside, which is achieved by balancing 
extracellular adenosine generation and inactivation mechanisms (cellular uptake 
and/or extracellular deamination) (Correia-de-Sá & Ribeiro, 1996; Goncalves & 
Queiroz, 1993). Although adenosine transport may be faster than its subsequent 
intracellular metabolism (for a review see Geiger, 1991), numerous studies have 
shown that phosphorylation of adenosine by adenosine kinase is the primary 
metabolic pathway regulating both intra- and extracellular levels of the nucleoside 
(Arch & Newsholme, 1978b; Lloyd & Fredholm, 1995). In the urinary bladder, 
parallel formation of adenosine from the hydrolysis of ATP released from 
stimulated neuronal and non-neuronal cells (e.g. urothelial cells, interstitial cells, 
fibroblast-like cells, smooth muscle fibers) is also possible. Therefore, it is 
conceivable that adenosine contributes to an overall homeostatic role on bladder 
activity during instability conditions (e.g. inflammation, hypoxic/ischemic insults, 
outlet obstruction) when endogenous adenosine becomes elevated. Extracellular 
inactivation may restrict adenosine actions to the release/production sites and 
may limit diffusion of the exogenously added nucleoside towards the active zones 
(see e.g. Correia-de-Sá et al., 2006; Duarte-Araújo et al., 2004). 
 Once in the extracellular milieu, adenosine may interact with membrane-
bound P1 receptors (Fredholm et al., 2001). In humans, the A3, A1 and A2A 
receptor subtypes are activated by submicromolar concentrations of adenosine 
(0.29 µM, 0.31 µM, and 0.73 µM, respectively) while the adenosine A2B receptor 
is activated at much higher concentrations of the nucleoside (23.5 µM) (Fredholm 
et al., 2001). This pattern differs significantly from that found in other mammals 
where the A3 receptor has low affinity for adenosine. These findings suggest that 
the human adenosine A1, A2A and A3 subtypes respond to physiological 
concentrations of adenosine (between 30 and 300 nM), while the A2B receptor 
subtype requires higher concentrations of the agonist for activation which may 
rise from 10 to 1000 fold in pathological conditions.  
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ADENOSINE RECEPTORS EXPRESSION IN THE URINARY BLADDER 
 First studies aiming at characterizing pharmacologically P1 receptors in 
the urinary bladder were performed in mice and supported the role of both pre-
synaptic (via A1 receptors) and post-synaptic (via A2 receptors) effects (Acevedo 
et al., 1992; Nicholls et al., 1992). The role of low affinity A2B and A3 receptor 
subtypes has been more difficult to characterize (see below). Paradoxically, RT-
PCR analysis has detected all four adenosine receptor subtypes in the rat urinary 
bladder: A2A and A2B being more expressed than A1, whereas A3 was the least 
expressed (Dixon et al., 1996). A similar pattern was detected for the mRNA 
expression of adenosine receptors in the human bladder epithelial carcinoma T24 
cell line (Phelps et al., 2006). Another study in female rats confirmed the 
predominance of the A2B receptor mRNA in the urinary bladder and reported 
increases in P1 receptor mRNA with age (Owen et al., 2012). Because PCR 
results do not necessarily correlate with the presence of functional adenosine 
receptors displayed on the cell surface, further characterization of these data by 
western blot analysis and functional assays are highly recommended. 
 Using western blot analysis and immunofluorescence localization, Yu and 
col. detected the expression of all four types of adenosine receptors in the bladder 
urothelium of female Sprague-Dawley rats (Yu et al., 2006). The A1 receptors 
were predominantly localized to the apical membrane of umbrella cells, whereas 
A2A, A2B and A3 receptors were localized intracellularly or on the basolateral 
membrane of umbrella cells and the plasma membrane of underlying cell layers. 
Signals for the A1 receptor were also observed in the underlying submucosal 
connective tissue, but suburothelial tissue elements (possibly connective cells, 
myofibroblasts or blood vessels) were more strongly labeled with the A2A 
antibody. Although information regarding location of adenosine receptors on the 
detrusor is still scant, there are reports suggesting that A2B receptors are 
abundantly expressed in rat bladder smooth muscle (Stehle et al., 1992; Yu et 
al., 2006). In addition, there are pharmacological evidences for the presence of 
A1, A2A and A3 receptors on detrusor muscle, often with conflicting results 
depending on the species and experimental settings (Gopalakrishnan et al., 
2002; Vesela et al., 2011; Yang et al., 2000). Surprisingly, there is little data 
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characterizing the adenosine receptor subtype(s) involved in the human urinary 
bladder function.  
 
EFFECTS OF ADENOSINE IN THE UROTHELIUM 
 There are innumerous studies demonstrating that the urothelium can 
release ATP in response to stretch and chemical stimuli, in animals and in 
humans (Ferguson et al., 1997; Timóteo et al., 2014; Wang et al., 2003), but it is 
unknown whether this contributes to the high concentrations of adenosine found 
in urine (Heyne et al., 2004; Vidotto et al., 2003). However, it has been 
demonstrated that about 50% of the extracellular adenosine available is the result 
of the break-down of ATP (Smith & Lu, 1991) which is currently regarded to be 
the most important route of generating extracellular adenosine (Zhang & Xia, 
2012). In vitro degradation studies of ATP in a guinea-pig detrusor strip organ 
bath setup showed that ATP was rapidly broken down within minutes to form 
mainly, but not exclusively, adenosine (Cusack & Hourani, 1984). Magnesium-
dependent adenosine triphosphatase (Mg2+-ATPase) as well as 5′-nucleotidase 
and alkaline phosphatase were identified in epithelial cells of the rat urinary 
bladder (Zhang et al., 1991). The four members of the NTPDase family, as well 
as 5′-nucleotidase, are expressed in the mouse bladder, as demonstrated by RT-
PCR (Yu et al., 2011). The relative contribution of distinct ectonucleotidases to 
the modulation of purinergic signalling depends on differential tissue distribution, 
regulation of cell expression, targeting to specific membrane domains, but also 
on substrate preference and availability. This might explain the different kinetics 
of ATP metabolism and adenosine accumulation between luminal and serosal 
sides of the urothelium (Lewis & Lewis, 2006). Ussing chamber experiments with 
the rabbit urothelium showed that adenosine concentration rises in the incubation 
fluid by stretching the tissue, providing that the experiments are done in the 
presence of iodotubercidin (an inhibitor of adenosine kinase) and erythro-9-(2-
hydroxy-3-nonyl)adenine (EHNA, an inhibitor of ADA) (Prakasam et al., 2012; Yu 
et al., 2006); the highest concentration of adenosine was recorded at the serosal 
surface of the urothelium, with concentrations approaching 200 nM. Previous 
studies from the same group showed that increased pressure stimulates ATP 
release from both surfaces of the uroepithelium, but mucosal release of the 
nucleotide was 50-fold greater than serosal release (Wang et al., 2005). The 
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disparity between the site of preferential ATP and adenosine accumulation at the 
two urothelial surfaces led those authors to hypothesized that hydrolysis of 
released ATP by ectonucleotidases would play a minor role on adenosine 
biosynthesis in the rabbit urothelium.  
 Fine-tuning regulation of extracellular purines in the urothelium is more 
complex than first hypothesized. Besides adenosine being originated from the 
breakdown of released adenine nucleotides via the ectonucleotidase pathway, it 
has been demonstrated that it may negatively modulate stretched-induced ATP 
release over many minutes by modulating exocytosis in the apical membrane of 
umbrella cells (Yu et al., 2006). A more acute (within seconds) effect to modulate 
distension-induced ATP release from the urothelium has been suggested 
(Dunning-Davies et al., 2013). Distension-induced ATP release was decreased 
by adenosine (1-10 µM) and enhanced by ADA and the A1 receptor antagonist, 
1,3-dipropyl-8-cyclopentylxanthine (DPCPX), but not by blocking A2 receptors 
with 3,7-dimethyl-1-propargyl-xanthine (DMPX). The mechanism by which 
adenosine reduces urothelial ATP release remains unknown, but it might depend 
on changes in the transepithelial potential by interference with mechanosensitive 
Na+ channels (identified as amiloride-sensitive epithelial Na+ channels or ENaC), 
which may ultimately favor Ca2+ outflow via Na +/Ca2+ exchange in urothelial cells 
(Wu et al., 2011). These findings support a dominant role of A1 receptors in 
regulating ATP release from the urothelium. This information, which was obtained 
in rabbit umbrella cells, is in harmony with rat cystometry data showing that 
luminal application of the A1 receptor agonist, CCPA, significantly decreased the 
frequency of the micturition reflex in clear opposition to that observed upon 
increasing ATP concentration inside the bladder (Kitta et al., 2014). Conflicting 
results, however exist, as adenosine acting probably via A1 receptors decreased 
the threshold pressure needed to stimulate the micturition reflex, thus increasing 
bladder hyperactivity, in a model of cyclophosphamide-induced cystitis 
(Prakasam et al., 2012). Whether adenosine exerts diverse effects to control 
bladder function under pathological conditions versus control situations through 
coupling to distinctive intracellular signaling pathways, needs clarification. 
 Whereas adenosine binds to its receptors and impacts organ-protective 
functions (Cohen & Downey, 2008), chronic elevation of extracellular adenosine 
is harmful to tissues (Zhou et al., 2010). Hence, the half-life time of extracellular 
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adenosine is kept short (seconds to minutes, depending on species) through the 
action of enzymes and transporters. Taking into consideration that adenosine 
levels at the luminal site of the urothelium are 10-fold below those found in the 
serosal side, one may hypothesize that the adenosine inactivation mechanisms 
are particularly active at the luminal surface of the bladder; this has also 
relevance to keep low urinary adenosine originated upstream the bladder urinary 
tract (e.g. kidney) (Jackson et al., 2011). In this respect, ADA seems to be most 
important enzyme to control adenosine levels at the mucosal surface of the 
bladder, while adenosine kinase and nucleoside transporters seem to play more 
significant roles at the serosal side of the uroepithelial cell layer (Prakasam et al., 
2012). This hypothesis gains further support considering previous studies 
showing that the basolateral surface of polarized epithelial cells are endowed with 
equilibrative nucleoside transporters (Loffler et al., 2007). 
 
 
EFFECTS OF ADENOSINE AT THE DETRUSOR NEUROMUSCULAR 
JUNCTION 
 The adenosine content of human bladder smooth muscle is 6.7 times 
higher than striated muscle and the adenosine/ATP ratio is 1:9 compared with 
1:450 for striated muscle (Wedenberg et al., 1994). Several studies have shown 
that adenosine concentration-dependently relaxes pre-contracted urinary bladder 
detrusor strips exposed to carbachol, ACh, potassium depolarization, or electrical 
field stimulation in rats, guinea-pigs (Acevedo et al., 1992; Brown et al., 1979; 
Burnstock et al., 1978a; King et al., 1997; Nicholls et al., 1992) and humans 
(Rubinstein et al., 1998). Maximum relaxation by adenosine never exceeded 50% 
of ACh-induced tension in the isolated human detrusor (Rubinstein et al., 1998). 
Despite increased ATP-induced contractions have been associated with 
interstitial cystitis, detrusor overactivity, outlet obstruction, inflammation, 
neurogenic bladder, spinal cord lesions and aging, there are no reports on 
different responses to adenosine in these situations. 
 Characterization of the adenosine receptor subtype responsible for 
detrusor relaxation has been difficult to establish due to differences in target 
species and experimental protocols. Based on the rank potency order of P1 
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agonists to reduce contractile responses caused by ATP or ACh, it seems that 
an A2 receptor subtype might be involved (Acevedo et al., 1992; Nicholls et al., 
1992). Characterization of the A2 receptor subtype implicated in this process is 
hindered by the absence of highly selective and potent ligands for A2B receptors. 
In the guinea-pig bladder smooth muscle cells adenosine evokes membrane 
hyperpolarization by activation of KATP channels involving activation of adenylate 
cyclase, generation of cyclic AMP and stimulation of protein kinase A 
(Gopalakrishnan et al., 2002). In this study, the non-selective A2 receptor agonist, 
5’-N-ethylcarboxamidoadenosine (NECA), was equipotent to the selective A2A 
receptor agonist, CGS21680C, and these were more potent than A1 and A3 
selective agonists, 2-choloro-N6-cylcopentyladenosine (CCPA) and 2-chloro-N6-
(3-iodobenzyl) adenosine-5’-N-methylcarboxamide (2-Cl-IBMECA), respectively. 
Moreover, the selective A2A receptor antagonist, ZM241385, inhibited the 
changes in membrane potential evoked by adenosine and NECA on detrusor 
smooth muscle cells. However, there are conflicting data with the use of the A2A 
receptor agonist CGS21680C as it relaxed the guinea-pig detrusor strips pre-
contracted with KCl (Gopalakrishnan et al., 2002) but caused only a slight 
inhibition compared to NECA on carbachol-induced contractions in the urinary 
bladder of rats (Nicholls et al., 1992) and pigs (Hernandez et al., 1999). This also 
insinuates a role for low affinity A2B receptors in this process. In fact, the A2B 
selective antagonist, PSB 1115, blocked the relaxant effect of adenosine when it 
was applied in high concentrations (Aronsson et al., 2010). Thus, so far there is 
no clear cut evidence to decide which A2 receptor subtype predominantly 
participates in adenosine relaxation of the detrusor muscle (question mark in 
Figure 5).  
 Other authors claimed that the A1 receptor may also partially operate 
adenosine-induced relaxation of the rat urinary bladder (acting at the detrusor 
and urothelium), since the selective A1 receptor antagonist DPCPX, but not the 
A2A receptor antagonist, SCH58261, blocked the effect of the nucleoside (Vesela 
et al., 2011). Conversely, findings obtained under different experimental 
conditions showed that the A1 receptor may be responsible for contraction of 
isolated detrusor cells from cats by acting via pertussis toxin-sensitive Gi3 protein, 
phospholipase C-b3 and the release of intracellular Ca2+ (Yang et al., 2000). 
Controversy regarding the effects of adenosine in the urinary bladder detrusor 
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increases given that data demonstrate that blockage of A3 receptors may 
potentiate adenosine relaxation, suggesting that stimulation of A3 receptors 
induces detrusor contraction in the rat (Vesela et al., 2011). 
 Besides direct actions of adenosine on P1 receptors located on detrusor 
smooth muscle fibers, the nucleoside and its analogues may act indirectly by 
inhibiting nerve-evoked contractions; this was evidenced in rats (Acevedo et al., 
1992; Burnstock et al., 1978a; King et al., 1997; Parija et al., 1991), guinea-pigs 
(Burnstock et al., 1978a), cats (Yang et al., 2000), and humans (Husted et al., 
1983). Interestingly, inhibition of evoked transmitters release by adenosine is 
much more pronounced than the effect of the nucleoside on pre-contracted 
human detrusor smooth muscle (Figure 5).  
 The rank potency order of adenosine analogues to reduce nerve-evoked 
contractions is clearly different from that required to reduce ATP- and/or 
carbachol-induced contractions. Being A1 receptor agonists, like N6-(R-2-
phenylisopropyl)adenosine (R-PIA) and N6-cyclohexyladenosine (CHA), the 
most potent ligands on electrically-evoked detrusor contractions, whereas NECA 
was the most potent agonist on detrusor contractions caused by ATP or 
carbachol (Acevedo et al., 1992; Nicholls et al., 1992). These findings are 
consistent with idea that adenosine inhibition of nerve-evoked detrusor 
contractions is related to the activation of pre-synaptic A1 receptors (Williams, 
1987). 
Adenosine also seems to have an important role in NANC, probably 
nitrergic, inhibition of the bladder neck. ATP-induced relaxation of this tissue 
seems to be mediated by metabotropic P2Y1 and A2A receptors after its 
breakdown to ADP and adenosine, respectively (Hernandez et al., 2009). 
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Figure 5. Schematic representation of adenosine effects on the detrusor 
neuromuscular transmission. Inhibition of nerve-evoked contractions by adenosine in 
the human detrusor is due to a preferential activation of A1 receptors on cholinergic nerve 
efferents, while the nucleoside produces less potent relaxation by directly targeting 
receptors on smooth muscle fibers. AcCoA  represents acetyl coenzyme A, and ChAT,  
choline acetyl transferase. 
 
EFFECTS OF ADENOSINE IN THE CONTROL OF MICTURITION REFLEX 
 Adenosine receptors are broadly distributed in the central nervous system 
being A1 and A2A receptors the most expressed subtypes (Dixon et al., 1996). 
The A1 receptor is widely distributed in the brain, spinal cord and peripheral 
nervous system (Fredholm et al., 2001), whereas the A2A receptor is 
predominantly expressed in basal ganglia and in presynaptic terminals of sensory 
afferents (Dunwiddie & Masino, 2001; Kaelin-Lang et al., 1998). 
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 Most of the evidence for the modulatory role of adenosine on the 
micturition reflex, both in the periphery and in the central nervous system, comes 
from cystometry experiments performed in the rat. It has been reported that both 
R-PIA and NECA adenosine analogues administered intrathecaly delayed the 
voiding reflex (Sosnowski & Yaksh, 1990). More recently, it was found that 
activation of A1 receptors or inhibition A2A receptors in the brain or in the spinal 
cord cause an inhibitory effect on the micturition reflex (Kitta et al., 2014). These 
authors demonstrated that amplification of the inhibitory A1-receptor-mediated 
effect was observed in the brain of rats with bladder overactivity caused by 
intravesical instillation of acetic acid, whereas the A2A receptor tonus increased 
in the spinal cord. A peripheral inhibitory action was observed in this model when 
A1 agonists were applied into the lumen of the urinary bladder. Interestingly, A1 
and A2A receptor mediated effects control the micturition reflex acting 
predominantly on the afferent arm of the reflex, without significant changes in the 
voiding pressure. 
 
 
ROLE OF ADENOSINE ON LOWER URINARY TRACT SYMPTOMS 
 The physiological effect of adenosine is now considered a new direction 
in halting the progression of damage in several organ systems. During the last 
decades a huge amount of evidences implicate the purinergic system in the 
pathogenesis of urinary bladder syndromes (Burnstock, 2014), however not 
much is known on the role of adenosine in bladder dysfunctions. Nevertheless, a 
study in a rat model of Parkinson disease suggests that bladder overactivity in 
this condition was, at least in part, caused by increased activity of A2A receptors 
in the brain (Kitta et al., 2012). This is not surprising given that these receptors 
are selectively co-localized and negatively interplay with dopamine D2 receptors 
on GABAergic output neurons of the striatopallidal pathway (Mori & Shindou, 
2003).  
 There are also studies suggesting the involvement of P1 receptors in the 
regulation of the inflammatory response (Hasko et al., 2008; Sitkovsky et al., 
2004). In rats with cyclophosphamide induced cystitis, the A1 receptor activation 
mediates important pro-inflammatory responses (Aronsson et al., 2010) and 
paradoxical voiding effects (Prakasam et al., 2012, see above). In fact, blockade 
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of A1 receptors with DPCPX normalized bladder contractile responses and 
prevented inflammatory bladder wall changes induced by cyclophosphamide. 
The A1 receptor-mediated relaxation is perhaps replaced by A2B receptors 
function, while A3 receptors mediate contraction (Vesela et al., 2011). On the 
other hand, adenosine activation of A2A has been shown to provide potent anti-
inflammatory effects and A2A receptor are highly expressed in immune cells such 
as monocyte/macrophages, neutrophils and T cells (see e.g. (Sitkovsky et al., 
2004). In human urothelial cells infected with Escherichia coli, the expression of 
A1 and A2B mRNA was decreased and the expression of A2A was increased 
suggesting that adenosine may regulate inflammatory reactions in response to 
infection via A2A receptors (Save et al., 2009).  
 In the quest for new treatment options for OAB, modulation of endogenous 
adenosine levels and/or P1 receptors activity stands as an interesting prospect. 
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CHAPTER 2 
OUTLINE AND AIMS 
 
 
 
 
 
 
“I keep six honest serving-men, 
They taught me all I knew; 
Their names are What and Why and When 
and How and Where and Who.” 
 
Rudyard Kipling 
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The main objective of this thesis was to investigate changes in the 
purinergic signalling mechanisms in patients with bladder dysfunctions aiming at 
unveiling novel targets to diagnose and therapeutically manage these conditions. 
We approached this task by looking initially to detrusor changes induced by BOO 
and afterwards looking at changes in the urothelium and ATP concentrations in 
the urine. Therefore, we could divide this work in two parts: one studying the 
efferent branch of the micturition reflex by looking at detrusor samples from BPH 
patients and controls; and a second part where we look at the afferent branch, by 
studying bladder urothelium and urinary ATP concentrations from patients with 
LUTD and controls. 
 On the efferent side of the micturition reflex there are significant gaps on 
our knowledge on how the purinergic component of atropine-resistant 
contractions realy work, what are the actual changes on ACh release in the 
diseased bladder and how purines interact with ACh release. For that matter on 
Section 3.1 we aimed to fill these gaps by studying smooth muscle contraction, 
ACh release, purine metabolism and immunolocalization of purinoceptors in 
detrusor samples from patients with BOO due to BPH and control samples 
collected from cadaveric organ donors. 
 On the afferent side, although there is plenty of information on ATP release 
from nerves and from the urothelium, the assessment of  ATP concentrations in 
urine has not been consistently studied. Consequently, on Section 3.2 we looked 
at urinary ATP concentration on patients with bladder dysfunctions and assessed 
the viability of ATP as a non-invasive biomarker of bladder dysfunctions. With 
that purpose we evaluated urine samples from patients with OAB, BOO and 
controls. 
 More specific aims are described in each article. 
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3.1 EFFECTS OF PURINES ON ACETYLCHOLINE RELEASE IN 
THE DETRUSOR 
 
 
 
 
 
 
 
“Oh tell me Lord how could it be, 
That though our cells make ATP, 
It's not all used for energy, 
But sometimes is secreted free. 
It puzzles you, it puzzles me, 
While Geoffrey Burnstock smiles with glee 
At the many roles of ATP.” 
 
Samuel C. Silverstein 
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ABSTRACT 
 
This study was designed to investigate whether reduced adenosine formation 
linked to deficits in extracellular ATP hydrolysis by NTPDases contributes to 
detrusor neuromodulatory changes associated with bladder outlet obstruction in 
men with BPH. The kinetics of ATP catabolism and adenosine formation, as well 
as the role of P1 receptor agonists on muscle tension and nerve-evoked [3H]ACh 
release were evaluated in mucosal-denuded detrusor strips from BPH patients 
(n=31) and control organ donors (n=23). The neurogenic release of ATP and 
[3H]ACh was higher (P<0.05) in detrusor strips from BPH patients. The 
extracellular hydrolysis of ATP and, subsequent, adenosine formation was slower 
(t½ 73 vs 36 min, P<0.05) in BPH detrusor strips. The A1 receptor-mediated 
inhibition of evoked [3H]ACh release by adenosine (100 µM), NECA (1 µM) and 
R-PIA (0.3 µM) was enhanced in BPH bladders. Relaxation of detrusor 
contractions induced by acetylcholine required 30-fold higher concentrations of 
adenosine. Despite VAChT-positive cholinergic nerves exhibiting higher A1 
immunoreactivity in BPH bladders the endogenous adenosine tonus revealed by 
adenosine deaminase is missing. Restoration of A1 inhibition was achieved by 
favoring (1) ATP hydrolysis with apyrase (2 U.mL-1) or (2) extracellular adenosine 
accumulation with dipyridamole or EHNA, as these drugs inhibit adenosine 
uptake and deamination, respectively. In conclusion, reduced ATP hydrolysis 
leads to deficient adenosine formation and A1 receptor-mediated inhibition of 
cholinergic nerve activity in the obstructed human bladder. Thus, we propose that 
pharmacological manipulation of endogenous adenosine levels and/or A1 
receptor activation might be useful to control bladder overactivity in BPH patients. 
CHAPTER 3 | RESULTS/ PUBLICATIONS 
Role of endogenous purines in lower urinary tract dysfunctions 71 
 
INTRODUCTION 
Detrusor dysfunction associated with bladder outlet obstruction has long 
been considered a key factor in the mechanism through which BPH causes 
persistent LUTS (reviewed in Mirone et al., 2007). Although there is a lack of 
information regarding the way obstruction may cause bladder dysfunction, 
morphologic and functional abnormalities of the bladder detrusor are frequent in 
patients affected with BPH. Most of these changes can be regarded as a 
consequence of mechanical stress and hypoxic changes caused by BOO at the 
molecular level in the epithelium, smooth muscle fibres, extracellular matrix, and 
neuronal network of the urinary bladder (Mirone et al., 2007). 
Although it is generally accepted that ACh acting on smooth muscle 
muscarinic receptors is the primary effector controlling bladder emptying, neural 
stimulation of the bladder is only partially inhibited by atropine in many species, 
including humans (Cowan & Daniel, 1983; Dean & Downie, 1978). In keeping 
with the purinergic hypothesis proposed by Burnstock, it is now accepted that 
ATP is responsible for the atropine-resistant component of parasympathetic 
contraction of the detrusor (Burnstock, 2011; Levin et al., 1986). While the 
purinergic component of detrusor contraction via P2 purinoceptors activation is 
lacking in healthy humans, it may increase with age (Yoshida et al., 2001) and is 
responsible for up to 40% of nerve-evoked bladder contractions in pathological 
conditions, including hypertrophic unstable bladder, overactive detrusor, 
neurogenic bladder and interstitial cystitis (reviewed in Ruggieri & Braverman, 
2006).  
In patients with idiopathic detrusor instability, appearance of atropine-
resistant P2 purinergic tone is related to decreased ecto-NTPDase activity, thus 
limiting the breakdown of ATP released from bladder nerves or the urothelium 
(Harvey et al., 2002). Nonetheless, decreased activity of ecto-NTPDases may 
also have profound implications for endogenous adenosine formation and P1 
receptors activation. Surprisingly this mechanism has never been explored in the 
human bladder despite the fact that the adenosine content of human bladder 
smooth muscle is 6.7 times higher than in the striated muscle and the 
adenosine/ATP ratio is 1:9 compared with 1:450 for skeletal muscle (Wedenberg 
et al., 1994). 
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Previous studies have shown that adenosine partially relaxes pre-
contracted urinary bladder detrusor strips exposed to carbachol, ACh, or 
potassium depolarization in rats, guinea-pigs (Acevedo et al., 1992; Brown et al., 
1979; Burnstock et al., 1978a; King et al., 1997; Nicholls et al., 1992) and humans 
(Rubinstein et al., 1998). Besides direct actions of adenosine on P1 receptors 
located on detrusor smooth muscle fibers, the nucleoside and its analogues may 
act indirectly by inhibiting nerve-evoked contractions as demonstrated in rats 
(Acevedo et al., 1992; Burnstock et al., 1978a; King et al., 1997; Parija et al., 
1991), guinea-pigs (Burnstock et al., 1978a), cats (Yang et al., 2000) and humans 
(Husted et al., 1983). All four subtypes of adenosine receptors (A1, A2A, A2B and 
A3) have been identified in the bladder of experimental animals and humans by 
RT-PCR analysis; results show that A2A and A2B mRNAs are more expressed 
than A1, with the A3 being the least expressed receptor (Dixon et al., 1996; Owen 
et al., 2012). Discrepancy between the relative abundance of A1 and A2 receptor 
subtypes in the detrusor (Dixon et al., 1996) may be attributed to their preferential 
localization on tiny nerve terminals and smooth muscle fibers, respectively 
(Acevedo et al., 1992; Nicholls et al., 1992), which supports previous 
pharmacological data obtained in rodents. There are, however, no published 
reports on subtype distribution of adenosine receptors in the human urinary 
bladder.   
Therefore, this study was designed to investigate the kinetics of ATP 
catabolism and adenosine formation, as well as the role of specific adenosine 
receptor ligands on electrically-evoked [3H]ACh release and muscle tension in 
mucosal-denuded detrusor strips, which were collected from men with outflow 
obstruction due to BPH (patients) and control organ donors. Because RT-PCR 
results do not necessarily correlate with the presence of functional adenosine 
receptors on the cell surface, we evaluated the expression of adenosine receptor 
subtypes in the human detrusor by immunofluorescence confocal microscopy. 
 
PATIENTS AND METHODS 
Human detrusor samples. 
Samples of human detrusor were collected from the bladder dome of thirty 
one male patients (62±6 years of age) with bladder outlet obstruction due to BPH 
submitted to transvesical prostatectomy and from twenty three male organ 
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donors (56±4 years of age) at the time of harvesting organs for transplantation. 
BOO and prostate enlargement were confirmed by uroflowmetry and 
ultrasonography, respectively. Collected samples were immediately placed at 4-
6°C in mannitol transplantationsolution at 400 mOsm/kg (M-400) not 
supplemented with ATP or adenosine (230 mM mannitol, 15 mM KH2PO4, 43 mM 
K2HPO4·3H2O,15 mM KCl, and 10 mM NaHCO3, pH 7.4) and transported to the 
laboratory. Experiments were performed within the first 24 h after collection, 
which corresponds to the tissue viability window. This study and all its procedures 
were approved by the Ethics Committees of CHP and ICBAS-UP and were 
authorized by the National Transplantation Committee. All BPH patients signed 
an informed consent approved by the Ethics Committee of CHP for using the 
biological material. Regarding deceased organ donation, the legal frame work 
allows the “Presumed Consent” stating that residents in Portugal are consenting 
donors unless the individual previously objected during his or her life. The 
investigation conforms to the principles outlined in The Code of Ethics of the 
World Medical Association (Declaration of Helsinki). 
 
Quantification of ATP and [3H]ACh release. 
After dissecting out the mucosa through cleavage at the lamina propria, 
detrusor muscle strips (~1.5mm x 5mm) were mounted in 3-mL capacity vertical 
perfusion chambers heated at 37°C. The procedures used for labeling the 
preparations and measuring evoked [3H]ACh release were described previously 
(Carneiro et al., 2014; Correia-de-Sa et al., 2006; Duarte-Araújo et al., 2004). 
Briefly, the preparations were superfused with gassed (95% O2 and 5% CO2) 
Tyrode’s solution (pH 7.4) containing (mM): NaCl 137, KCl 2.7, CaCl2 1.8, MgCl2 
1, NaH2PO4 0.4, NaHCO3 11.9, glucose 11.2 and choline 0.001. After a 30 min 
equilibration period, cholinergic neurons were loaded with 1 µM [3H]choline 
(specific activity 2.5 µCi nmol-1) under electrical field stimulation (EFS, 1 Hz-
frequency, 0.5 ms pulse width, 40 V) during 40 min. Washout of the preparations 
was performed for 60 min, by superfusion (15 mL min-1) with Tyrode’s solution 
supplemented with the choline uptake inhibitor, hemicholinium-3 (10 µM). Tritium 
content was measured by liquid scintillation spectrometry (TriCarb2900TR, 
Perkin Elmer, Boston, USA) (% counting efficiency: 58±2%) after appropriate 
background subtraction, using 400-µL bath samples collected automatically 
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every 3 min with a fraction collector (Gilson, FC203B, France). In control 
experiments, aliquots of matched samples were immediately freeze-dried in liquid 
nitrogen and preserved at -80ºC for subsequent ATP quantification by 
bioluminescence using the luciferin-luciferase ATP kit HS II (Roche Applied 
Science, Indianapolis, USA) according to manufacturer’s instructions. 
Luminescence was determined using a multi-detection microplate reader 
(Synergy HT, BioTek Instruments) (Carneiro et al., 2014; Pinheiro et al., 2013; 
Timóteo et al., 2014) . 
[3H]ACh release was evoked by two periods of electrical field stimulation 
(S1 and S2, 200 pulses of 0.5 ms duration delivered at 10 Hz frequency). 
Therefore, the evoked [3H]ACh release was calculated by subtracting the basal 
tritium outflow from the total tritium outflow during the stimulation period  (see 
e.g.(Carneiro et al., 2014; Correia-de-Sá et al., 2006; Duarte-Araújo et al., 2004). 
Likewise, stimulation-evoked release of ATP was calculated by subtracting the 
basal release, measured in the sample collected before stimulation, from the total 
release of the nucleotide determined after stimulus application (Carneiro et al., 
2014; Pinheiro et al., 2013; Timóteo et al., 2014). 
 
Myographic recordings 
Detrusor muscle strips without the mucosa were mounted in 10-mL 
capacity perfusion chambers connected to isometric force transducers. The 
changes in tension were recorded continuously with a PowerLab data acquisition 
system (Chart 5, v.4.2; AD Instruments, USA). Tissues were preloaded with 5 
mN of tension and allowed to equilibrate for 90 min in Tyrode’s solution, at 37ºC. 
To evaluate the inhibitory role of adenosine (0.03-3 mM) and its enzymatically 
stable analogue, 5’-(N-ethylcarboxamide) adenosine (NECA, 0.3-300 µM), on 
detrusor strips contractions induced by ACh (10 µM), these drugs were added to 
the incubation media 6 min before ACh which contacted with the preparations for 
2 min before washout of all drugs. Under these experimental conditions, 
exogenous ACh (0.1-1000 µM) concentration-dependently increased myogenic 
contractions of detrusor strips from control individuals and BPH patients with a 
similar potency (EC50 3 µM); a higher (P<0.05) maximal contraction amplitude 
was achieved in control preparations (4.74±0.46 mN/mg of wet weight, n=8) than 
in obstructed human bladders (2.64±0.27 mN/mg of wet weight, n=14). ACh, 
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applied in the low micromolar concentration range close to the EC50 value, has 
been instrumental to evoke sustained myogenic contractions to investigate the 
effects of detrusor smooth muscle relaxants (see e.g. Parija et al., 1991; Husted 
et al., 1983).  
 
Kinetic of the extracellular catabolism of adenine nucleotides by HPLC 
For the kinetic experiments of the extracellular catabolism of adenine 
nucleotides, detrusor strips without the mucosa were mounted in a 2-mL organ 
bath. All experiments were performed at 37°C. Preparations were superfused 
with gassed (95% O2 and 5% CO2) Tyrode’s solution. After equilibrium, the 
preparations were incubated with 30 µM of ATP or AMP (zero time). Samples of 
75 µl were collected from the organ bath at different times up to 45 min for HPLC 
(with UV detection) analysis (LaChrome Elite, Merck, Germany) of the variation 
of substrate disappearance and product formation (Correia-de-Sá et al., 2006; 
Duarte-Araújo et al., 2004; Vieira et al., 2014). The stoichiometry of ATP and 
AMP conversion into their metabolites was kept unaltered (30 µM). Considering 
that the curvilinear decrease of the initial substrate with time is characteristic of 
first-order kinetics, the half-degradation time was estimated frompolynomial fitting 
of linear semi-logarithmic progress curves of the catabolism of adenine 
nucleotides for each separate experiment (see e.g. Duarte-Araújo et al., 2004).  
  
Immunofluorescence staining and confocal microscopy observation 
Detrusor strips without the mucosa were stretched in all directions and 
pinned onto a Petri dish coated with Sylgard®. The strips were then fixed in PLP 
solution (paraformaldehyde 2%, lysine 0.075 M, sodium phosphate 0.037 M, 
sodium periodate 0.01 M) for 16 h at 4ºC. Sixteen-micron sections were 
incubated with selected primary antibodies (Table 1) diluted in an incubation 
buffer (foetal bovine serum 5%, serum albumin 1%, Triton X-100 0.3% in PBS), 
at 4 ºC, for 16 h. For double immunostaining, antibodies were combined before 
application to tissue samples. After washing away unbound primary antibody, the 
sections were incubated with secondary antibodies in the dark for 2 hours, at 
room temperature. Negative controls were carried out by replacing the primary 
antibodies with non-immune serum; cross-reactivity of the secondary antibodies 
was tested in control experiments in which primary antibodies were omitted. 
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Specificity of primary antibodies used to target human P1 receptors were all 
previously validated in heterologous expression systems according to references 
provided in manufacturers’ websites. Finally, tissue samples were mounted on 
optical-quality glass slides using VectaShield as antifade mounting media 
(VectorLabs) and stored in the dark at 4 ºC. Observations were performed and 
analyzed with a laser-scanning confocal microscope (Olympus FluoView, 
FV1000, Tokyo, Japan). During documentation of detrusor sections from control 
and BPH patients, settings on the confocal microscope were kept unaltered to 
minimize bias. 
 
 
Table 1 – Primary and secondary antibodies used to label human detrusor 
strips 
 
 
Drugs and Solutions 
Acetylcholine, adenosine deaminase (ADA, type VI, 1803 U.mL-1, EC 
3.5.4.4), ATP, ADP, AMP, adenosine, apyrase (from potato, EC 3.6.1.5), EHNA, 
inosine, hemicholinium-3, R-PIA, NECA, DPCPX, choline chloride, 
paraformaldehyde (prills), lysine, sodium periodate, anhydrous glycerol, fetal 
bovine (Sigma, St Louis, MO, USA); dipyridamole (Boehringer Ingelheim, 
Germany); [methyl-3H] Choline chloride (etanol solution, 80.6 Ci.mmol-1) 
Primary Antibodies Code Host Dilution Source 
Anti-VAChT ab69000 Goat (gt) 1:75 Abcam 
Anti-A1 receptor ab75177 Rabbit (rb) 1:250 Abcam 
Anti-A2A receptor sc-13937 Rabbit (rb) 1:75 Santa Cruz 
Anti-A2B receptor ab1589P Rabbit (rb) 1:75 Abcam 
Anti-A3 receptor sc-7508 Goat (gt) 1:50 Santa Cruz 
Secondary Antibodies Code Host Dilution Source 
Alexa Fluor 488 anti-rb A-21206 Donkey 1:1500 Molecular probes 
Alexa Fluor 568 anti-gt A-11057 Donkey 1:1500 Molecular probes 
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(PerkinElmer, Boston, USA); serum albumin, Triton X-100 (Merck,Darmstadt, 
Germany). EHNA was dissolved in a 5 mM stock solution in ethanol. DPCPX was 
dissolved in a 5 mM stock solution in 99% dimethylsulphoxide + 1% NaOH 1M 
(v.v-1). ZM 241385 and R-PIA were dissolved in 5 and 50 mM stock solutions in 
DMSO, respectively. All stock solutions were stored as frozen aliquots at -20ºC. 
Dilutions of these stock solutions were made daily and appropriate solvent 
controls were done.  
 
Presentation of data and statistical analysis 
Results are expressed as mean ± SD, with n indicating the number of 
individuals used for a particular set of experiments. Only one experimental 
procedure (e.g. agonist in the absence and in the presence of the antagonist) 
was performed per individual. Statistical analysis of data was carried out using 
Graph Pad Prism 6.04 for Windows software (La Jolla, USA). Paired and 
unpaired Student’s t-test with Welch’s correction was used for statistical analysis 
when parametric data was considered. One-way analysis of variance (ANOVA) 
followed by the Holm-Sidak correction was used for multiple comparisons. 
P<0.05 (two-tailed) values were considered statistically significant.  
 
RESULTS 
Downregulation of ecto-NTPDase1/CD39 and ecto-5’-nucleotidase/CD73 lead to 
deficient adenosine formation in the detrusor of BPH patients 
Figure 6 illustrates the kinetics of the extracellular catabolism of ATP (30 
µM) and, subsequent, formation of ADP and AMP in mucosal-denuded detrusor 
strips from control individuals and BPH patients. Extracellular ATP (30 µM) was 
hydrolyzed with a half-degradation time of 36±5 min (n=6) in control individuals 
(Figure 6A), but the catabolism of the nucleotide was significantly (P<0.05) slower 
(t½ = 73±16 min, n=5) in detrusor strips from BPH patients (Figure 6B)  In both 
groups, the amount of AMP generated in the extracellular milieu was higher 
(P<0.05) than that of ADP at all time points considered after ATP (30 µM) 
application (Figure 6, panels C and D).  
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Figure 6 – The extracellular catabolism of ATP is slower in mucosal-denuded 
detrusor strips from patients with outflow obstruction due to benign prostatic 
hyperplasia (BPH) as compared to control organ donors (Control). ATP (30 µM) 
was added at zero time to the incubation medium. Samples were collected from the 
incubation fluid at the indicated times on the abscissa and analysed by HPLC with UV 
detection to quantify ATP (filled circles) and its metabolites, ADP (open lozenges) and 
AMP (filled triangles). Average results obtained from six control individuals (panels A and 
C) and five BPH patients (panels B and D); the vertical bars represent SD and are shown 
when they exceed the symbols in size. 
 
This pattern suggests a dominant involvement of ecto-NTPDase1/CD39 
(also called ATP diphosphohydrolase or apyrase, EC 3.6.1.5) converting 
extracellular ATP directly into AMP, removing two phosphate at a time with almost 
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no release of the intermediate ADP. As a matter of fact, the activity of ecto-
NTPDase1/CD39 calculated 5-min after ATP (30 µM) application by the ratio of 
[AMP]:[ATP+ADP] per min decreased (P<0.01) from 11.40±0.85 x10-3 (n=6) in 
control subjects to 6.94±0.53 x10-3 (n=5) in BPH patients, while up to this time 
point no ADP could be detected in incubation media (Figure 6, panels C and D).  
Figure 7 shows that extracellular AMP (30 µM) is subsequently 
dephosphorylated into adenosine, inosine and hypoxanthine in the human 
detrusor. Interestingly, hydrolysis of AMP (30 µM) to adenosine and inorganic 
phosphate by ecto-5’-nucleotidase/CD73 (EC 3.1.3.5) was significantly (P<0.05) 
diminished in bladder samples from BPH patients (t½ = 79±7 min, n=5; Figure 
7B) compared to control individuals (t½ = 45±4 min, n=5; Figure 7A). Impairment 
of the extracellular AMP (30 µM) catabolism in the detrusor of BPH patients led 
to a significant (P<0.01) decrease in adenosine formation (Figure 7D) compared 
to control individuals (Figure 7C); this difference reached a maximum of 
4.14±0.58 µM (n=5) at 10-min incubation time which diminished thereafter. The 
decrease in the rate of adenosine formation from extracellular AMP was also 
accompanied by a deficient generation of inosine resulting from the irreversible 
deamination of adenosine catalyzed by ecto-adenosine deaminase (ecto-ADA, 
also known as adenosine aminohydrolase, EC 3.5.4.4) (Figure 7, panels C and 
D). Inosine was then deribosylated by purine nucleoside phosphorylase (EC 
2.4.2.1) leading to small amounts of hypoxanthine.  
All together these results indicate that adenosine formation from the 
extracellular catabolism of adenine nucleotides is impaired in the detrusor of BPH 
patients due to deficient activity of both ecto-NTPDase1/CD39 and ecto-5’-
nucleotidase/CD73. 
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Figure 7 – The kinetics of extracellular AMP dephosphorylation is slower in 
mucosal-denuded detrusor strips from patients with outflow obstruction due to 
benign prostatic hyperplasia (BPH) as compared to control organ donors 
(Control). AMP (30 µM) was added at zero time to the incubation medium. Samples 
were collected from the incubation fluid at the indicated times on the abscissa and 
analysed by HPLC with UV detection to quantify AMP (filled triangles) and its 
metabolites, adenosine (ADO, open squares), inosine (INO, filled squares) and 
hypoxanthine (HX, filled lozenges). Average results obtained from five individuals of 
each group, control (panels A and C) and BPH (panels B and D); the vertical bars 
represent SD and are shown when they exceed the symbols in size 
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Exogenous NTPDase1/CD39 (apyrase) re-adjusts cholinergic nerve 
hyperactivity to control levels in the detrusor of BPH patients 
Electrical field stimulation of detrusor strips increases the outflow of 
[3H]ACh above the basal level (Figure 8). Prevention of the evoked tritium outflow 
in the absence of calcium (Ca2+Æ + EGTA, 1 mM) and in the presence of 
tetrodotoxin (1 µM) indicates that [3H]ACh release results from vesicle exocytosis 
of depolarized nerve terminals (data not shown). The amount of [3H]ACh released 
from stimulated cholinergic nerves during S1 was 1.5-fold higher (P<0.001) in the 
detrusor of BPH patients (27.6±2.7 x 103 DPM.g-1 of wet tissue weight, n=12) 
than in control organ donors (11.1±0.2 x 103 DPM.g-1 of wet tissue weight, n=14). 
In some of the experiments we measured in parallel the ATP content of collected 
samples. Electrical stimulation of detrusor strips from BPH patients produced 2.5-
fold higher (P<0.001) amounts of ATP in the incubation fluid (4.9±0.4 pM, n=4) 
than those observed in control individuals (1.4±0.2 pM, n=8). Exogenously added 
apyrase (2 U.mL-1), the enzyme that catalyses ATP inactivation into AMP 
bolstering the formation of adenosine, decreased [3H]ACh release from 
stimulated cholinergic nerves. The inhibitory effect of apyrase (2 U.mL-1) was 
more evident (P<0.05) in detrusor strips from BPH patients (18±6%, n=4) than 
from control subjects (2±4%, n=4), i.e. in conditions where extracellular ATP 
accumulation was higher (Figure 8).  
 
Adenosine A1 receptors located on cholinergic nerve endings play a dominant 
role to reduce detrusor activity in the human bladder  
Despite the observation that adenosine is able to relax pre-contracted 
detrusor strips from the human bladder (Rubinstein et al., 1998), we found that 
this is only valid for concentrations of the nucleoside in the millimolar range 
(Figure 9). 
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Figure 8 - Effects of apyrase on electrically-evoked [3H]ACh release from 
urothelium-denuded detrusor strips from control individuals (A) and patients with 
outflow obstruction due to BPH (B). Tritium outflow (ordinates) is expressed as a 
percentage of the total radioactivity present in the tissue at the beginning of the collection 
period (Fractional release, %) (see e.g. (Duarte-Araújo et al., 2004). Abscissa indicates 
the times at which samples were collected. [3H]ACh release was elicited by electrical 
field stimulation (10 Hz, 200 pulses of 0.5 ms duration) twice, starting at 12th (S1) and 
39th (S2) minutes after the end of washout (zero time). Apyrase (2 U.mL-1, closed circles) 
was added to the incubation media 15 min before S2 (horizontal bar). The vertical bars 
represent SD of four different individuals. *P<0.05 (unpaired Student’s t-test with Welch’s 
correction) represent significant differences when compared to the situation without 
apyrase. Note that the spontaneous tritium outflow was not changed in the presence of 
apyrase.  
 
In our hands, adenosine reduced acetylcholine (10 µM) induced 
contractions of BPH patient’s detrusor only when it was applied in a 3 mM 
concentration (Figure 9B), but not when the nucleoside was tested in lower 
(eventually more physiological) amounts (30 and 300 µM). The enzymatically 
stable adenosine analogue, NECA (0.3-300 µM), which activates preferentially 
A2 receptors (IC50 ~ 16 nM), was unable to cause relaxation of the pre-contracted 
human detrusor (Figure 9A and 9B), notwithstanding the fact that A2A and/or A2B 
subtypes are considered the most expressed receptors in the detrusor smooth 
muscle (Dixon et al., 1996; Owen et al., 2012). Water solubility limitation 
precluded the use of millimolar concentrations of NECA.  
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Figure 9 – Adenosine and its stable analogues, NECA and R-PIA, preferentially 
activates DPCPX-sensitive inhibitory A1 receptors on cholinergic nerve terminals 
of the human detrusor and their potency increase in patients with outflow 
obstruction due to benign prostatic hyperplasia (BPH) as compared to controls. 
(A) Shows myographic recordings of mucosal-denuded detrusor strips from BPH 
patients. Contractile responses were elicited by ACh (10 µM) applied either in the 
absence or in the presence of NECA (0.3-300 µM) and adenosine (30-3000 µM), which 
concentration-response curves are shown in (B). The vertical bars represent SD of an n 
number of individuals. *P<0.05 (unpaired Student’s t-test with Welch’s correction) 
represent significant differences when compared to the control situation without any drug 
added (100%, horizontal dashed line). (C) Effects of NECA (1 µM) and adenosine (100 
µM) on electrically-evoked [3H]ACh release from mucosal-denuded detrusor strips of 
BPH patients; NECA (1 µM) and adenosine (100 µM) were added to the incubation 
media 15 min before S2 (horizontal bar). The vertical bars represent SD of four different 
individuals. (D) Shows the inhibitory effects of NECA (1 µM) and R-PIA (300 nM) on 
electrically-evoked [3H]ACh release from detrusor strips of organ donors (control) and 
BPH patients in the absence and in the presence of DPCPX (100 nM); the selective A1 
receptor antagonist was present throughout the assay, including S1 and S2. The 
ordinates are changes in S2/S1 ratios compared to the S2/S1 ratio obtained without 
addition of any drug. The data are means ± SD of four to six individuals. #,*P<0.05 
(unpaired Student’s t-test with Welch’s correction) represent significant differences when 
compared to control individuals or to the situation where the adenosine analogue was 
tested in the absence of DPCPX, respectively. 
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Figure 9 (panels C and D) also shows that adenosine (100 µM) and its 
analogues, NECA (1 µM) and R-PIA (0.3 µM, a selective A1 receptor agonist), 
inhibit [3H]ACh release from stimulated cholinergic nerves of the human detrusor, 
when these drugs were used in concentrations unable to cause relaxation of 
myogenic contractions induced by acetylcholine (10 µM, EC50~3 µM). The 
inhibitory effects of NECA (1 µM) and R-PIA (0.3 µM) were of higher magnitude 
in BPH patients than in control individuals (Figure 9D). Likewise, the native 
compound adenosine (100 µM) diminished nerve-evoked [3H]ACh release by 
9±8% (n=5, P>0.05) and 39±2% (n=5, P<0.05) in the detrusor of control organ 
donors and BPH patients, respectively. The selective A1 receptor antagonist, 
DPCPX (100 nM), significantly (P<0.05) attenuated the inhibitory effects of NECA 
(1 µM) and R-PIA (0.3 µM) on evoked [3H]ACh release (Figure 9D), thus 
suggesting that A1 receptors located on cholinergic nerve endings exert a 
dominant effect to reduce detrusor hyperactivity in the human bladder. 
The immunolocalization studies shown in Figure 10A suggest that A1 and 
A2A are the most expressed receptors in the human detrusor, whereas 
immunoreactivity of A2B and A3 receptors is less evident. Co-localization 
experiments show for the first time a differential distribution of the A1 receptor, 
which is localized preferentially on vesicular acetylcholine transporter (VAChT)-
positive cholinergic nerves (Figure 10B), whereas the A2A receptor is diffusely 
expressed on smooth muscle fibers of the human detrusor (Figure 10A, panel E). 
Interestingly, the A1 receptor immunolabelling becomes more intense in the 
detrusor of obstructed BPH patients as compared to control individuals (Figure 
10A, respectively panels A and C). The relative increase in A1 receptor 
immunoreactivity in the detrusor of obstructed BPH patients was not evidenced 
for any other P1 receptor subtype.    
 
Inhibition of adenosine uptake and/or deamination rehabilitates the A1 receptor 
inhibitory tonus in the detrusor of BPH patients 
To study the net tonic inhibitory effect of endogenous adenosine on 
[3H]ACh release from stimulated cholinergic nerves of the human detrusor, we 
tested the effect of adenosine deaminase (ADA, 0.5 U.mL-1), the enzyme that 
inactivates adenosine by converting it into inosine (Arch & Newsholme, 1978a). 
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In contrast to apyrase (2 U.mL-1) that catalyses ATP metabolism into AMP 
bolstering the formation of adenosine (see also Figure 8), ADA (0.5 U.mL-1) had 
virtually no effect (P>0.05) on evoked [3H]ACh release from the human detrusor 
(Figure 11). 
 
Figure 10 – (A) Confocal micrographs showing the immunoreactivity against A1, 
A2A, A2B and A3 receptors in transverse sections of the detrusor from organ donors 
(control) and BPH patients. A1, A2A, A2B and A3 receptor immunoreactivity is shown in 
green. Images are representative of five individuals per group, Control and BPH. A1 and 
A2A are the most expressed receptors in the human detrusor (panels A-H), whereas 
immunoreactivity of A2B and A3 receptors is only vestigial (panels I-P). The A1 receptor 
immunolabelling is more evident (arrows) in the detrusor of obstructed BPH patients 
(panel C) as compared to controls (panel A). Scale bars = 50 µm. (B) Co-localization 
experiments show that the A1 receptor is localized with VAChT in cholinergic nerve 
terminals; yellow staining denotes co-localization.Fluorescence intensity plots drawn 
from lines crossing regions of interest delineated in the overlay image clearly evidence 
co-localization of A1 receptors (green) and VAChT-positive (red) cholinergic nerve 
terminals. (C) Cross-reactivity of secondary antibodiesin control experiments in which 
primary antibodies were omitted(see Table 1). Differential interference contrast (DIC) 
images are also shown for comparison.    
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Discrepancies between the effects of ADA (0.5 U.mL-1) and apyrase (2 
U.mL-1) prompted us to evaluate whether the A1-receptor-mediated inhibitory 
control of [3H]ACh release from stimulated cholinergic nerves could emerge by 
favoring endogenous adenosine accumulation in the human detrusor with 
dipyridamole (0.5 µM, a nucleoside uptake blocker) (Griffith & Jarvis, 1996) or 
EHNA (50 µM, an adenosine deaminase inhibitor) (Agarwal et al., 1977). These 
drugs reduced [3H]ACh release from stimulated cholinergic nerve terminals. The 
inhibitory effects of adenosine uptake and deamination blockers were not 
significantly (P>0.05) different in bladders from control individuals and BPH 
patients (Figure 11). Pretreatment with the selective A1 receptor antagonist, 
DPCPX (100 nM), abolished the inhibitory effects of both dipyridamole (0.5 µM, 
9±6%, n=4) and EHNA (50 µM, 7±1%, n=5) on evoked [3H]ACh release from 
detrusor strips of BPH patients, indicating that their effects are indeed mediated 
by increases in the extracellular concentration of adenosine leading to activation 
of membrane-bound A1 inhibitory receptor.  
 
 
DISCUSSION 
It is widely accepted that purines, in particular ATP, are involved in a 
number of physiological processes in the lower urinary tract. ATP was shown (i) 
to be a co-transmitter with ACh in the parasympathetic control of bladder 
contraction (Burnstock et al., 1972), (ii) to activate sensory nerves during bladder 
filling conveying both normal and abnormal sensations like urgency and pain 
(Aizawa et al., 2011; Birder & Andersson, 2013), and (iii) to participate in the 
central control of bladder reflexes (Rocha et al., 2001). However, not so much is 
known about the effects of adenosine, the breakdown product of extracellular 
ATP metabolism. First reports of the effect of adenosine in the lower urinary tract 
suggested that it reduces the tone and spontaneous activity of the guinea-pig 
urinary bladder (Burnstock et al., 1978b; Burnstock et al., 1972). 
ATP release from both neuronal and non-neuronal cells (e.g. urothelial 
cells, interstitial cells, fibroblast-like cells, smooth muscle fibers) and its 
extracellular metabolism into adenosine has been observed in the urinary bladder 
of rodents (Cusack & Hourani, 1984; Yu et al., 2011; Zhang et al., 1991). Roughly 
50% of the extracellular adenosine results from the breakdown of ATP (Smith & 
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Lu, 1991) which is currently regarded to be the most important route of generating 
extracellular adenosine (Zhang & Xia, 2012). 
 
 
Figure 11 – Effects of adenosine deaminase (ADA), apyrase, erythro-9-(2-hydroxy-
3-nonyl)adenine (EHNA) and dipyridamole (Dipy) on electrically-evoked [3H]ACh 
release from urothelium-denuded detrusor strips from cadaveric organ donors 
(control) and BPH patients. ADA (0.5 U.mL-1), apyrase (2 U.mL-1), EHNA (50 µM) and 
Dipy (0.5 µM) were applied 15 min before S2. The ordinates are changes in S2/S1 ratios 
compared to the S2/S1 ratio obtained without addition of any drug. The data are means 
± SD of four to six individuals. *,#P<0.05 (unpaired Student’s t-test with Welch’s 
correction) represents significant differences when compared with zero percent of 
change or with the effect of the same drug in control individuals, respectively. 
 
Using mucosal-denuded human detrusor strips, we show here that in 
control conditions the ecto-NTPDase1/CD39 enzyme exerts a dominant role 
converting ATP directly into AMP, which is then sequentially hydrolyzed into 
adenosine and inosine by ecto-5’-nucleotidase/CD73 and ecto-adenosine 
deaminase, respectively. Despite the distribution of ectonucleotidase subtypes 
may present specificities among species and differ within the various layers of 
the bladder wall, immunofluorescence studies in the mouse showed that ecto-5’-
nucleotidase/CD73 is present exclusively in the detrusor smooth muscle together 
with ecto-NTPDase1/CD39 (Yu et al., 2011). Data from a previous study 
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demonstrated that adenosine formation from extracellular ATP is negligible in 
isolated epithelial cells from the human urinary tract (Mohlin et al., 2009). This 
layout suggests that biosynthesis of adenosine from released ATP is positioned 
to favor a more important role of the nucleoside in suburothelial and detrusor 
muscle layers as compared to the urothelium where ecto-5’-nucleotidase/CD73 
is almost absent if one excludes the basal cell layer (Yu et al., 2011); see also 
preliminary results in the human bladder in ref. (Correia-de-Sá, 2010). 
Adenosine is a homeostatic metabolite in most organic systems mainly 
because it regulates neuronal excitability, vasodilation, smooth muscle 
relaxation, and release of vasoactive and neuroactive substances (Burnstock, 
2014; Sheth et al., 2014); the nucleoside is also protective against ischemic and 
inflammatory insults. Therefore, we hypothesized that deficits in adenosine 
formation from released adenine nucleotides along with lifetime increments of 
ATP could contribute to detrusor overactivity in BPH patients. Deterioration of 
bladder neuromodulatory control has been hypothesized to explain the increase 
on nerve-evoked detrusor contractions in obstructed patients (Kosan et al., 
2008). We show here that detrusor strips from BPH patients release higher 
amounts of ATP and ACh when stimulated electrically. The greater purinergic 
tone observed in detrusor strips from obstructed BPH patients (see also Bayliss 
et al., 1999) may be partially related to the impairment of ecto-NTPDase1/CD39 
activity, thus limiting the breakdown of ATP released from bladder nerves and/or 
the urothelium; a situation that is in agreement with data from several pathological 
bladder conditions (Harvey et al., 2002). In this study, we expanded this concept 
by demonstrating that decreased activity of ectonucleotidases impacts on 
endogenous adenosine formation and, thus, on the inhibitory P1 receptors tonus 
of the human bladder. In parallel to the slower kinetics of the extracellular ATP 
catabolism, we demonstrated that AMP dephosphorylation leading to adenosine 
formation via ecto-5’-nucleotidase/CD73 was significantly decreased in bladder 
samples from obstructed BPH patients as compared to control individuals.  
Several authors have shown that adenosine directly relaxes pre-
contracted urinary bladder detrusor strips in different species (Acevedo et al., 
1992; Brown et al., 1979; Burnstock et al., 1978a; King et al., 1997; Nicholls et 
al., 1992), including humans (Rubinstein et al., 1998). However, our results 
clearly indicate that adenosine-induced relaxation of detrusor contractions 
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requires high (unphysiological) millimolar concentrations of the nucleoside. On 
the contrary, our findings show that inhibition of nerve-evoked ACh release by 
adenosine and its stable analogues, NECA and R-PIA, was 30-times more potent 
than the relaxing effects of the nucleoside on ACh-induced detrusor contractions. 
Involvement of the A1 receptor in the inhibitory action of adenosine and its 
analogues on transmitter release from the stimulated human detrusor was 
suggested by the selective blockade of their effects with DPCPX. 
Immunolocalization confocal microscopy data demonstrate for the first time that 
VAChT-positive cholinergic nerves are endowed with A1 receptors, whereas the 
A2A receptor is diffusely expressed on smooth muscle fibers of the human 
detrusor. A1 receptor immunostaining is more intense in the detrusor of 
obstructed BPH patients as compared to control individuals, which may be 
caused in reaction to long-term deficits of adenosine formation from the 
catabolism of released ATP (see above). Thus, up-regulation of A1 receptors on 
cholinergic nerves innervating the detrusor may contribute to explain the 
increased inhibitory sensitivity of nerve-evoked [3H]ACh release to exogenous 
adenosine receptor agonists in bladders from BPH patients.  
The way adenosine builds its influence to control cells communication 
depends on the extracellular concentration of the nucleoside, which is achieved 
by balancing extracellular formation and inactivation mechanisms, both cellular 
uptake via equilibrative nucleoside transporters and/or extracellular deamination 
into inosine by adenosine deaminase (Correia-de-Sá & Ribeiro, 1996; Gonçalves 
& Queiroz, 1993). Given the disparity between deficits in the adenosine-mediated 
tone (detected by the lack of effect of ADA on evoked [3H]ACh release) and up-
regulation of inhibitory A1 receptors expression in the detrusor of BPH patients, 
we evaluated whether the A1-receptor-mediated control of [3H]ACh release could 
be rehabilitated by favoring adenosine accumulation with inhibitors of the 
nucleoside uptake system and adenosine deaminase. We concluded that both 
dipyridamole and EHNA might be useful for decreasing cholinergic nerve 
hyperactivity in patients with obstructed bladder due to BPH. Taking into 
consideration that there are differences in the potency of activation of pre-
synaptic A1 receptors on cholinergic nerves and A2A receptors on smooth muscle 
fibers, prolongation of endogenous adenosine lifetime may be clinically safe 
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because it would hardly affect detrusor contractile tension that is essential to 
overcome outlet pressure during voiding in BPH patients.        
Interestingly, in vivo cystometry experiments performed in the rat showed 
that both NECA and R-PIA administered intrathecally delayed the voiding reflex 
(Sosnowski & Yaksh, 1990). Moreover, prolongation of the intercontraction 
interval without affecting the amplitude of micturition was also observed when A1 
receptor agonists were applied into the lumen of the urinary bladder (Kitta et al., 
2014). Overall, these findings suggest that adenosine controls the micturition 
cycle by acting predominantly on the nervous circuitry, both central and 
peripheral, without significantly affecting the voiding pressure that would result in 
urinary retention.  
We are aware of possible limitations of the current study which may be 
attributed to age-related variance in the bladder cholinergic and purinergic tone 
among BPH patients (62±6 years of age) and the slightly younger control group 
(56±4 years of age). Although we did not explore the urological status of control 
men before harvesting the tissue, care was taken to prevent inclusion of 
individuals in the control group with past history of LUTS, as far as we could 
perceive from the clinical records of the intensive care unit and from interviewing 
close relatives. Yoshida et al. (2001) demonstrated age-related increases and 
decreases respectively in purinergic and cholinergic contractions of stimulated 
strips of the bladder of patients undergoing total cystectomy due to bladder 
carcinoma, but they also did not attempt to define if the patients had any kind of 
bladder dysfunction (Yoshida et al., 2001). We show here that electrical-
stimulation of detrusor strips from BPH patients release 2.5-times more ATP than 
control preparations, which is in agreement with the purinergic neurotransmission 
changes detected in obstructed bladder patients using myographic recordings 
(Saito et al., 1997). Controversy however exists concerning the negative 
correlation between age and the cholinergic neurotransmission (Yoshida et al., 
2004), because we observed a 1.5-fold increase rather than a decrease in 
evoked ACh release from the bladder of BPH patients, meaning that age-related 
changes cannot be the sole factor contributing to modifications in the bladder 
function among BPH patients and younger controls. 
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In conclusion, data from this study show for the first time that impairment 
of ecto-NTPDase1/CD39 activity unbalances extracellular ATP accumulation and 
endogenous adenosine formation leading to increased neuronal excitation in 
mucosal-denuded detrusor strips from BPH patients. While extracellular ATP 
accumulation may contribute to hyperexcitation of suburothelial nerve afferents 
via P2X3 receptors and to detrusor reactivity via P2X1 subunit-containing 
receptors, our study demonstrates that deficits in adenosine formation may also 
play a role in generating symptoms of bladder dysfunction in BPH patients. The 
loss of the inhibitory tone exerted by prejunctional A1 receptors on ACh release 
from stimulated cholinergic nerves in the detrusor may, thus, be a target for 
therapeutic intervention of bladder dysfunctions associated with outflow 
obstruction due to BPH. Evidence for the therapeutic potential of adenosine A1 
receptor activation to decrease acetic acid-induced bladder overactivity has been 
recently gathered using anesthetized rats (Kitta et al., 2014).   
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ABSTRACT 
Objective: This study was designed to investigate the role of ATP on 
cholinergic neurotransmission in human detrusor strips isolated from control 
individuals and from obstructed patients due to BPH.  
Methods: Human detrusor samples were collected from 41 patients 
submitted to transvesical prostatectomy due to BPH and 26 male cadaveric organ 
donors.  Urothelium-denunded detrusor strips were loaded with [3H]-choline and 
the release of [3H]ACh release was evoked by two periods of electrical field 
stimulation (10 Hz, 200 pulses of 1 ms duration). We also performed myographic 
recordings using isolated human detrusor strips to compare the magnitude of 
ACh- and ATP-induced bladder contractions in the two groups of individuals.  
Results: Desensitization of ionotropic P2X1-3 receptors with the 
enzymatically-stable ATP analogue, a,b-MeATP (30 µM, applied for 15 min), 
significantly reduced the release of [3H]ACh from stimulated detrusor strips by 
14±6% and 52±7% in control individuals and BPH patients, respectively. 
Likewise, blockade of P2X receptors with PPADS (10 µM, a non-selective 
antagonist), TNP-ATP (10 nM, a preferential P2X2/3 antagonist) and A317491 
(100 nM, a selective P2X3 antagonist) decreased nerve-evoked [3H]ACh release 
by 6±8%, 27±9% and 20±2%, respectively, in control individuals. The inhibitory 
effects of PPADS (10 µM) and TNP-ATP (10 nM) were amplified to 43±6% and 
43±6%, respectively, in the bladder of BPH patients, whereas A317491 (100 nM)-
induced inhibition of transmitter release was kept unaltered (24±4%). Myographic 
recordings using epithelum-denuded detrusor strips showed that while the 
contractile activity of ACh (100 µM) decreased (p<0.05) from 4.74±0.46 mN 
(n=12) in control individuals to 2.64±0.27 mN (n=24) in BPH patients, ATP (3 
mM)-induced contractions of the detrusor increased in BPH patients (1.13±0.24 
mN, n=6) compared to controls (0.16±0.05 mN, n=6). 
Conclusion: Data suggest that besides the well–characterized P2X1 
receptor-mediated contractile activity of ATP in the human detrusor, 
endogenously released ATP facilitates the release of ACh from stimulated 
cholinergic nerve terminals through the activation of prejunctional P2X2/3 
receptors. We also show here for the first time that the dual excitatory role of ATP 
at the cholinergic neuromuscular junction of the human bladder is exagerated in 
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obstructed patients due to BPH, leading us to hypothesize that it might contribute 
to detrusor overactivity and storage symptoms often seen in patients. 
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INTRODUCTION  
Detrusor dysfunction associated with BOO can be a significant cause of 
LUTS. BOO can lead to detrusor overactivity and reduced bladder compliance 
causing storage-phase symptoms, and/or detrusor underactivity that causes 
further deterioration of voiding symptoms (Mirone et al., 2007). Detrusor 
overactivity has an huge impact on quality of life and can be found in half to two 
thirds of patients with clinically-dignosed BPH (Mirone et al., 2007). The fact that 
the prevalence of detrusor overactivity is reduced by 50% after prostatic surgery 
(Abrams et al., 1979), suggests that it is caused (at least in part) by obstruction. 
Despite this notion, the mechanisms underlying detrusor overactivity caused by 
obstruction are largely unknown (Andersson, 2003). Detrusor underactivity, 
which usually appears at the end stage of bladder dysfunction due to obstruction, 
is defined by the International Continence Society as a contraction of reduced 
strength and/or duration resulting in prolonged and incomplete emptying of the 
bladder. Although, a bit forgotten from the scientific literature, this aspect of the 
bladder physiology is gaining increased attention (van Koeveringe et al., 2011). 
Detrusor underactivity has been associated with age (Van Mastrigt & Rollema, 
1992) and its prevalence is thought to be increasing due to ageing of the 
population. Until now, treatment is based on catheterization and there is no 
effective drug therapeutic available. 
Nowadays, there is a considerable bulk of evidence supporting a role of 
purines in the pathophysiology of detrusor overactivity and in detrusor changes 
due to BOO (Burnstock, 2011). In humans, normal detrusor contraction is 
exclusively under cholinergic control since it is fully blocked by atropine (Fry et 
al., 1999). However, in hypertrophic bladders secondary to prostatic obstruction 
there is some degree of atropine resistance (Bayliss et al., 1999; Sjogren et al., 
1982). Atropine-resistant contractions have been attributed to ATP, since they 
are blocked by desensitisation of ionotropic P2X receptors with the ATP stable 
analogue, α,β-methylene ATP (Bayliss et al., 1999). Despite these evidences, 
the importance of the purinergic component of detrusor contraction varies 
significantly between species (Ford et al., 2006; Wust et al., 2002) and changes 
in cholinergic and purinergic component in response to obstruction may differ 
substantially between rodents and man. In rodents and rabbits, the ATP-
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mediated component has an important role in normal bladder contraction, but it 
does not seem to be exaggerated in obstructed (Banks et al., 2006) and 
neurogenic (Yokota & Yamaguchi, 1996) bladders, rendering these models less 
suitable for studying (purinergic) detrusor changes after BOO. 
It has been attributed to ATP a prominent role in detrusor contractions in 
men with BPH, essentially by evoking more powerful smooth muscle contractions 
and by being credited its responsability for atropine-resistant contractions in 
these patients (Bayliss et al., 1999). This has been partially attributed to 
decreased ecto-ATPase activity (Harvey et al., 2002) leading to reduced 
inactivation and, thus, increased lifetime of ATP released by the urothelium and 
bladder efferent nerves. Purinergic component strengthening can also be 
explained by showing that ATP is released in higher amounts in obstructed than 
in control bladders, as we did in a recent report using urothelium-denuded 
detrusor strips stimulated electrically (Silva-Ramos et al., 2010; Silva-Ramos et 
al., 2015a).  
Besides its action as a neurotransmitter/co-transmitter in several 
myoneural junctions, ATP can act presynaptically as a neuromodulator 
controlling the release of ACh and other neurotransmitters in several tissues 
(Duarte-Araújo et al., 2009; Ribeiro et al., 1996). The neuromodulatory role of 
ATP has been demonstrated in the bladder of rats and pigs (D'Agostino et al., 
2012; King et al., 1997). In porcine detrusor stimulated electrically, ATP facilitated 
cholinergic neurotransmission via the activation of presynaptic P2X3 receptors 
(D'Agostino et al., 2012). These authors showed that the ATP-mediated 
neuromodulation was significantly increased by blocking the nucleotide 
breakdown with the ecto-ATPase inhibitor, ARL67156. In a recent report, our 
group showed that pathological deficits of detrusor ATP inactivation observed in 
BPH patients are responsible for extracellular ATP accumulation and decreased 
adenosine formation resulting in cholinergic hyperexcitation of the human 
bladder. While in the previous study we focused our attention on the deficient 
adenosine tonus and, subsequent, downregulation of A1-mediated inhibition of 
ACh release (Silva-Ramos et al., 2015a), the pre-synaptic repercussion of 
surplus ATP accumulation at the cholinergic neuromuscular synapse remains to 
be determined in the human detrusor. In this context, the present study was 
designed to investigate the role of ATP on nerve-evoked ACh release from 
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human detrusor strips isolated from control individuals and from BPH patients. 
Filling this gap in our knowledge may provide novel targets for therapeutic 
intervention in detrusor overactivity and/or underactivity secondary to BOO.  
 
MATERIALS AND METHODS 
Tissue collection.  
 Samples of human detrusor were collected from the bladder dome of 41 
patients with bladder outlet obstruction (BOO) due to BPH during transvesical 
prostatectomy (aged 71±7 years) and from 26 male cadaveric organ donors 
without known lower urinary tract pathology (aged 50±17 years). BOO and 
prostate enlargement were confirmed by uroflowmetry and ultrasonography, 
respectively. Collected samples were immediately placed at 4-6°C in mannitol 
transplantation solution at 400 mOsm/kg (M-400) not supplemented with ATP or 
adenosine (230 mM mannitol, 15 mM KH2PO4, 43 mM K2HPO4·3H2O,15 mM KCl, 
and 10 mM NaHCO3, pH 7.4) and transported to the laboratory. Experiments 
were performed within the first 24 h after collection, which corresponds to the 
tissue viability window. This study and all its procedures were approved by the 
Ethics Committees of CHP and ICBAS-UP and were authorized by the National 
Transplantation Committee. All BPH patients signed an informed consent 
approved by the Ethics Committee of CHP for using the biological material. 
Regarding deceased organ donation, the legal frame work allows the “Presumed 
Consent” stating that residents in Portugal are consenting donors unless the 
individual previously objected during his or her life. The investigation conforms to 
the principles outlined in The Code of Ethics of the World Medical Association 
(Declaration of Helsinki). 
 
[3H]ACh release experiments.  
 Human detrusor strips (~1.5mm x 5mm) were mounted in vertical 
superfusion organ baths. The procedures used for labeling the preparations and 
measuring evoked [3H]ACh release followed the previously described protocol 
with minor modifications (Correia-de-Sá et al., 1991). After a 30 min equilibration 
period, cholinergic nerve terminals were labeled for 40 min with 1 mM [3H]-choline 
(specific activity 2.5 mCi nmol-1) under electrical stimulation (EFS, 1-Hz 
frequency, 1-ms pulse width). Washout of the preparations was performed during 
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60 min, by superfusion (15 ml min-1) with Tyrode’s solution supplemented with 
choline uptake inhibitor, hemicholinium-3 (10 µmol L-1). Tritium outflow was 
evaluated by liquid scintillation spectrometry (TriCarb2900TR, Perkin Elmer, 
Boston, USA) (% counting efficiency: 55±2%) after appropriate background 
subtraction, using 400-µL bath samples collected automatically every 3 min with 
a fraction collector (Gilson, FC203B, France). [3H]ACh release was evoked by 
two periods of electrical field stimulation (S1 and S2, 200 pulses of 0.5 ms duration 
delivered at 10 Hz frequency). Therefore, the evoked [3H]ACh release was 
calculated by subtracting the basal tritium outflow from the total tritium outflow 
during the stimulation period (see e.g.Carneiro et al., 2014; Correia-de-Sá et al., 
2006; Duarte-Araújo et al., 2004). 
 Test drugs were added 15 min before S2 and were present until the end of 
the experiments. The change in the ratio between the evoked [3H]ACh release 
during the two stimulation periods (S2/S1) relative to that observed in control 
situations (in the absence of test drugs) was taken as a measure of the effect of 
the tested drugs.  
 
Myographic recordings. 
 Detrusor muscle strips without the mucosa were mounted in 10-mL 
capacity perfusion chambers connected to isometric force transducers. The 
changes in tension were recorded continuously with a PowerLab data acquisition 
system (Chart 5, v.4.2; AD Instruments, USA). Tissues were preloaded with 5 
mN of tension and allowed to equilibrate for 90 min in Tyrode’s solution, at 37ºC.  
Contractile responses were elicited by cumulative applications of ACh (0.1-100 
µM) or ATP (0.01-3 mM).  
 
Immunofluorescence staining and confocal microscopy observation 
Detrusor samples fragments were fixed in PLP solution 
(paraformaldehyde 2%, lysine 0.075 M, sodium phosphate 0.037 M, sodium 
periodate 0.01 M) for 16 h at 4 ºC. Fixed tissue was cryoprotected with a solution 
containing 20% anhydrous glycerol dissolved in 0.1 M phosphate buffer, frozen, 
sectioned (16 µm) and incubated with a blocking buffer solution consisting in 
foetal bovine serum 10%, bovine serum albumin 1%, Triton X-100 0.3% in PBS, 
for 2 h with constant stirring. After blocking and permeabilization, samples were 
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incubated with rabbit anti-P2X1 primary antibody (1:50; Alomone #APR-001, 
Jerusalem, Israel) diluted in the incubation buffer (foetal bovine serum 5%, serum 
albumin 1%, Triton X-100 0.3% in PBS), at 4 ºC, for 16 h. After washing away 
unbound primary antibody, the sections were incubated with donkey anti-rabbit 
IgG secondary antibody (1:1000; Alexa fluor 488, #A-21206, Invitrogen) in the 
dark for two hours, at room temperature. Finally, tissue samples were mounted 
on optical-quality glass slides using VectaShield with DAPI as mounting media 
(VectorLabs) and stored in the dark at 4 ºC. Observations were performed and 
analyzed with a laser-scanning confocal microscope (Olympus FluoView, 
FV1000, Tokyo, Japan). 
 
Drugs and Solutions.    
Hemicholinium-3, choline chloride and pyridoxal phosphate-6-azo 
(benzene-2,4-disulfonic acid) tetrasodium salt hydrate (PPADS) were from Sigma 
(St Louis, MO, USA.); ATP, α,β-methylene ATP, 2',3'-O-(2,4,6-
Trinitrophenyl)adenosine-5'-triphosphate tetra(triethylammonium) salt (TNP-
ATP), 6-N,N-diethyl-d-β,γ-dibromomethylene ATP trisodium salt (ARL67156), 5-
[[[(3-phenoxyphenyl) methyl] [(1S)-1,2,3,4-tetrahydro-1-naphthalenyl] amino] 
carbonyl]-1,2,4-benzenetricarboxylic acid sodium salt hydrate) (A317491), 8,8'-
[carbonylbis(imino-3,1-phenylenecarbonylimino)]bis-1,3,5-naphthalene-
trisulphonic acid hexasodium salt (NF023) were obtained from Tocris Bioscience 
(Bristol, UK); [methyl3H]choline chloride (in ethanol, 85.5 Ci.mmol-1) was from 
Perkin Elmer (Boston,USA); PPADS was made up as 3 mmol·L−1, while  TNP-
ATP was made up as 10 mmol·L−1 stock solution in distilled water.  A317491 was 
prepared in DMSO. All the other compounds were dissolved in Tyrode's 
solution. PPADS was kept protected from light to prevent photodecomposition. 
All stock solutions were stored as frozen aliquots at -20 ºC. Dilutions of these 
stock solutions were made daily and appropriate solvent controls were done. No 
statistically significant differences between control experiments, made in the 
absence or in the presence of the solvents at the maximal concentrations used 
(0.5% v/v), were observed. 
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Presentation of data and statistical analysis 
Results are expressed as mean ± SD, with n indicating the number of 
individuals used for a particular set of experiments. Only one experimental 
procedure (e.g. agonist in the absence and in the presence of the antagonist) 
was performed per individual. Statistical analysis of data was carried out using 
Graph Pad Prism 6.04 for Windows software (La Jolla, USA). Paired and 
unpaired Student’s t-test with Welch’s correction was used for statistical analysis 
when parametric data was considered. One-way analysis of variance (ANOVA) 
followed by the Holm-Sidak correction was used for multiple comparisons. 
Pearson r was used to test correlations. P<0.05 (two-tailed) values were 
considered statistically significant. 
 
RESULTS 
Effect of ATP on nerve-evoked [3H]ACh release from human detrusor strips. 
The release of [3H]ACh induced by electrical field stimulation of human 
detrusor strips was significantly higher in samples from BPH patients (27.6±2.7 x 
103 DPM.g-1 of wet tissue weight, n=12) than from control subjects (11.1±0.2 x 
103 DPM.g-1 of wet tissue weight, n=14) (Figure 12). Desensitization of ionotropic 
P2X1-3 receptors with the enzymatically-stable ATP analogue, a,b-MeATP (30 
µM, applied for 15 min), significantly (p<0.05) reduced the release of [3H]ACh 
from stimulated detrusor strips by 14±6% (n=6) in control individuals and by 
52±7% (n=4) in BPH patients (Figure 12). A similar inhibitory response pattern 
was obtained using the non-selective P2 receptor antagonist, PPADS (10 µM); 
this compound reduced [3H]ACh release from stimulated detrusor strips by 6±8% 
(n=4) and 43±6%  (n=4) in control individuals and BPH patients, respectively 
(Figure 13). While the selective P2X1 antagonist, NF023 (3 µM), was without 
effect, nerve-evoked [3H]ACh release from human detrusor strips was also 
decreased by TNP-ATP (10 nM, a preferential P2X2/3 antagonist) and 
A317491(100 nM, a selective P2X3 antagonist) (Figure 13). The inhibitory effect 
of the selective P2X3 antagonist, A317491(100 nM), was roughly similar in 
detrusor strips from control individuals (20±2%, n=4) and BPH patients (24±4%, 
n=5), whereas TNP-ATP (10 nM) reduced more potently [3H]ACh release from 
obstructed bladders (43±6%, n=4) than from control preparations (27±9%, n=4). 
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Alltogether these findings suggest that facilitatory P2X2/3 heteromers are 
upregulated on cholinergic nerve terminals of obstructed bladder strips, where 
they may be responsible for the increase in the purinergic tone underlying nerve-
mediated detrusor overactivity. 
 
Figure 12. Desensitization of ionotropic P2X1-3 receptors with a,b-MeATP reduced 
the release of 3H]ACh from stimulated detrusor strips from (A) control individuals 
and (B) BPH patients  Tritium outflow (ordinates) is expressed as a percentage of the 
total radioactivity present in the tissue at the beginning of the collection period (Fractional 
release, %) (see e.g.(Duarte-Araújo et al., 2004). Abscissa indicates the times at which 
samples were collected. [3H]ACh release was elicited by electrical field stimulation (10 
Hz, 200 pulses of 0.5 ms duration) twice, starting at 12th (S1) and 39th (S2) minutes after 
the end of washout (zero time). ab-MeATP(30µM, red dots) was added to the incubation 
media 15 min before S2 (horizontal bar); for comparison purposes, we show a time 
course of tritium outflow in control conditions (blue dots) where no drug was added during 
the collecting period. The vertical bars represent SD of four (A) to six (B)  different 
individuals. Note that the spontaneous tritium outflow was not changed in the presence 
of  ab-MeATP(30µM) 
 
Contractile responses of isolated human detrusor strips to ACh andATP. 
 Bath application of acetylcholine (ACh, 0.01-100 µM) concentration-
dependently increased smooth muscle tension in the detrusor of control organ 
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donors, but cholinergic-induced contractions had a smaller amplitude in samples 
from patients with bladder outlet obstruction due to BPH (Figure 14A). For 
instance, the contractile activity of ACh (100 µM) decreased (p<0.05) from 
4.74±0.46 mN (n=12) to 2.64±0.27 mN (n=24) in control individuals and BPH 
patients, respectively. To exclude bias due to age difference betweeen BPH 
patients (71±7 years) and control organ donors (50±17 years), we performed a 
correlation analysis between age and the magnitude of ACh (10 µM)-induced 
contractions; we obtained a Pearson’s r value of -0.048, which did not reach 
statistical significance (p=0.810).Therefore, ageing does not seem to contribute, 
on its own, to decrease the sensitivity of detrusor smooth muscle cells to ACh. 
 
Figure 13. Effects of P2X receptor antagonists on electrically-evoked [3H]ACh 
release from human detrusor strips from cadaveric organ donors (control) and 
BPH patients..PPADS (10 µM), NF023 (3 µM), TNP-ATP (10 nM) and A317491 (100 
nM) were applied 15 min before S2. The ordinates are changes in S2/S1 ratios compared 
to the S2/S1 ratio obtained without addition of any drug. The data are means ± SD of four 
to six individuals. *,#P<0.05 (unpaired Student’s t-test with Welch’s correction) 
represents significant differences when compared with zero percent of change or with 
the effect of the same drug in control individuals, respectively. 
 
In aggreement with data in the literature, ATP (0.01-3 mM) was virtually 
devoid of effect on detrusor strips from control individuals (Figure 14A), but the 
nucleotide concentration-dependently increased (P<0.05) the tension of detrusor 
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strips isolated from BPH patients. At the maximal concentration tested, ATP (3 
mM)-induced detrusor contractions in BPH patients reached 40% (1.13±0.24 mN, 
n=6) of the effect caused by 100 µM ACh and this value was significantly (p<0.05) 
higher than that observed in the strips from control individuals (0.16±0.05 mN, 
n=6) (Figure 14A). 
 The competitive inhibitor of human NTPDase1 (Ki 11±3 µM) and 
NTPDase3 (Ki 18±4 µM), ARL67156 (100 µM), significantly (p<0.05) potentiated 
the contractile effect of ATP (0.1-3 mM) on detrusor strips isolated from BPH 
patients (Figure 14B). 
 
Figure 14. A. Contractile responses of isolated human detrusor strips from control 
individuals and BPH patients to ACh (0.1-100 µM) andATP (0.01-3 mM). The vertical 
bars represent SD of an n number of individuals. *P<0.05 (unpaired Student’s t-test with 
Welch’s correction) represent significant differences when compared to control organ 
donors. B. Pretreatment with the NTPDase inhibitor, ARL67156 (100 µM), 
potentiated ATP (0.1-3mM)-induced contractions of detrusor strips isolated from 
BPH patients. Bars represent mean±SD of three individuals. *P<0.05 (unpaired 
Student’s t-test with Welch’s correction) represent significant differences when 
compared to the the effect of ATP alone. 
 
These results strenghten our previous assumption that NTPDase1/CD39 
may be the main responsible for ATP/ADP inactivation in the human detrusor 
(Silva-Ramos et al., 2015a), also taking into consideration that ARL67156 has 
only marginal effects on NTPDase2, NTPDase8 and ecto-5′-nucleotidase/CD73 
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activities (Levesque et al., 2007). Involvement of ATP-preferring NTPDase3 is 
also possible, but this enzyme exhibits an intermediate pattern of product 
formation leading to a transient accumulation of diphosphonucleosides (Robson 
et al., 2006), which we did not observe in the enzymatic kinetic experiments 
performed in the human detrusor using ATP as substrate (Silva-Ramos et al., 
2015a; see also Chapter 3 / Article 1). Interestingly, the potentiating effect of 
ARL67156 (100 µM) on ATP-induced contractions was observed in detrusor 
samples from obstructed patients even though this pathological condition has 
been associated to partial impairment of ecto-NTPDase1/CD39 activity (Harvey 
et al., 2002). 
 
The detrusor of BPH patients express higher levels of P2X1 receptors than 
control individuals 
 Immunofluorescence confocal microscopy studies demonstrate the 
presence of P2X1 receptors on the human detrusor. The immunolabeling pattern 
shows that P2X1 receptors are distributed along the plasma membrane of 
smooth muscle fibers (Figure 15)(see also (Elneil et al., 2001). Data also show 
that detrusor samples from BPH patients exhibit higher amounts of P2X1 
immunoreactivity compared to control individuals (Figure 15), which is in 
agreement with our functional results and with RT-PCR studies (O'Reilly et al., 
2001).  
 
          
 
 
Figure 15. Confocal micrographs showing the P2X1 receptor immunoreactivity 
(green fluorescence) in the detrusor of a cadaveric organ donor (Control) and a 
patient with BOO (due to BPH). Similar results were obtained in 4 additional 
experiments. Scale bar = 20 μm.  
 
BPH Control 
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DISCUSSION 
In a previous study, we showed that cholinergic neurotransmission was 
increased in mucosal-denuded detrusor strips from BPH patients compared to 
control organ donors and that this could be due, at least in part, to deficits in the 
activity of ecto-NTPDase1/CD39 subsequently unbalancing extracellular ATP 
accumulation and endogenous adenosine formation (Silva-Ramos et al., 2015a; 
see also Chapter 3 / Article 1). Here, we show that extracellular ATP 
accumulation increases bladder tension in obstructed patients by two synergistic 
mechanisms. One, is mediated through direct activation of ionotropic P2X1 
receptors which are more expressed on smooth muscle fibres of obstructed 
human bladders. The second one, is operated indirectly through facilitation of 
ACh release from stimulated cholinergic nerve efferents via the activation of 
P2X2/3 receptor heteromers sensitive to PPADS, TNP-ATP and A317491 
antagonists and to desensitization by the enzymatically-stable ATP analogue, 
a,b-MeATP. The unbalance between the excessive ATP-mediated P2X2/3 
receptor facilitation of ACh release and the loss of the adenosine A1-receptor-
mediated inhibitory tone of cholinergic nerve terminals contributes to increase 
detrusor reactivity in obstructed patients with BPH. While the purinergic-related 
detrusor overactivity may be a burden for patients with BOO, which is certaninly 
worth to be explored therapeutically using P2X receptor antagonists and/or 
adenosine A1 receptor modulators (e.g. receptor agonists, uptake and deaminase 
inhibitors), its maintenance/potentiation in later stages of the disease may be 
attractive to overcome detrusor underactivity. Even though we did not explore 
specifically this possibility, we could increase ATP-mediated contractions of 
detrusor strips from BPH patients using a competitive inhibitor of human 
NTPDase1/CD39, ARL67156 (100 µM). Therefore, we hypothesize that 
manipulation of the purinergic tone is even more relevant to overcome detrusor 
underactivity taking into consideration that cholinergic activity is substantially 
impaired in patients with BOO due to BPH (see below). 
The effect of BOO on the release of ACh was only previously studied in 
animals. In a rat model of obstruction, the release of ACh (per weight of wet 
tissue) from stimulated detrusor strips decreased in parallel with the reduction in 
the density of nerves innervating the bladder (Murakami et al., 2008). However, 
density changes must take into account that obstructed bladders exhibit 
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hypertrophy of the smooth muscle cells and substantial intercellular deposition of 
collagen and elastic fibres, which caused a 4-fold increase in bladder versus body 
weight ratio. Therefore, if one corrects the amount of ACh release by the increase 
in bladder weight secondary to obstruction in the Murakami study, we easily reach 
the conclusion that the absolute amount of ACh released in response to electrical 
stimulation is similar (or even higher) in obstructed than in control rat bladders 
and the same certainly occurs with the number of nerves existing in the bladder 
of the two groups of animals. Moreover, experimental evidences agree that 
animal models of bladder outlet obstruction do not exactly mimic the pathological 
features observed in BOO caused by BPH in men; obstruction in animal models 
generates very rapidly rigid bladders, whereas the bladder of obstructed BPH 
patients is relatively elastic and this pathological feature develops progressivley 
during several years. As a matter of fact, the bladder of BPH patients changes 
gradually resulting in increases in the bladder mass less than 100% of the original 
weight (Kojima et al., 1996), which is far from the 4-fold bladder weight gain 
observed by the Murakami group as soon as 2 weeks after surgery to partially 
oclude bladder outlet in the rat (Murakami et al., 2008); these findings were 
reproduced by other authors who observed a 6.3-fold increase in bladder weight 
due to detrusor hypertrophy 6-weeks after surgical obstruction of the rat bladder 
(Hampel et al., 2002). Rapid development of smooth muscle hypertrophy and 
intersticial fibrosis supports for the inverse relationship between detrusor 
contractility and degree of outlet obstruction in obstructed animal models (Austin 
et al., 2004; Moore et al., 2002) and may explain why the detrusor 
decompensates so early in the course of experimental obstruction (Michel & 
Barendrecht, 2008), which is a situation that is observed only at later stages of 
the human disease. Investigation of the mechanisms underlying species 
differences in reaction to BOO, namely the changes in detrusor morphology and 
functional activity, is beyond the scope of the present study but it certainly 
deserves future attention as they might prove useful to the discovery of novel 
therapeutic targets to preserve detrusor function during the course of the human 
disease.      
Previous studies using obstructed human bladder samples admitted that 
this pathological condition was associated with a partial bladder denervation 
compared to control specimens (Gosling, 1997; Harrison et al., 1987). 
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Unfortunately, these authors did not directly assess cholinergic innervation of the 
human bladder and, most importantly, they also failed to actually measure 
bladder denervation, i.e. reduction in the number of nerve fibres. As criticised 
above regarding animal studies, a decrease in the density of nerve fibres within 
the bladder wall is not an index of bladder denervation because one must take 
into account smooth muscle hypertrophy and more or less extensive interstitial 
deposition of extracellular matrix proteins (e.g. collagen, elastin), which moves 
apart nerve fibres and tiny axon terminals. The partial denervation hypothesis 
was also sustained by functional studies showing that muscle biopsies from 
patients with detrusor instability due to BOO demonstrated supersensitivity to 
ACh and reduction in nerve-mediated responses compared with strips from 
stable bladders (Harrison et al., 1987). Yet, in this respect, functional studies are 
not consensual (Michel & Barendrecht, 2008; Turner & Brading, 1997). We are 
aware that discrepancies among detrusor responsiveness to ACh in BPH versus 
control patients may be a consequence of age differences between the two 
groups (Mansfield et al., 2005; Yoshida et al., 2001). We excluded this possibility 
because in our study we detected no significant correlation between age and the 
magnitude of ACh-induced detrusor contractions. 
Notwithstanding this dispute, we found that electrical field stimulation of 
utothelium-denuded detrusor strips from obstructed BPH patients release 
significantly (p<0.05) higher amounts of [3H]ACh than the samples isolated from 
control organ donors. Thus, if the partial denervation hypothesis is confirmed, our 
data suggest that the amount of ACh released per nerve unit must be highly 
enhanced in the bladder of BPH patients. Interestingly, we showed here that the 
amplitude of ACh-induced contractions was significantly attenuated in obstructed 
BPH bladders compared to control organ donors and similar situation was 
observed regarding carbachol-induced contractions in rats tested 6 months after 
surgery to cause BOO (Murakami et al., 2008). Reduction of cholinergic 
sensitivity of detrusor smooth muscle fibres may attenuate nerve-evoked 
contractions of obstructed human bladders, even though ACh release is being 
released in excess from activated cholinergic nerve efferents. All these nuances 
of the cholinergic neurotransmission must be taken into account before drawing 
any conclusion from the analysis of separate experimental data.  
CHAPTER 3 | RESULTS / PUBLICATIONS 
Role of endogenous purines in lower urinary tract dysfunctions 109 
 
More importantly, our results suggest that anticholinergic agents may be 
less effective in treating detrusor overactivity in BPH patients. Since the majority 
of these compounds are competitive muscarinic antagonists blocking 
preferentially M3 receptors on smooth muscle fibres, their action may be 
substantially hampered in obstructed BPH patients because ACh release is 
facilitated leading to increased levels of the transmitter in the synaptic cleft and/or 
muscarinic receptors activity is downregulated by excessive cholinergic 
exposure, as it has also been demonstrated in the BOO rat (Braverman & 
Ruggieri, 2003). It, thus, appears that net cholinergic neurotransmission in 
obtructed bladders from BPH patients is compensated by the increase in ACh 
release from activated nerve terminals, but this does not fully explain detrusor 
overactivity often seen in BPH patients unless one hypothesizes the 
release/accumulation of a second extracellular messenger, like ATP, responsible 
for increasing the activity of cholinergic nerve efferents and detrusor activity. 
According to this theory, blockade of purinergic signals may be a valuable 
alterative worth to test for treating detrusor overactivity in BPH patients resistent 
to antimuscarinics.                     
The role of ATP in the process of enhancing detrusor contraction in 
obstructed patients seems pivotal. ATP has long been considered as a “damage 
signaller” in several systems and the nucleotide has important roles in tissue 
remodelling secondary to injury (Burnstock & Verkhratsky, 2010). The exact 
mechanism by witch the purinergic signalling cascade is activated in the detrusor 
of BPH patients is not yet established. There is a considerable bulk of evidence 
showing that BOO causes tissue ischemia (Azadzoi et al., 1996; Belenky et al., 
2003; Saito et al., 1997; Yamaguchi et al., 2014) and this may trigger the release 
of purines from affected cells. Experimentally-induced ischemia secondary to 
hypoxia-reoxygenation cycles increases atropine-resistant nerve-mediated 
contractions in the rat detrusor, an effect that can be blocked by P2X antagonists 
(Elliott et al., 2013). Furthermore, ischemia lowers tissue pH, which is usually 
associated with deficits in the activity of NTPDases leading to extracellular ATP 
accumulation (Kukulski et al., 2005) along with the upregulation of ionotropic P2X 
receptors expression and signalling (Zhang et al., 2014). Although we did not 
address this issue in this study, ischemia-induced purinergic signalling 
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upregulation may be a mechanism worth to explore in the future in order to 
explain the pathophysiology of detrusor overactivity in BPH patients.  
We show here for the first time that endogenously released ATP facilitates 
ACh outflow from utothelium-denuded human detrusor strips and this effect 
seems to be significantly amplified in obstructed BPH patients. Facilitation of ACh 
release by ATP has been previously shown in other synapses (Magalhães-
Cardoso et al., 2003; Sperlágh et al., 2007). Our results suggest that ATP-
mediated facilitation of ACh release is dependent on the activation of ionotropic 
P2X1-3 receptors, as these receptor subtypes are the only amenable to 
desensitization by α,β-methylene ATP. Similar results were obtained in the 
porcine detrusor  (D'Agostino et al., 2012); these authors showed that that short-
term administration of ATP or α,β-methylene ATP significantly increased ACh 
release, but the facilitatory effect disappeared upon prolonging the time of 
incubation with the two compounds. In contrast to the well-known contractile 
effect of ATP, via P2X1 receptors activation, in the human detrusor, this receptor 
subtype does not participate in ATP neuromodulation. This was concluded 
because the selective P2X1 receptor antagonist, NF023, was devoid of effect on 
nerve-evoked ACh release from detrusor strips of control organ donors and BPH 
patients. Blockade of P2X2/3 heteromers with TNP-ATP, as well of the P2X3 
receptor with its selective antagonist, A317491, significantly decreased the 
release of ACh from stimulated detrusor strips of control individuals. Interestingly, 
the inhibitory effect of TNP-ATP almost doubled its magnitude in samples 
collected from obstructed BPH patients, whereas the effect resulting from 
selectively blocking the P2X3 receptor with A317491 remained unaltered. These 
findings suggest that both P2X2/3 and P2X3 receptors may be involved in ATP-
mediated facilitation of nerve-evoked ACh in the human bladder, but 
enhancement of the purinergic neuromodulation detected in bladders of 
obstructed BPH patients might result from the upregulation of the P2X2/3 
receptor subtype. The presence of P2X3 receptors and P2X2/3 heteromers has 
been detected in peripheral nerves by immunofluorescence microscopy (Dunn et 
al., 2001). These receptors have been found in suburothelium nerve fibers of the 
human bladder (Brady et al., 2004) and their presence was also detected in nerve 
bundles of rat and human detrusors (Lee et al., 2000; Neuhaus et al., 2012). 
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In conclusion, data produced here and in previous studies support the idea 
that in the bladder of BPH patients several mechanisms are activated towards 
the generation of stronger detrusor contractions, including (1) deficits in the 
metabolism of ATP leading to (2) increased contractile responses mediated by 
post-junctional P2X1 receptors, (3) activation of facilitatory ionotropic P2X2/3 
receptors and decreased adenosine A1-receptor-mediated inhibitory tonus on 
cholinergic nerves that end-up to (4) facilitate ACh release from stimulated nerve 
terminals, which (5) partially compensates the lack of sensitivity of cholinoceptors 
present on smooth muscle fibres. Recent papers have pointed out, that P2X3 
(and/or P2X2/3) antagonists could be potential candidates for the treatment of 
painful bladder and OAB syndromes (Ford & Undem, 2013; Smith, 2013). 
Besides the relevance of P2X3 receptors in mediating bladder sensations, our 
data add important information concerning the implication of these receptors on 
cholinergic neuroexcitability and detrusor overactivity that must be also 
accounted. Our results also shed light on possible ways to increase bladder 
performance in situations of detrusor underactivity resulting from BOO. Until now 
there is no pharmacological treatment for detrusor underactivity and this is a clear 
unmet medical need (Osman et al., 2014). It is appealing the prospect of 
enhancing detrusor performance in these patients through the activation of 
presynaptic P2X2/3 receptors, either by using subtype-specific receptor agonists 
or by inhibiting the activity of NTPDase1/CD39, as we did with ARL67156. 
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3.2 URINARY ATP IN HEALTH AND DISEASE 
 
 
 
 
 
 
   What’s in a name: “purine” comes from “urine”! 
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ABSTRACT 
Background: Diagnosis of bladder outflow obstruction in patients with 
lower urinary tract symptoms is challenging without using invasive urodynamic 
tests. Recently, we showed in vitro that urothelial strips from patients with BPH 
release more ATP than controls. Here, we tested whether urinary ATP can be 
used as a wall tension transducer non-invasive biomarker to detect BOO in 
patients with BPH.  
Methods: 79 male patients with BOO and 22 asymptomatic controls were 
recruited  
prospectively. Patients were asked to complete the International Prostate 
Symptom Score (IPSS) questionnaire and to void at normal desire into a urinary 
flowmeter, the postvoid residual volume was determined by suprapubic 
ultrasonography. Urine samples from all individuals were examined for ATP, 
creatinine and lactate dehydrogenase, 
Results: BOO patients had significantly higher (p<0.001) urinary ATP 
normalized by the voided volume (456±36 nmol) than age-matched controls 
(209±35 nmol). Urinary ATP amounts increased with the voided volume, but the 
slope of this rise was higher in BOO patients than in controls. A negative 
correlation was detected between urinary ATP and flow rate parameters, namely 
maximal flow rate (r=-0.310, p=0.005), Siroky flow-volume normalization (r=-
0.324, p=0.004), and volume-normalized flow rate index (r=-0.320, p=0.012). We 
found no correlation with LUT symptoms IPSS score. Areas under the receiver 
operator characteristics (ROC) curves were 0.91 (95% CI 0.86-0.96, p<0.001) for 
ATP alone and 0.88 (95% CI 0.81-0.94, p<0,001) when adjusted to urinary 
creatinine.  
  Conclusions: Patients with BOO release higher amounts of ATP into the 
urine than the control group. The high area under the ROC curve suggests that 
urinary ATP can be a high-sensitive non-invasive biomarker of BOO, which may 
have a discriminative  
value of detrusor competence when comparing BPH patients with low urinary flow 
rates.  
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INTRODUCTION  
 Lower urinary tract symptoms are very frequent in adult men. The etiology 
is multifactorial. Although BOO due to benign prostatic hyperplasia is a common 
cause of LUTS, bladder dysfunction and disorders outside the urinary tract can 
cause these symptoms as well (Gratzke et al., 2015). European studies estimated 
a prevalence of about 50% of BOO in patients with LUTS due to BPH (Ockrim et 
al., 2001; Oelke et al., 2007). 
 One of the challenges clinicians face when evaluating patients with LUTS 
due to BPH is to determine the existence of BOO. Diagnosing obstruction is vital 
to establish a proper therapeutic plan and define prognosis. Although medical 
history and physical examination are paramount they are subjective and more 
objective complimentary tests are usually recommended (D'Silva et al., 2014). 
Uroflowmetry and ultrasound imaging focusing on the evaluation of bladder wall 
thickness, prostatic volume, intravesical prostatic protrusion and postvoid 
residual volume (PVR) allow gross estimation of the degree of obstruction. 
However these methods are not reliable due to inter-observer variability, low 
accuracy and lack of standardization (Oelke, 2010; Oelke et al., 2007). As a 
matter of fact, obstruction is considered an urodynamic concept that is 
characterized by increased detrusor pressure and decreased urinary flow rate 
during voiding, justifying why the pressure flow study (PFS) is considered the 
gold-standard method for this diagnosis. Its invasive nature, limited access and 
high cost are major obstacles for using this test in routine clinical practice. Several 
authors have been trying to design novel non-invasive methods for measuring 
detrusor pressure with limited success, which are still considered experimental 
(Elterman et al., 2013). 
 ATP is known to be released by the urothelium in response to mechanical 
stimuli (Ferguson et al., 1997; Vlaskovska et al., 2001). Once bladder filling 
reaches a threshold of vesical pressure, ATP released from urothelial cells may 
activate P2X3 receptors located in suburothelial nerve fibers that convey sensory 
information to the central nervous system (Birder, 2006; Cockayne et al., 2000). 
Ussing chamber experiments demonstrated that the amount of ATP released to 
the luminal side of the urothelium is 50-fold higher than that detected in the 
serosal side in response to similar stimulation conditions (Wang et al., 2005). 
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Moreover, we and others provided evidences showing that the ATP catabolism 
by ectonucleotidases is faster in the serosal compared to the luminal side of the 
urothelium (Silva-Ramos et al., 2015b; Wang et al., 2005). This favors ATP 
accumulation in the bladder lumen, which can be detected in urine samples and 
voided urodynamic fluid. For instance, the amount of ATP measured in the 
urodynamic fluid instilled during cystometry inversely correlated with first desire 
to void in women with OAB (Cheng et al., 2013; Cheng et al., 2010). Our own 
data show that urinary ATP measured during voiding at normal desire is 
significantly higher in women with detrusor overactivity compared to age-matched 
controls (Silva-Ramos et al., 2013b). These findings agree with cystometry 
experiments in freely moving rats showing that intravesical ATP stimulates the 
micturition reflex (Pandita & Andersson, 2002). 
 Besides this association between urinary ATP and bladder sensitivity, ATP 
can also be seen like a pressure transducer because urothelial cells respond to 
tension-induced deformation by releasing ATP (Ferguson et al., 1997). As per the 
Laplace’s Law stating that wall tension is proportionate to the pressure times half 
of the radius of a spherical vessel, we hypothesized that urinary ATP amounts 
would be significantly higher in patients with BOO as a consequence of increased 
bladder pressure during voiding in a similar manner to that occurring in patients 
with detrusor overactivity (Kumar et al., 2010; Silva-Ramos et al., 2013b). In 
support of this theory, we recently showed that electrical stimulation of mucosal 
strips containing only the urothelium with the attached lamina propria from BPH 
patients increased the isometric tissue tension above the spontaneous phasic 
activity and released five times more ATP than the control preparations (Silva et 
al., 2015). These findings clearly indicate that besides urothelium stretching 
during bladder filling the isometric increase in transmucosal pressure can also 
contribute to ATP release in the human bladder. In order to translate in vitro 
experimental findings to the clinical practice, this study was designed to test if 
patients with BOO due to BPH have higher urinary ATP amounts than 
asymptomatic controls and whether measurement of urinary ATP is reliable to 
determine non-invasively the existence of increased bladder pressure due to 
BOO.  
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METHODS  
Patients and procedures. 
This study and all its procedures were approved by the Ethics Committees 
of Centro Hospitalar do Porto (CHP) and of Instituto de Ciências Biomédicas de 
Abel Salazar (Medical School) of the University of Porto (ICBAS-UP). All subjects 
signed an informed consent prior to examinations and for using the biological 
material. The investigation conforms to the principles outlined in the Declaration 
of Helsinki. A total of 101 men were enrolled in this study, including 79 patients 
with BOO (40-79 years of age, mean 66±9 years) and 22 asymptomatic 
volunteers (40-75 years of age, mean 53±11 years) recruited among hospital staff 
and patients’ attendants from the orthopedics clinic. Exclusion criteria of 
volunteers included any LUTS, any urinary tract infection, any intervention on 
lower urinary tract, malignancy, neurological disease (e.g., diabetes mellitus, 
prolapsed of intravertebral discs, spinal trauma, etc.), or medications known to 
affect the lower urinary tract function (e.g., anticholinergics, alpha blockers, 
adrenergic stimulants, antibiotics, etc.). Patients were enrolled between March 
2012 and February 2015 from the waiting list for prostatic surgery to relieve BOO 
due to BPH of the Department of Urology of CHP. The indication for surgery was 
the responsibility of the attending urologist. Patients with history of malignancy of 
any sort (including bladder and/or prostate cancer), pelvic radiotherapy, 
neurologic disease, any systemic or inflammatory condition, active urinary tract 
infections, renal impairment (Chronic Kidney Disease Stage > 2) or indwelling 
urinary catheterism, were excluded. Patients were asked to complete a 
Portuguese version of the International Prostate Symptom Score (IPSS) 
questionnaire and to void comfortably at normal desire in a standing position into 
a gravimetric urinary flowmeter (Flowmaster, MMS, Enschede, The Netherlands). 
Adequate privacy was provided to each participant to minimize psychological 
inhibition. Voided volume was recorded and postvoid residual volume was 
estimated by suprapubic ultrasonography. Voids under 100 ml and over 500 ml 
were excluded from the comparative analysis in order to curtail extreme variations 
among the two study groups and because accurate representation of maximal 
flow rates in Siroky flow-volume normograms requires a minimum voided volume 
(Siroky et al., 1979). Urine samples obtained from natural voids were used for 
rapid dipstick test and urine culture. Subjects testing positive for nitrites, 
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leucocytes or infection, were also excluded. A third urine sample was aliquoted, 
snap frozen in liquid nitrogen and preserved at −80°C until ATP determination. 
These samples were also used to measure urinary creatinine (Cr) and lactate 
dehydrogenase (LDH, EC 1.1.1.27) activity (see e.g. Silva-Ramos et al., 2013b). 
LDH is a fairly stable intracellular enzyme that is widely used as an indicator of 
cell integrity providing that its values are kept at a low level. ATP values were 
normalized to urinary volume and creatinine in order to reduce sample variation 
and to discard kidney influence on ATP amounts. All biochemical tests were done 
blindly. Data on prostatic volume and prostate-specific antigen (PSA) were 
collected from patient’s clinical records. 
 
Measurement of urinary ATP. 
 Undiluted urine samples were defrosted till 25°C and afterwards 
centrifuged at 3000 g at room temperature for 20 seconds to remove cellular 
debris. The supernatant was separated. A mixture of luciferin-luciferase was 
added according to the manufacturer instructions using the ATP 
Bioluminescence Assay Kit HS II (Roche Applied Science Indianapolis, Indiana, 
USA). ATP detection was evaluated using a multi-mode microplate reader 
(Synergy HT, BioTek Instruments Inc., Vermont, USA) controlled via BioTek’s 
Gen5™ Data Analysis Software. Sample bioluminescence was compared to that 
of standard amounts of ATP used in the same concentration range; standard ATP 
samples were prepared daily (cf. Silva-Ramos et al., 2013b). All samples were 
run in duplicate. The minimum ATP detection limit in these experimental 
conditions was 10−12 M (10−16 moles in 100 µl samples) and luminescence 
correlated linearly to ATP concentration till 10−6 M. Dilution of urine samples were 
done whenever necessary in order to fit interrogation values in the linear part of 
the ATP calibration curve.  
 
Measurement of urinary creatinine and LDH. 
 Each urine sample remaining from ATP measurements was used to 
quantify urinary creatinine and the lactate dehydrogenase (LDH, EC 1.1.1.27) 
activity (Silva-Ramos et al., 2013b). The quantitative determination of urinary 
creatinine was performed in vitro on a Cobas Integra 800 analyser using the 
kinetic colorimetric Creatinine Jaffé Gen.2 assay according to the manufacturers’ 
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instructions (Roche Diagnostics GmbH, Mannheim, Germany). LDH is an 
oxidoreductase enzyme that catalyses the interconversion of pyruvate and 
lactate. The LDH Activity Assay kit (Sigma-Aldrich, Saint Louis, MO, USA) is 
based in the reduction of nicotinamide adenine dinucleotide (NAD) to 
nicotinamide adenine dinucleotide plus hydrogen (NADH), which is specifically 
detected by colorimetric (450 nm) assay. 
 
Statistical Analysis. 
 Statistical analyses were performed using IBM SPSS Statistics software 
version 21, (New York, USA). Results are reported as mean values ± standard 
deviation (SD) of samples collected during the first void, unless stated otherwise. 
Kolmogorov-Smirnov test was used to check for normality of cumulative data 
distribution. Unpaired Student’s t-test with Welch’s correction and Mann-Whitney 
U-test were used for statistical analysis between groups when parametric or 
nonparametric data was considered, respectively. For multiple comparisons, one-
way ANOVA nonparametric Kruskal-Wallis test with Dunn’s post test modification 
was used. Correlation between variables was analyzed using Pearson or 
Spearman test according to the normality of data distribution. P<0.05 (two-tailed) 
values were considered statistically significant. The diagnostic potential of urinary 
ATP measurements was assessed by receiver operating characteristics (ROC) 
plots. Area Under the Curve (AUC) comparisons were made using Hanley and 
McNeil method with MedCalc software (Ostend, Belgium) (Hanley & McNeil, 
1983). 
 
RESULTS 
 Table 2 shows that urinary ATP concentration was significantly (p<0.001) 
higher in BOO patients than in asymptomatic controls. This was also verified 
when urinary ATP was normalized to urine creatinine levels (ATP/Cr, pmol/mg, 
p<0.0001) to discard a putative kidney influence on urinary ATP (Table 2, see 
Silva-Ramos et al., 2013b). It is worth to mention that urine creatinine levels were 
not significantly different (p>0.05) between the two studied groups (Table 2). 
Damage of cells does not account to the higher ATP concentrations found in the 
urine of BOO patients, because urinary LDH activity was consistently low, did not 
significantly differ between the two groups (1.80±0.63 U/ml in BOO patients vs. 
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1.63±0.17 U/ml in asymptomatic controls; p>0.05) and no correlation was 
observed between urinary ATP values and LDH activity in BOO patients (r=-
0.085, p=0.467) (Table 3). 
 The ROC graphs are commonly used in medical decision making to depict 
true positive vs. false positive rates. A high AUC is consistent with urinary ATP 
concentration as such (0.91; 95% CI 0.86 to 0.96; p<0.001) or adjusted to urine 
creatinine levels (0.88; 95%CI 0.81 to 0.94; p<0.001) being high-sensitive non-
invasive biomarkers for discriminating symptomatic BOO patients from 
asymptomatic controls (Figure 15). There were no significant (p>0.05) differences 
between AUCs of ATP and ATP/Cr. By selecting the cutoff point of 1.36 nM for 
ATP and 1.31 pmol/mg for ATP/Cr using Youden’s index (Youden, 1950), the 
sensitivity and specificity were 85% and 80% respectively for ATP (nM) and 80% 
and 80% respectively for ATP/Cr. 
 Taking into consideration that BOO patients voided smaller (p<0.001) 
volumes of urine compared to control individuals (see Table 2) we corrected 
urinary ATP by the corresponding voided volume. After this normalization, urinary 
ATP amounts (expressed in nmol per void) were still significantly (p<0.0001) 
higher in BOO patients than in asymptomatic controls (Table 2). 
 
Table 2 - Urinary measurements in BOO patients and in assymptomatic controls. 
 
 
 
Controls 
n=22 
Mean±SD 
BOO 
n=79 
Mean±SD 
p value 
ATP (nM) 1.03±0.18 2.62±0.19 <0.001 
Voided volume (ml) 265.80±24.69 177.10±9.62 <0.001 
ATP x Voided volume 
(nmol) 208.80±34.62 456.00±36.00 <0.0001 
ATP/Cr (nmol/mg) 1.11±3.02 3.99±4.80 <0.0001 
Creatinine (mg/dl) 116.20±10.20 96.70±5.77 ns 
LDH (U/ml) 1.80±0.63 1.63±0.17 ns 
CHAPTER 3 | RESULTS / PUBLICATIONS 
Role of endogenous purines in lower urinary tract dysfunctions 123 
 
Moreover, data from Figure 16 suggest that there is a positive correlation 
between the ATP amount in urine samples and voided volumes both in 
asymptomatic men (r=0.584, p<0.005, n=22) and in BOO patients (r=0.5170, 
p=0.0001, n=79). As a matter of fact, the slope of the interpolation line between 
urinary ATP and voided volumes was steeper in BOO patients (2.095) than in 
asymptomatic controls (0.837) (Figure 16), indicating that the urine of BOO 
patients possesses higher average ATP amounts than control individuals when 
the samples were corrected for the voided volume. 
 
Table 3- Characteristics of patients with BOO and their correlation to urinary ATP 
(nmol). p values refer to the significance of the correlation.  
 
  
We also explored possible correlations between urinary ATP amounts with 
a set of clinical parameters in patients with BOO due to BPH (Table 3). BPH 
patients included in this study reported moderate urinary symptoms (average 
 Mean ±SD Pearson’s r p value (n) 
Qmax (ml/s) 9.15±3.01 -0.310 0.005 (76) 
Siroky class -1.76±0.09 -0.324 0.004 (76) 
VQImax 0.64±0.03 -0.320 0.012 (50) 
PVR (ml) 68.63±7.65 0.097 0.509 (50) 
VV (ml) 177.10±9.62 0.517 <0.001 (76) 
VV+PVR (ml) 242.40±14.02 0.556 <0.001 (50) 
LDH (U/ml) 1.63±0.17 0.085 0.467  (75) 
Prostatic Volume (ml) 78.18±4.41 -0.048 0.683  (76) 
PSA (ng/ml) 3.32±0.25 -0.033 0.783 (74) 
IPSS 15.07±0.73 -0.735 0.269 (76) 
Voiding subscore 9.07±0.50 -0.044 0.709 (76) 
Storage subscore 6.00±0.40 -0.178 0.124 (76) 
QOL score 3.79±0.16 -0.087 0.454 (76) 
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IPSS score of 15.3±6.6 from a maximum of 35 ponts,n=79) i.e. well above the 
bothersome LUTS defined as an IPSS score over 7 (see Table 3). None of the 
parameters recommended for clinical assessment of patients suffering from 
prostatism correlated positively with urinary ATP. More importantly, we found an 
inverse correlation between maximal uroflow rates (Qmax, ml/s) measured during 
voiding at normal desire and urinary ATP amounts in patients with BOO due to 
BPH (Table 3). Uroflow rate is highly dependent on the voided volume (VV) and 
flow-volume relationships (e.g. Siroky normogram) are commonly used, although 
with certain limitations, in the clinical practice (see e.g. Agarwal et al., 2014). 
 
 
Figure 15 – Receiver-Operator Characteristics (ROC) curves of urinary ATP 
concentration as such (ATP, blue line) and corrected for the urinary creatinine 
(ATP/Cr, green line) plotted as continuous variables to discriminate true positive 
from false positive rates among BOO patients and asymptomatic controls. An area 
under the curve (AUC) value of 1.0 indicates perfect discrimination value without any 
overlap, whereas a value of 0.5 indicates a matter of chance. Please note that both ATP 
and ATP/Cr have AUCs significantly (p<0.001) superior to 0.5 (null hypothesis), but there 
were no differences (p>0.05) between the two variables.  
 
The European Association of Urology guidelines also recommend 
documentation of PVR because bladder volume (VV+PVR) may have a higher 
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discriminatory value in interpreting flow rates and this parameter may indicate the 
degree of impact of BOO on detrusor function in uroflow reports. Data in Figure 
17 show that urinary ATP reached maximal values in BOO patients with flow-
volume relationship values three standard deviations below the average 
according to the Siroky normogram (Siroky et al., 1979) (see also Table 3). Both 
voided volume (VV, r=-0.517, p<0.001) and bladder volume (VV+PVR, r=-0.556, 
p<0.001), but not the post-void residual urine (PVR, r=-0.097, p=0.509), positively 
correlated with urinary ATP (Table 5). We also found a negative correlation 
between urinary ATP amounts and the volume-normalized uroflow rate index 
(VQImax = Qmax/ (𝑉𝑉	 + 𝑃𝑉𝑅) (r=-0.267, p=0.032) (Agarwal et al., 2014). 
 
 
 
Figure 16 -Relationship between urinary ATP amounts per void (nmol) and voided 
volumes (ml) in BOO patients (black circles) and asymptomatic controls (white 
circles). Please note that the slope of the interpolation line between urinary ATP and 
voided volumes was steeper in BOO patients (full line, 2.095) than in asymptomatic 
controls (dotted line, 0.837). 
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Figure 17 - Relationship between urinary ATP amount per void (nmol) and the 
Qmax. Abscissa values represent the standard deviation below the mean for Qmax 
using the Siroky nomogram. Patients with lower Qmax (3 SD below the mean) had 
significantly higher urinary ATP (p=0.015, one-way ANOVA). Whiskers and outliers 
(squares and triangles) are plotted according to Tukey’s method. 
 
Significant correlations between urinary ATP and uroflowmetry tests 
contrast with often reported lack of correlation among Qmax and patients 
perception of BOO-related urinary symptoms (IPSS score, r=-0.039, p=0.735) 
and/or dissatisfaction concerning their quality of life (QOL score, r=-0.087, 
p=0.454), respectively. Nonetheless, 18 out of 79 BOO patients exhibiting high 
ATP per void (>400 nmol, above the median) and low uroflow rate (Qmax < 10 
ml/s) had significantly higher IPSS scores than the rest of the population (mean 
difference of 4.04±0.89, p<0.001). This feature may be mostly attributed to 
increases in urinary voiding symptoms compared to urinary storage symptoms; a 
mean difference of 4.50±0.11 (p<0.001, n=18) was observed between the IPSS 
voiding and storage subscores, but such a difference did not exist in the group of 
patients with low ATP amounts per void and higher flow rates (mean difference 
of 2.44±0.82, p>0.05, n=59). 
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DISCUSSION 
 Here we show that urinary ATP is significantly higher in patients with BOO 
due to BPH than in asymptomatic controls. Although it is difficult to prove that 
urinary ATP obtained by voiding at normal desire is derived mainly from the 
bladder mucosa, prior investigations have demonstrated that the uroepithelium 
plays a dominant role (Sui et al., 2014). Since the pioneering report by Ferguson 
et al. (Ferguson et al., 1997), mounting evidences support the role of mechanical 
stress (pressure, stretch, hypoosmotic stimulation) as a trigger for ATP release 
from the urothelium. In fact, ATP can mediate pressure signals in several organ 
systems, from controlling vascular tone in response to stretch (Bodin & 
Burnstock, 1996) to transducing touch sensations in the skin (Nakamura & 
Strittmatter, 1996). So, during normal bladder filling, ATP is released by the 
urothelium as the bladder distends. The voiding reflex is triggered when urothelial 
cells deformation by the progressive rise in bladder wall tension reaches a 
threshold that is proportionate to the internal pressure times half of the radius 
(Laplace’s Law). The higher the bladder volume and, subsequent, wall tension 
the higher amount of ATP is released from urothelial cells. During voiding an extra 
pressure is delivered to the urothelium by the underlying smooth muscle 
contraction. Since the detrusor of patients with BOO due to BPH has to generate 
more pressure to overcome obstruction it is plausible that more ATP is released 
into the urine of these patients providing that contractility of the detrusor is 
maintained or exaggerated. Our data show that the total amount of ATP 
normalized per voided volume in the urine of BOO patients is much higher than 
in asymptomatic controls despite the latter voided higher volumes of urine 
(increased bladder distension), yet, no correlation was found between urinary 
ATP and the PVR in obstructed patients. Using mucosal strips from the human 
bladder stimulated electrically to increase the isometric tissue tension, we 
reported previously that patients with BOO due to BPH release five times more 
ATP than control individuals (Silva et al., 2015). 
 Besides the increase in mechanically-induced ATP release from the 
urothelium of BOO patients, other mechanisms may also account to the higher 
urinary ATP amounts in these patients. It has been reported that ATP can cause 
more ATP to be released by urothelial cells creating a “vicious cycle” through the 
activation of P2 purinoceptors (Sun et al., 2001). Besides this, decreased ATP 
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catabolism has also been proposed to explain higher amounts of urinary ATP in 
BOO patients compared to asymptomatic controls. Reports from our and other 
groups have shown that the ATP catabolism is hindered in the bladder of patients 
with BOO and detrusor overactivity (Harvey et al., 2002; Silva-Ramos et al., 
2015a). Decreases in the activity of ecto-NTPDases have been observed both in 
the mucosa (unpublished observations from our group) and in the smooth muscle 
layer, where ATP released from parasympathetic nerves can reach higher 
amounts in BPH patients than in controls (Silva-Ramos et al., 2015a). Whether 
surplus ATP accumulation in the detrusor has impact on ATP concentrations 
being measured in the urine of BPH patients is a matter of debate and requires 
experimental confirmation. We can, of course, speculate whether the urothelial 
barrier is damaged on the bladder of BPH patients, allowing more ATP from the 
muscle and nerves to be detected in the bladder lumen, yet evidence for this 
assumption is still lacking. Nonetheless, strengthening the purinergic tone 
through the abnormal production, release and metabolism of ATP is possible in 
obstructed bladders, as it has been increasingly reported in other urological 
diseases (reviewed in Burnstock, 2011).  
 In a previous study, Sugaya and co-workers  proposed that measurement 
of urinary ATP can be used as a marker of pathologic bladder function (Sugaya 
et al., 2009). Our group added some information suggesting that urinary ATP may 
be a highly sensitive dynamic biomarker for assessing detrusor overactivity in 
women with OAB syndrome (Silva-Ramos et al., 2013b). Although it is estimated 
that significant number of BPH patients also have detrusor overactivity (Andersen 
& Nordling, 1980), we could not control this variable due to ethical constrains 
limiting the use of unnecessary invasive urodynamic tests (e.g. filling cystometry 
and pressure flow studies) in patients with moderate LUTS like the group 
analyzed in this study. The European Association of Urology guidelines consider 
invasive urodynamic tests as optional, unless more accurate diagnostic is 
required in severe cases of LUTS in young individuals or in patients with normal 
urinary flow rates, when neurologic dysfunction is suspected, and in patients 
previously submitted to prostatic surgery (Gratzke et al., 2015). None of such 
cases were included in our study. In the Sugaya’s study, ATP/Cr levels in the 
urine of BPH patients decreased 4 weeks after blockage of a1-adrenoceptors with 
tamsulosin along with the improvement of LUTS, thus suggesting that alleviating 
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outlet resistance may reduce urinary ATP concentrations (Sugaya et al., 2009). 
The lack of correlation between urinary ATP and prostate size, PSA values and 
post-void residual urine observed in our study (see also (Sugaya et al., 2009) 
contrasts with the significant inverse correlation between urinary ATP and 
uroflowmetry parameters, namely maximal flow rate (Qmax), volume-normalized 
flow rate index and flow-volume Siroky categories, thus suggesting that urinary 
ATP amounts reflect most probably the activity of the bladder above the 
obstruction. Correlation between bladder activity and urinary ATP levels is 
perhaps more straightforward in women with overactive bladders as they do not 
have a prostate gland, but the argument may be still valid in men’s bladders.  
 Looking at the relationship between urinary ATP and patients’ perception 
about LUTS severity, we could not find any significant correlation when the total 
IPSS or IPSS subscores were used in the entire population of BPH patients. This 
is not surprising since, the IPSS does not correlate with or predict urodinamically 
documented BOO and the same also applies to prostate size, PSA values and 
post-void residual urine (Yoshida et al., 2004). It is also known that non-invasive 
tests to study the dynamics of urine flow are more reliable than subjective 
symptoms in predicting BOO due to BPH, but artifacts can also appear from poor 
technique or poor interpretation of the curves obtained. False Qmax values may 
occur, which can be circumvented by taking into account the shape of the uroflow 
curve and the voided/bladder volume. As a matter of fact, we show here that 
urinary ATP correlates inversely with Qmax and also with the flow-volume scores 
given by the Siroky normogram and the volume-corrected flow rate index. Urinary 
ATP positively correlates with the urine volume inside the bladder before voiding 
that can be appreciated summing the VV plus the PVR. As per the Laplace’s Law, 
force-relationship of detrusor contraction depends on luminal pressure, bladder 
volume and state of muscle activation and is characteristically hyperbolic. Thus, 
the force and velocity of contraction of detrusor corresponds to the “vis-a-tergo” 
strain generated by bladder filling, i.e. VV+PVR in an uroflow analysis. Taking 
this into account, Agarwall et al. found that VQImax was more discriminatory than 
the respective values of Qmax in the investigation of the degree of bladder 
dysfunction in patients with BOO, neurogenic bladder and detrusor underactivity 
(Agarwal et al., 2014). Anyway, these results strengthen our assumption that 
urinary ATP may be an important marker of urinary bladder tension rising 
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proportionately to urine accumulation (bladder radius) and to detrusor contraction 
(pressure) in order to overcome bladder outlet resistance during voiding. 
Therefore, in BPH patients with low flow rates urinary ATP per void may 
discriminate positively increases in urethral resistance (bladder wall tension due 
to obstruction) from patients exhibiting detrusor hypoactivity, as the latter may 
present low urinary ATP amounts. As a matter of fact, we found that the 
discriminatory power of urinary ATP increased significantly in BOO patients with 
a Qmax < 10 ml/s and in those with a Qmax below the -1 SD line in the flow-
volume Siroky normogram when a lower end cut-off amount of ATP of 400 nmol 
is imposed. Using these criteria, we found that voiding symptoms perceived by 
BPH patients gained significance compared to the IPSS storage subscore in 
patients presenting higher ATP per void and lower flow rates. It should, however, 
be emphasized that a superior value obtained by increasing the number of 
evaluated parameters does not underscore the importance of urinary ATP 
normalized by the voided volume or by the urinary creatinine which also have 
high AUCs on ROC graphs (~0.90).   
 Even though we have recruited BOO patients and asymptomatic controls 
with the same age range (40-79 years of age), the mean age in both groups 
reflects the epidemiology of BPH disease which tends to affect older men (66±9 
years of age in BOO patients vs. 53±11 years of age in asymptomatic controls). 
Controversy still exists in the literature concerning the relevance of age in urinary 
ATP amounts; there is one paper showing that ATP release increases with age 
(Yoshida et al., 2004), yet others found no relationship between utinary ATP and 
age (Gill et al., 2015; Sugaya et al., 2009). In our study, we also failed to find any 
significant correlation between age and urinary ATP in the control group (r=-
0.051, p=0.412). This was also verified extending the age range of asymptomatic 
controls to younger individuals (20-83 years of age, mean 42±15 years; r=0.067, 
p=0.629, n=48). Covariance analysis of our data showed that the higher urinary 
ATP amounts in BOO patients is independent of age (p<0.001). Under these 
circumstances, it is not plausible that age alone account significantly to the 
observed differences in urinary ATP between asymptomatic controls and BOO 
patients.  
 It has been shown in previous studies that urinary ATP positively 
correlates with bladder distension by saline instillation during cystometry testing 
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(Cheng et al., 2014), as well as with the voided volume in healthy women (Silva-
Ramos et al., 2013b). Data presented here show that the same also occurs in 
asymptomatic men. This is in keeping with the concept that urinary ATP 
originates mostly from the physiological distension of the urothelium (Ferguson 
et al., 1997; Wang et al., 2005). While a similar situation occurs in BOO patients, 
the slope of the interpolation line between the total urinary ATP normalized per 
voiding volume was significantly steeper than that in asymptomatic controls. This 
normalization was necessary because the voiding volumes obtained from BPH 
patients were smaller than those verified in the controls and we wanted to 
compare the amount of ATP released into the bladder lumen in isovolumetric 
conditions. Therefore, one may conclude without much hesitations that the 
urinary bladder of BOO patients release higher amounts of ATP during voiding at 
normal desire, confirming our in vitro experiments using surgical samples from 
the mucosa of some of these patients stimulated electrically (Silva et al., 2015). 
As per the Laplace’s law, keeping the radius (urine volume) constant the increase 
in urinary bladder tension and, thus, ATP release, essentially depends on 
detrusor contraction (pressure) to overcome outlet resistance during voiding. 
Increased ATP release from uroepithelial cells resulting in urinary 
accumulation of the nucleotide has also been observed in patients with OAB 
presenting detrusor overactivity (Kumar et al., 2010; Silva-Ramos et al., 2013b) 
and painful bladder syndrome (Kumar et al., 2007; Sun et al., 2001). It is worth to 
mention that these two conditions are complex clinical syndromes without any 
identifiable cause that affect mainly women and are based on self-reported 
symptoms of urinary urgency and frequency, associated or not with incontinence 
in the first situation and chronic pelvic pain or discomfort in the latter. In the 
present study, we used male patients selected for prostatic surgery to relieve 
BOO due to BPH. Notwithstanding this, a significant number of BPH patients may 
present detrusor overactivity (Andersen & Nordling, 1980), yet in this case 
diagnostic accuracy might increase if invasive urodynamic testing for involuntary 
contractions of the detrusor muscle during bladder filling is performed in addition 
to non-invasive uroflowmetry combined with urinary biomarkers, such as ATP. 
Gender differences must also be taken into account when comparing urinary ATP 
concentrations in any clinical condition; this is because for yet unknown reasons, 
we and others found higher urinary ATP concentrations in healthy women 
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compared to age-matched men (2.65±0.40 nM, n=36 vs. 1.03±0.18 nM, n=22, 
respectively; p<0.001) (cf. Silva-Ramos et al., 2013b; Sugaya et al., 2009). 
Besides gender preference and chronic pelvic pain, increased urinary ATP 
concentrations observed in patients with bladder pain syndrome / interstitial 
cystitis would be best valorized if combined with other potential biomarkers 
targeting alterations of the urothelium barrier function that are characteristic of 
this condition; these include glycoprotein antiproliferative factor (APF), epidermal 
growth factor (EGF), and heparin-binding EGF-like growth factor, among others 
(Fry et al., 2014).  
In most publications, urinary biomarkers are normalized to the urinary 
concentration of creatinine in order to reduce sample variation and to discard 
kidney influence on ATP amounts. Here, we found that the urinary creatinine was 
about the same (p>0.05) in BOO patients and asymptomatic controls. Our data 
show that the predictive value of urinary ATP to determine the existence of 
increased bladder pressure due to outlet obstruction is roughly similar either 
adjusting or not ATP amounts to the urinary concentration of creatinine. Overall 
these findings demonstrate that urinary creatinine concentration does not 
accompany urinary ATP accumulation and further strengths our argument that 
most urinary ATP originates in the lower urinary tract particularly in the bladder 
and not upstream in the kidney. Under these conditions, adjusting ATP amounts 
to urinary creatinine is meaningless.  
We are also aware that to validate a diagnostic biomarker one should 
compare its performance to the gold standard method, which is in this case the 
urodynamic pressure flow study, in order to document increased detrusor 
pressure and decreased urinary flow. Notwithstanding this, while we could 
measure urinary ATP amounts in asymptomatic controls, it would not be ethical 
to perform invasive urodynamic tests in this population. This constrain would also 
limit the comparative analysis of specificity / sensitivity of both methods using 
ROC graphs. Anyway these results support a role of ATP as a possible marker 
of obstruction and should encourage further studies examining the relationship 
between urinary ATP and specific urodynamic tests (e.g. pressure flow study) in 
more severe cases of BOO. 
Another limitation for the use of urinary ATP measurements in clinical 
practice implies the meticulous exclusion of patients with urinary tract infections 
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and malignancy. For decades urinary ATP as been proposed as a marker of 
bacterial infection of the urinary tract (Thore et al., 1975). Although never used in 
clinical practice, this concept has recently been disputed since urine samples 
from patients with positive urine culture had lower ATP concentrations than 
controls (Gill et al., 2015), which might happen because inflammatory cells 
release, but also metabolize extensively, the nucleotide by intracellular and 
membrane-bound nucleotidases. Anyway, we excluded urinary tract infections by 
urine culture and a significant intracellular source of ATP due to breakdown of 
urothelial cells by detecting low LDH activity in tested samples. 
In conclusion, the results obtained in this study support an important role 
of ATP in the pathophysiology of LUTS due to BPH. Furthermore, the putative 
role of urinary ATP as a dynamic biomarker of BOO should also be considered. 
In fact, a high area under the ROC curve is consistent with urinary ATP either 
alone or adjusted to urinary creatinine being a highly-sensitive pressure 
transducer biomarker for discriminating detrusor competence when comparing 
BOO patients with low urinary flow rates. AUC scores of about 90% are similar to 
predictive urine test strips for diagnosing urinary tract infections (Sultana et al., 
2001) and are significantly higher than the PSA value for diagnosing prostate 
cancer, which is around 70% (Thompson et al., 2005). The possibility of 
diagnosing BOO with a non-invasive biochemical test is appealing. While BPH is 
a very common disorder, the diagnostic of associated BOO is difficult in the 
clinical practice. Overall LUTS are poor predictors of BOO (de la Rosette et al., 
1998) and symptoms alone are insufficient for the diagnosis. Most of the time, the 
diagnostic of BOO is inferred from symptoms and signs, ultrasound examination 
of the lower urinary tract and uroflowmetry testing. None of these assessments 
are individually very accurate, but altogether portray a fairly good idea of the 
clinical status of the patient in terms of BOO. In more doubtful situations, which 
are not that uncommon, more invasive exams like pressure-flow study are 
needed. Moreover, one condition that is getting more and more attention which 
troubles the clinical diagnostic of BOO is voiding dysfunction characterized by 
low flow rates due to detrusor underactivity. This clinical entity is very common in 
aged patients and its prevalence seems to be rising (Osman et al., 2014). Until 
now the only exam able to distinguish detrusor underactivity from BOO is the 
pressure flow study. There is, therefore, an unmet clinical need for a simple, non-
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invasive test to screen these patients. Although this study did not address 
specifically this issue, we may speculate about the discriminative power of urinary 
ATP per void in BOO patients presenting detrusor hypoactivity. According to our 
prediction, low urinary ATP amounts per void are expected to occur in these 
patients due to failure in increasing the bladder pressure and, thus, the nucleotide 
release from the urothelium, as a consequence of obstruction.  
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ABSTRACT 
Background: Nowadays, there is a considerable bulk of evidence showing 
that ATP has a prominent role in the regulation of human urinary bladder function 
and in the pathophysiology of detrusor overactivity. ATP mediates 
nonadrenergic-noncholinergic detrusor contractions in overactive bladders. In 
vitro studies have demonstrated that uroepithelial cells and cholinergic nerves 
from overactive human bladder samples release more ATP than controls. Here, 
we compared the urinary ATP concentration in samples collected non-invasively 
from OAB women with detrusor overactivity and age- matched controls.  
Methods: Patients with neurologic diseases, history of malignancy, urinary 
tract infections or renal impairment (creatinine clearance <70 ml/min) were 
excluded. All patients completed a 3-day voiding diary, a 24 h urine collection and 
blood sampling to evaluate creatinine clearance. Urine samples collected during 
voluntary voids were immediately freeze-preserved for ATP determination by the 
luciferin-luciferase bioluminescence assay; for comparison purposes, samples 
were also tested for urinary NGF by ELISA.  
Results: The urinary content of ATP, but not of NGF, normalized to 
patients’ urine creatinine levels (ATP/Cr) or urinary volume (ATP.Vol) were 
significantly (P<0.05) higher in OAB women with detrusor overactivity (n=34) than 
in healthy controls (n = 30). Significant differences between the two groups were 
still observed by boosting urinary ATP/Cr content after water intake, but these 
were not detected for NGF/Cr. In OAB patients, urinary ATP/Cr levels correlated 
inversely with mean voided volumes determined in a 3-day voiding diary.  
Conclusion: A high area under the receiver operator characteristics (ROC) 
curve (0.741; 95% CI 0.62–0.86; P<0.001) is consistent with urinary ATP/Cr 
being a highly sensitive dynamic biomarker for assessing detrusor overactivity in 
women with OAB syndrome.  
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INTRODUCTION 
Overactive bladder is a complex clinical syndrome based on self-reported 
symptoms of urinary urgency associated with incontinence in up to one-third of 
cases, usually accompanied by daytime frequency and nocturia, in the absence 
of proven infection or other obvious pathology (Abrams et al., 2002). It has been 
reported an overall prevalence of 12.8% in women (Irwin et al., 2006), and a 
significant impact on patients quality of life (Coyne et al., 2011). The precise 
pathogenesis underlying OAB remains to be clarified and might be multifactorial. 
OAB symptoms are often associated with detrusor overactivity, which is 
diagnosed by invasive urodynamic testing as involuntary contractions of the 
detrusor muscle during bladder filling. Regrettably, the relationship between 
clinical symptoms and urodynamic findings is not reliable (Bates et al., 1970; 
Hashim & Abrams, 2006). In fact, procedure constrains such as saline infusion 
rate and temperature, patient position, and anxiety, may yield distinct urodynamic 
results (Brostrom et al., 2002), which makes urodynamic confirmation of detrusor 
overactivity with only limited clinical value regarding the severity or prognosis of 
idiopathic OAB (Nitti et al., 2010; Rovner et al., 2011). This renders urodynamic 
investigation with suboptimal characteristics to evaluate OAB patients and urge 
the search for new accurate, reliable and non-invasive tests to predict detrusor 
overactivity and to assess patients’ therapeutic outcome (reviewed in Farag & 
Heesakkers, 2011).  
Recently, low grade inflammatory mediators, such as cytokines, 
prostaglandin E2 (PGE2) and NGF, gained significant attention as urinary 
biomarkers of detrusor overactivity. Although they correlate with OAB symptom 
severity, they have not been shown to have independent prognostic benefit 
(reviewed in Cartwright et al., 2011) and they still cannot replace the standard 
filling cystometry in standard clinical practice (Farag & Heesakkers, 2011). For 
instance, pilot studies indicate that there is a wide variation of urinary NGF levels 
and not all patients with OAB have elevated urinary NGF (Kuo et al., 2010; Liu et 
al., 2010; Ochodnicky et al., 2011). 
Purinergic transmission has increasingly been accepted as having an 
important role in urinary tract dysfunction. It encompasses both efferent and 
afferent paths of the voiding reflex, and has particular relevance in the 
pathogenesis of detrusor overactivity (Burnstock, 2011; Ruggieri, 2006). Several 
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studies have reported that urothelium releases ATP in response to mechanical 
and chemical stimuli (Ferguson et al., 1997; Wang et al., 2005). These stimuli 
evoke a discharge in suburothelial low-threshold sensory nerves through P2X3 
receptors activation, since sensory nerve excitation is substantially reduced by 
P2X3 antagonists (Ito et al., 2008) and in P2X3 knock-out mice (Cockayne et al., 
2000), also the density of these receptors is increased in patients with detrusor 
overactivity (Moore et al., 1992). Conversely, intravesical instillation of ATP 
increases bladder activity in a concentration dependent manner (Pandita & 
Andersson, 2002); intravesical ATP decreases bladder capacity and micturition 
volume, with limited effect on detrusor pressure. Recently, evidence has been 
emerging in support of a role for suburothelial myofibroblasts in detrusor 
contraction, which also express P2X and P2Y purinoceptors (Fry et al., 2007). In 
detrusor smooth muscle fibres, P2X1 receptor subtype expression is also 
markedly increased in unstable bladders (reviewed in Burnstock, 2011). This 
implies that ATP is an important mediator of bladder sensory/effector pathways.  
Increased ATP release from the urothelium has also been demonstrated 
in animal models of OAB (Khera et al., 2004; Smith et al., 2005). In vitro studies 
conducted in our lab, as well as by others, showed that uroepithelial cells and 
cholinergic nerves from overactive or obstructed human bladder samples release 
more ATP than controls (Kumar et al., 2010; Silva-Ramos et al., 2010). 
Interestingly, strong evidences suggest that the primary source of ATP in the 
human bladder is the urothelium (Kumar et al., 2004). Thus, this study was 
prospectively designed to measure the urinary concentration of ATP in OAB 
women tested positively for detrusor overactivity and in age-matched controls to 
assess the putative role of ATP as a non-invasive biomarker of detrusor 
overactivity in OAB patients. For comparison purposes, urine samples were also 
tested for NGF levels. 
 
METHODS 
Patients and procedures 
This study and all its procedures were approved by the Ethics Committees 
of Centro Hospitalar do Porto (CHP) and of Instituto de Ciências Biomédicas de 
Abel Salazar (Medical School) of the University of Porto (ICBAS-UP). All patients 
signed an informed consent prior to examinations and for using the biological 
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material. The investigation conforms to the principles outlined in the Declaration 
of Helsinki. A total of 70 women were enrolled in this study, including 34 patients 
with overactive bladder symptoms and detrusor overactivity (aged 28-84 years, 
mean 57±13 years) and 36 controls (aged 34-67 years, mean 52±9 years) that 
included asymptomatic volunteers recruited among the hospital staff and patients 
with mild stress incontinence without overactive bladder symptoms and normal 
urodynamics (see Figure 18). This was a prospective study. Patients were 
consecutively selected (January 2010 - June 2011) from outpatients consulting 
the Department of Urology of CHP complaining from urgency (at least one 
episode daily), frequency (>8 voids/day) and reduced bladder capacity (mean 
voided volume <300ml). Detrusor overactivity was confirmed in all women with 
OAB by urodynamic testing performed within 12 months before collection of 
biological samples and the results were analysed in accordance to the criteria of 
the International Continence Society (ICS) defining detrusor overactivity as 
involuntary and spontaneous contractions of the detrusor occurring during the 
storage phase. Patients with history of malignancy, pelvic radiotherapy, 
neurologic disease, any systemic or inflammatory condition, active urinary tract 
infections, renal impairment (creatinine clearance <70 ml/min) or taking any 
medication that could affect bladder function within the 14 days time period before 
sample collection were excluded; pregnant women were also excluded from the 
study. Patients with incomplete emptying (post-void residual volume >100 ml) 
and with voiding dysfunction (Pdet at maximal flow >60 mm H2O) were also not 
included in the study. All patients completed a 3-day voiding diary, a 24h urine 
collection and blood sample collection to estimate creatinine clearance. Subjects 
were asked to void at normal desire into a sterile cup. Thus, urine sample 
collection in this work was non-invasive, which contrasts with previous studies 
that used urodynamic fluid voided after cystometric saline bladder filling (Cheng 
et al., 2013; Cheng et al., 2010). Two consecutive voids were used; the first void 
was collected upon patients’ arrival to consultation and the second void was 
collected after allowing patients to drink 500 mL of water ad libitum. Voided 
volume was recorded and post-void residual volume was estimated by 
ultrasonography. Mid-stream urine samples were divided into three tubes; one 
for sediment examination, another for creatinine measurement and a third was 
immediately freeze-dried in liquid nitrogen and preserved at -80ºC until ATP 
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determination. ATP values were normalized according to urinary creatinine (Cr) 
values to reduce sample variation and to discard kidney influence on ATP levels. 
ATP/Cr ratios were compared between patients and controls. 
 
Figure 18. Flow diagram of patient selection 
 
Measurement of urinary creatinine 
 The quantitative determination of urinary creatinine was performed in vitro 
on a Cobas Integra 800 analyser using the kinetic colorimetric Creatinine Jaffé 
Gen.2 assay according to the manufacturers’ instructions (Roche Diagnostics 
GmbH, Mannheim, Germany). 
 
Measurement of urinary ATP 
 Undiluted urine samples were defrosted till 25ºC and afterwards 
centrifuged at 3000 g at room temperature for 20 seconds to remove cellular 
debris. The supernatant was separated. A mixture of luciferin-luciferase was 
added according to the manufacturer instructions using the ATP 
Bioluminescence Assay Kit HS II (Roche Applied Science Indianapolis, Indiana, 
USA). ATP detection was evaluated using amulti-mode microplate reader 
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(Synergy HT, BioTek Instruments Inc., Vermont, USA) controlled via BioTek's 
Gen5™ Data Analysis Software. Sample bioluminescence was compared to that 
of standard amounts of ATP used in the same concentration range; standard ATP 
samples were prepared daily. All samples were run in duplicate. The minimum 
ATP detection limit in these experimental conditions was 10-12 M (10-16 moles in 
100 µl samples) and luminescence correlated linearly to ATP concentration till 
10-6 M. Each urine sample remaining was used to quantify the lactate 
dehydrogenase (LDH, EC 1.1.1.27) activity (Keiding, 1974). LDH is an 
intracellular enzyme which is commonly used as an indicator of cell integrity 
providing that its values are kept at a low level. 
 
Measurement of urinary NGF 
 Measurement of urinary NGF level was also done in a subset of urine 
samples used for ATP determination (technique reviewed by Kuo et al., 2010). 
After defrosting and homogenization, samples were used to measure NGF levels 
by the ELISA method, according to the manufacturer instructions. We determined 
urinary NGF concentration using the Emax ImmunoAssay System (Promega, 
Madison, EUA), a specific ELISA kit that has a minimum sensitivity of 7.8 pg/ml. 
All samples were run in duplicate. NGF values were also normalized according 
to urinary creatinine (Cr) values to reduce sample variation; obtained NGF/Cr 
ratios were compared between patients and controls. 
Routine measurements of blood and urine samples were performed in a 
blind manner by independent observers from Serviço de Química Clínica - Centro 
Hospitalar do Porto. Urinary ATP and NGF contents were tested in blind samples 
at Laboratório de Farmacologia e Neurobiologia (UMIB/ICBAS-UP). NGF 
measurements were re-tested and confirmed with the methodology in use at the 
Department of Urology, Centro Hospitalar de S. João and Faculty of Medicine, 
University of Porto. 
 
Statistical analysis 
 Statistical analyses were performed using GraphPad Prism 5.04 software 
(La Jolla, USA). Results are reported as mean values ± standard deviation (SD) 
of samples collected during the first void, unless stated otherwise. Kolmogorov-
Smirnov test was used to check for normality of data distribution. Unpaired 
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Student’s t-test with Welch’s correction and Mann-Whitney U-test were used for 
statistical analysis between groups when parametric or nonparametric data was 
considered, respectively. For multiple comparisons, one-way ANOVA 
nonparametric Kruskal-Wallis test with Dunn’s post test modification was used. 
Correlation between variables were analysed using the Spearman test. P<0.05 
(two-tailed) values were considered statistically significant. 
 
RESULTS 
In this study, efforts have been made to match age among OAB women 
with detrusor overactivity and the control group (P>0.05, see Table 4), since it 
has been described that urinary ATP may increase in older subjects (Sugaya et 
al., 2009); see in Table 5 the positive correlation between age and ATP/Cr levels 
found in our series (Spearman test, r=0.380, P<0.05). The two groups were also 
essentially similar (P>0.05) regarding creatinine clearance, urine pH and urinary 
LDH activity (Table 4). Early reports indicate that females with detrusor 
overactivity may have significantly lower urinary pH than controls (Moore et al., 
1990). This tendency did not reach statistical significance (P>0.05) in this series 
excluding any possible influence the pH might have on urinary ATP and NGF 
content in control and OAB patients. As expected, maximum and mean voided 
volumes determined from the 3-day voiding diary were significantly (P<0.05) 
lower in OAB patients than in controls (Table 4). 
Urinary ATP levels were significantly (P<0.05) higher in OAB women with 
detrusor overactivity as compared to the control group (Table 4 and Figure 19A). 
This was also verified when the ATP content was normalized either to urine 
creatinine levels (ATP/Cr, pmol/mg) (Figure 19C) or to the urinary volume 
(ATP.Vol, pmol) (Table 4); the latter reflects better the raw amount of ATP 
accumulated in the bladder during urine storage. Since no significant changes 
(P>0.05) were observed in the activity of the intracellular enzyme, LDH, in urine 
samples from OAB patients and age-matched controls (Table 4) and no 
correlation was found between ATP/Cr levels and LDH activity (Table 5), urinary 
cells damage might not account for changes detected in ATP levels in OAB 
patients and controls.  
The ROC graphs are commonly used in medical decision making. ROC 
graphs have long been used in signal detection theory to depict the tradeoff 
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between hit rates and false alarm rates of classifiers (Egan, 1975). A high area 
under the ROC curve (0.741; 95% CI 0.62 to 0.86; P<0.001) is consistent with 
urinary ATP/Cr being a highly sensitive biomarker for discriminating OAB women 
with detrusor overactivity (Figure 19E). 
TABLE 4 - Characteristics of OAB patients and controls. P<0.05 (unpaired 
Student’s t-test with Welch’s correction) represent significant differences from 
controls. 
 Controls (n=36) 
mean±SD 
OAB (n=34) 
mean±SD 
P 
Age (yrs) 51.8±8.7 57.3±12.8 0.055 
Creatinine clearance (ml/min) 98.9±9.6 116.7±7.1 0.171 
Urinary pH 6.7±0.4 5.9±0.3 0.135 
Urinary LDH (U/ml) 12.1±3.7 6.8±1.2 0.174 
3-Day Voiding Diary:    
Minimum Void Volume (ml) 86.6±21.3 73.7±23.5 0.263 
Maximum Void Volume (ml) 425.0±121.5 326.1±85.3 0.009 
Mean Void Volume (ml) 198.6±31.1 159.9±40.2 0.033 
1st Void (upon arrival):    
Volume 1st Void (ml) 203.3±56.5 210.8±61.7 0.810 
Urinary ATP 1st Void (pM) 2647±403 7004±1228 0.001 
Urinary ATP x Vol. 1st Void (pmol) 707.8±139.6 1556.1±290.9 0.012 
Urinary ATP/Cr 1st Void (pmol/mg) 7.2±1.7 27.5±8.3 0.022 
Urinary NGF 1st Void (pg/ml) 530.5±136.2 467.5±193.0 0.397 
Urinary NGF x Vol. 1st Void (ng) 117.9±42.3 67.5±15.7 0.126 
Urinary NGF/Cr 1st Void (pg/mg) 64.0±13.6 109.5±29.0 0.162 
2nd Void (after water intake):    
Volume of 2nd Void (ml) 310.0±77.5 260.9±66.9 0.181 
Urinary ATP 2nd Void (pM) 5700±978 10577±1533 0.006 
Urinary ATP x Vol. 2nd Void (pmol) 2003.1±366.4 3008.4±517.5 0.022 
Urinary ATP/Cr 2nd Void (pmol/mg) 42.5±7.2 89.1±19.3 0.029 
Urinary NGF 2nd Void (pg/ml) 526.0±227.1 296.2±128.4 0.185 
Urinary NGF x Vol. 2nd Void (ng) 82.7±24.0 39.2±10.4 (0.045) 
Urinary NGF/Cr 2nd Void (pg/mg) 86.0±17.4 121.7±33.8 0.352 
 
Although NGF levels normalized to creatinine content in the urine 
(NGF/Cr, pg/mg) tended to increase in OAB patients as compared to controls, 
CHAPTER 3 | RESULTS / PUBLICATIONS 
144  Role of endogenous purines in lower urinary tract dysfunctions	
 
Ph
D
 T
he
si
s:
 M
ig
ue
l S
ilv
a 
R
am
os
 
this trend did not reach statistical significance (P>0.05) (Figure 19D; see also Kim 
et al., 2006; cf. Antunes-Lopes et al., 2011). We found no significant correlation 
between ATP/Cr and NGF/Cr levels measured in parallel from samples collected 
from OAB patients (Spearman test, r=0.221, P>0.05), despite the two compounds 
showed some degree of correlation in the control group (Table 5). We did not 
found statistically significant differences in the concentration of NGF (pg/ml) 
measured in urine samples from control and OAB patients (Figure 19B) and the 
urinary NGF accumulation during bladder storage normalized to the urinary 
volume (NGF.Vol, ng) was even lower in OAB patients than in controls (Table 4). 
We detected a wide variation (and lack of correlation) of urinary NGF/Cr levels in 
paired samples collected from control individuals between the 1st and the 2nd void 
obtained after water intake, which was no better in women with OAB (Figure 20B 
and 20D, see also Table 5). These results suggest that NGF determination is 
highly dependent on the urinary volume (Table 4), a situation that has not been 
reported in previous studies. The statistical analysis presented in Table 4, shows 
that the mean urinary NGF content normalized to voided volume decreased 
significantly in OAB patients as compared to healthy controls as a consequence 
of forcing the desire to void by water intake (2nd void). This finding is in clear 
contrast to that occurring with urinary ATP; the urinary content of the nucleotide 
boosted in the 2nd void upon increasing the urinary volume by drinking water at 
libitum (for correlation analysis, see Table 5). It is worth noting that water intake 
(after 1st void) increases the sensitivity of urinary ATP determinations in OAB 
patients versus controls (Table 4, ROC curve area = 0.769; 95% CI = 0.64-0.90; 
P<0.001). 
TABLE 5. Correlation between variables analysed using the Spearman test. 
P<0.05 values were considered statistically significant. 
 
Controls 
r (Spearman 
approx.) 
P 
value 
OAB Patients 
r (Spearman 
approx.) 
P 
value 
ATP/Cr vs NGF/Cr 0.378 0.023 0.221 0.118 
ATP/Cr (1st vs 2nd voids) 0.774 <0.0001 0.381 0.013 
NGF/Cr (1st vs 2nd voids) -0.109 0.291 0.307 0.046 
Age vs ATP/Cr 0.380 0.019 -0.198 0.131 
Age vs NGF/Cr 0.217 0.134 -0.115 0.165 
LDH vs ATP/Cr -0.054 0.399 0.249 0.085 
LDH vs NGF/Cr -0.185 0.199 -0.450 0.006 
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Figure 19. Urinary ATP and NGF levels determined before (A: ATP, nM and B: NGF, 
pg/ml) and after normalization to urine creatinine content (C: ATP/Cr, pmol/mg and 
D: NGF, pg/mg) in women with OAB (n = 34) and age-matched controls (n = 
36).Columns are mean values ± standard deviation (SD). *P,0.05 (unpaired Student’s t-
test with Welch’s correction) represent significant differences from controls. In E and F, 
represented are the ROC curves of urinary ATP/Cr and urinary NGF/Cr in OAB patients, 
respectively. Please note that, for this cohort, ATP/Cr has a better area under de curve 
(AUC=0.7407; 95% confidence interval (CI)=0.62–0.86; P,0.001) than NGF/Cr (AUC = 
0.5391; 95% CI = 0.39–0.69; P,0.001).  
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Figure 20. Analysis of ATP/Cr (pmol/mg) and NGF/Cr (pg/mg) content in paired urine 
samples collected from control women (A and B) and OAB patients (C and D) at arrival 
to the consultation (1st void) and after water intake (2nd  void). See Table 2, for correlation 
between variables (Spearman test). 
 
Figure 21A, shows that urinary ATP/Cr levels correlate inversely with the 
mean voided volume determined in a 3-day voiding diary in OAB patients. In other 
words, urinary ATP/Cr was maximal in OAB patients who reported a mean voided 
volume less than 100 ml (observed in 9 out of a total of 34 patients). These 
findings contrast with data from the control group where ATP levels normalized 
to urine creatinine content (ATP/Cr, pmol/mg) positively correlates with the mean 
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voided volume (Spearman test, r=0.522, P<0.01) (see Figure 21A) and fully 
agree with the concept that physiological distension of the urothelium releases 
ATP into the lumen of the bladder (Ferguson et al., 1997; Wang et al., 2005). No 
other parameter analyzed in this study changed significantly (P>0.05) between 
the three subgroups identified using the mean voided volume as criteria, namely 
age and urine measurements of creatinine, pH and LDH activity. Thus, finding a 
correlation between ATP/Cr levels and the mean voiding volume may be taken 
as a marker for the severity of detrusor overactivity and should be considered of 
clinical relevance in the follow-up of OAB syndrome. Using 200 ml as a cutoff 
value, we found that urinary NGF/Cr levels in OAB patients were significantly 
(P<0.05) higher than those found in the control group, but this difference 
disappeared in less severe forms of bladder overactivity (Figure 21B). 
 
 
 
Figure 21. Relationship between urinary (A) ATP/Cr (pmol/mg) and (B) NGF/Cr 
(pg/mg) content and the mean voided volume determined in a 3-day voiding diary 
for women with OAB and age-matched controls. Columns are mean values 
±standard deviation (SD) from n number of individuals (shown in parenthesis). *P,0.05 
(unpaired Student’s t-test with Welch’s correction) represent significant differences from 
controls.  
 
In this series, 25% of the women with detrusor overactivity complained of 
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urgency without incontinence (OAB dry), whereas the remaining group (75%) had 
urgency urinary incontinence (OAB wet). Figure 22 shows that urinary ATP/Cr, 
but not NGF/Cr, levels were significantly (P<0.05) higher than controls in women 
with OAB, despite they have been characterized as OAB dry or OAB wet. No 
significant differences (P>0.05) were, however, detected in urinary ATP/Cr and 
NGF/Cr levels among OAB patients of the two subcategories.  
 
 
Figure 22. Urinary (A) ATP/Cr (pmol/mg) and (B) NGF/Cr (pg/mg) content in women 
with detrusor overactivity complaining only of urgency (OAB dry, n = 7) and of 
urgency associated with urge urinary incontinence (OAB wet, n = 21) as compared 
to age-matched controls (n=36). Columns are mean values 6 standard deviation (SD). 
*,**P,0.05 (one-way ANOVA with Dunn’s multiple comparison test) represent significant 
differences from controls and between OAB dry and OAB wet subgroups, respectively.  
 
 
DISCUSSION 
To our knowledge, this is the first study so far designed to evaluate 
synchronous changes of both ATP and NGF levels in urine samples collected, 
non-invasively, during voiding at normal desire by OAB women with detrusor 
overactivity and age-matched controls. Data shows that ATP levels were 
significantly higher in OAB women with detrusor overactivity than in the control 
group and this was observed when ATP levels were normalized either to urine 
creatinine content (ATP/Cr, pmol/mg) or to the urinary volume (ATP.Vol, pmol). 
A high area under the ROC curve (0.741; 95% CI 0.62-0.86; P<0.001) indicates 
that urinary ATP/Cr may be a highly sensitive biomarker for discriminating OAB 
women with detrusor overactivity. In this series, we failed to obtain a similar 
pattern regarding urinary NGF measurements. Although we found a tendency for 
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NGF normalized to urine creatinine content (NGF/Cr) to increase in OAB patients 
as compared to controls, this tendency did not reached statistical significance 
(P>0.05). Moreover, no significant correlation between urinary ATP/Cr and 
NGF/Cr levels was found in the samples collected from OAB women with detrusor 
overactivity.  
Interestingly, ATP levels measured in paired samples collected after water 
intake (2nd void) consistently exceeded those verified in the samples collected 
upon arrival to the consultation (1st void), both in controls and OAB patients. That 
is, for a given patient or control, ATP/Cr content in the 2nd void boosted and 
significantly correlated with the amount detected in the previous (1st) void. This 
situation was clearly different if one considers NGF/Cr measurements. In keeping 
with the assumption that urinary NGF content is sensitive to urinary volume 
variations, we found a wide dispersion between measurements of NGF in paired 
samples obtained from 1st and 2nd voids, both in controls and in patients with 
OAB. Our findings fully agree with in vitro experiments demonstrating that 
mechanical distension of bladder urothelium from patients with OAB release 
significantly more ATP than controls (Kumar et al., 2010). Thus, water intake may 
increase the sensitivity of urinary ATP measurement as a biomarker of detrusor 
overactivity in OAB patients (ROC curve area = 0.769; 95% CI = 0.64-0.90; 
P<0.001). Given that the mean voided volume during the provocative 2nd void 
significantly increases with respect to the 1st void one would expect that the 
concentration of the nucleotide should dilute accordingly, yet this was not the 
case probably because raw ATP production by bladder distension exceeds the 
water dilution factor, particularly in OAB patients. This was verified even though 
urinary ATP measured in this study might have been underestimated due to the 
hydrolysis of the nucleotide by ecto-NTPDases bound to urothelial cells during 
urine bladder storage. Thus, the more frequent the voids (e.g. OAB patients with 
detrusor overactivity) the higher urinary ATP levels should be measured. Despite 
this, we measured higher than control levels of ATP in urine samples collected 
from OAB patients upon arrival to the consultation (1st void) where no significant 
differences were detected in the voided volume and inferred time to void (see 
Table 4). ATP may, thus, be regarded as a novel and important dynamic urinary 
biomarker of detrusor overactivity which levels reflect adequately bladder 
distension under pathological conditions.  
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Several mechanisms may account for increased ATP levels in the urine of 
OAB women with detrusor overactivity. Hypertrophy and hyperplasia of the 
urothelium and underlying smooth muscle layers are frequently observed in 
overactive bladders. Thus, OAB patients might have increased urinary ATP levels 
produced by thickening of the epithelium taking into account that uro-epithelium 
is in close contact with the urine and is a major source of the nucleotide in the 
bladder (Kumar et al., 2010; Silva-Ramos et al., 2010). Whether urothelial cells 
per se release more ATP in OAB patients than in healthy controls remains to be 
determined. In addition, it is known that parasympathetic nerves from overactive 
or obstructed human bladder strips release more ATP than controls (Kumar et 
al., 2010; Silva-Ramos et al., 2010). Enhanced urinary ATP content may also 
result from impairment of ecto-NTPDase activity observed in cells from OAB 
patients, as this finding may determine slower nucleotide inactivation kinetics in 
the bladder wall and its urinary accumulation (Harvey et al., 2002; Silva et al., 
2011).  
Data from this study demonstrate that urinary ATP/Cr levels correlated 
inversely with the mean voided volume obtained in a 3-day voiding diary applied 
to OAB patients. Although the urinary content of the nucleotide corrected to the 
creatinine level (ATP/Cr) was consistently higher in samples from OAB patients 
than in age-matched controls, differences tend to decrease when the clinical 
condition of the patients was less severe (e.g. mean voided volume higher than 
200 ml). This tendency fully agrees with the lack of differences in the 
concentration of ATP released during cystometric bladder filling in women with 
mild bladder pain syndrome and controls (Cheng et al., 2013). Previous reports 
also demonstrated an inverse correlation between first desire to void and ATP 
concentration in the voided urodynamic fluid collected from OAB patients during 
cystometry investigation (Cheng et al., 2010). Both findings are consistent with 
the hypothesis that ATP has a prominent role modulating the early filling 
sensation in patients with OAB, which yields to low bladder volumes at first desire 
to void and symptoms of urgency, frequency and reduced bladder capacity 
presented by patients of this series. Thus, higher concentrations of ATP would 
produce early voiding reflexes in OAB patients as suggested in this study. 
Recently, Sugaya and collaborators  investigated the urinary ATP/Cr ratio in a 
population of 30 women with OAB (aged 69±8 years old) and 6 younger female 
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controls (aged 37±6 years old) (Sugaya et al., 2009). The ATP/Cr ratio in the 
Sugaya’s study was about one log unit lower than that obtained in our work, 
probably because cryopreservation of urine samples was not undertaken before 
readings. These authors did not found statistically significant differences in the 
urinary ATP content between the two groups, yet patients with higher ATP/Cr 
ratio had more severe symptoms and worse quality of life scores than the group 
exhibiting lower urinary ATP content, which fully agrees with our findings. 
Moreover, they reported that ATP/Cr levels significantly decreased after 
treatment with anti-muscarinic drugs and the improvement of lower urinary tract 
symptoms was greater for patients with a high baseline urinary ATP/Cr level 
(Sugaya et al., 2009). These findings suggest that urinary ATP may be a marker 
of disease severity and might also be used to predict response to clinical 
intervention. Preliminary results from our group indicate that symptoms relief after 
intravesical botulinum toxin type A application in six female patients with detrusor 
overactivity of this series was accompanied by marked improvement of lower 
urinary tract symptoms along with a complete regression of urinary ATP/Cr to 
control levels (unpublished observations). 
By far the most studied biomarker of OAB has been NGF, as this 
neurotrophin is highly expressed in the urothelium and suburothelial region of 
patients with bladder dysfunction (reviewed in Antunes-Lopes et al., 2011; Kuo 
et al., 2010; Ochodnicky et al., 2011). There is some evidence from these pilot 
clinical studies using small patient populations that urinary NGF excretion is also 
elevated in patients with OAB. This tendency was also observed in this series, 
yet statistical significance was only obtained for women with the most severe 
forms of bladder overactivity reporting mean urinary volumes lower than 200 ml 
in the 3-day voiding diary. However, the peptide may be a downstream element 
of several bladder pathologies that may occur without urinary urgency (e.g. 
bladder inflammation, outlet obstruction, urolithiasis, neoplasia) (reviewed in Kuo 
et al., 2010; Ochodnicky et al., 2011). This may cause urinary NGF concentration 
to vary considerably amongst patients with similar complaints, yet it may still find 
some utility to assess OAB management as urinary NGF decreased after non-
pharmacological and pharmacological treatments (reviewed in Antunes-Lopes et 
al., 2011; Kuo et al., 2010). Preliminary results published in the literature showed 
a superior accuracy of brain derived neurotrophic factor (BDNF) over NGF in 
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diagnosing detrusor overactivity (Antunes-Lopes et al., 2011). In contrast to NGF, 
a direct release of BDNF from urothelial or smooth muscle cells was never 
demonstrated and one cannot ignore that other organs besides the bladder may 
also release neurotrophic factors (Castren & Rantamaki, 2010; Yu et al., 2012). 
Before adopting neurotrophins as urinary biomarkers of detrusor overactivity, one 
must also consider several limitations, in addition to the general lack of 
information about the levels of urinary neurotrophins in normal individuals. 
Methodological limitations include (a) the variation of urinary NGF and BDNF 
measurements by ELISA, as this method is not routinely available and requires 
technical expertise; (b) the binding of neurotrophins to proteins or cells potentially 
present in the urine of patients; and (c) the specificity of various antibodies 
against NGF and BDNF precursors, which may add variability to measured 
urinary neurotrophins. In addition, the reported dependence of urinary NGF 
content on variations of the voided volume (this study) and bladder distension 
(Kuo et al., 2010), as well as the lack of studies indicating that there is a clear-cut 
clinical correlation between neurotrophin levels in urine samples and the severity 
of detrusor overactivity, may contribute to question their sensitivity to identify 
individuals with specific bladder pathologies or patients with detrusor overactivity.  
In this regard, ATP has a very simple, inexpensive and highly reliable 
measurement method, the luciferin-luciferase bioluminescence assay. Technical 
limitation relies on the need for snap-freeze urine samples immediately after 
collection to avoid ATP degradation during storage. Moreover, urinary ATP is 
influenced by bacterial infection, kidney dysfunction and malignancy, so care 
must be taken to exclude such factors. In contrast to neurotrophins, differences 
between OAB patients and controls are independent on the urinary volume and, 
in fact, sensitivity of urinary ATP measurements in OAB patients may be 
enhanced by urine production and consequent bladder filling by water intake. 
This study proved that there is a positive correlation between urinary ATP levels 
and clinical symptoms evaluated by simply adding a 3-day voiding diary to 
analytical tests. Surprisingly or not, we found no statistical significant (P>0.05) 
differences between urinary ATP/Cr levels in OAB patients complaining of 
urgency without incontinence (OAB dry) and those reporting incontinence urinary 
urgency (OAB wet). This supports the notion that incontinence is inconsistently 
correlated and may have a pathophysiological mechanism distinct from detrusor 
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overactivity, which might be independent from ATP bladder production. Because 
several mechanisms may be involved in the pathophysiology of the OAB 
syndrome, one cannot exclude the benefit of using a panel of urinary biomarkers 
(including neurotrophins) to target detrusor overactivity and intervention follow-
up. Unfortunately, we found no correlation between ATP/Cr and NGF/Cr levels in 
urine samples collected from woman with OAB in this series.  
In conclusion, our results support an important putative role of ATP in the 
pathogenesis of detrusor overactivity. Data showed that OAB women with 
detrusor overactivity have high urinary levels of ATP compared to controls and 
that the nucleotide levels increase with water intake. The increased concentration 
of ATP in the urine of OAB patients is probably due to enhanced ATP release 
from proliferating urothelium, since uroepithelial cells are considered the primary 
source of ATP in the human bladder (Kumar et al., 2004). This hypothesis agrees 
with previous studies using experimental models of bladder disorders exhibiting 
enhanced release of ATP from the urothelium (Munoz et al., 2010; Sadananda et 
al., 2009). Moreover, in vitro studies demonstrated that uroepithelial cells from 
overactive human bladder samples release more ATP than controls and that the 
release of the nucleotide was resistant to blockade of neuronal activity with 
tetrodotoxin (Kumar et al., 2010; Silva-Ramos et al., 2010). Decreased ATP 
metabolism could also explain high levels of ATP in the urine of OAB patients as 
compared to controls. Reports from our and others groups, have shown that ATP 
catabolism is hindered in the bladder of patients with outlet obstruction and 
detrusor overactivity (Harvey et al., 2002; Silva-Ramos et al., 2010), which could 
also be the case of women with OAB. Thus, our findings are consistent with 
urinary ATP being a putative dynamic biomarker of detrusor overactivity in 
women with OAB. Non-invasive urinary ATP measurements may represent an 
improvement from other diagnostic and follow-up approaches requiring 
urodynamic investigations. Future studies are needed to further examine whether 
urinary ATP can also be used as a prognostic factor and to assess the therapeutic 
outcome in OAB women with detrusor overactivity. 
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ABSTRACT 
Objectives. Botulinum neurotoxin-A (BoNT-A) injections affect bladder 
activity through actions at both sensory and motor pathways of the micturition 
cycle. BoNT-A effectively inhibit the release of excitatory signaling messengers 
from non-neuronal cells, namely the urothelium, and from bladder nerve 
efferents. ATP released into the bladder lumen is significantly decreased by 
BoNT-A in cultured urothelial cells and in animal models of bladder diseases. 
Recently, our group showed that urinary ATP significantly increases in women 
with overactive bladder (OAB) syndrome compared to healthy controls. This 
prompted us to evaluate whether decreases in the urinary ATP content correlated 
with the improvement of OAB symptoms in patients injected with BoNT-A. 
Methods. Nineteen patients (13 women and 6 men) with OAB refractory to 
antimuscarinic medication completed the Portuguese version of the overactive 
bladder questionnaire (OABq) and were asked to void at normal desire into a 
sterile graduated cup. This procedure was done immediately before and 4 to 8 
weeks after injection of 100 U of onabotulinic toxin-A into the bladder wall. Urine 
samples were analysed to measure the concentration of ATP and creatinine and 
the activity of lactate dehydrogenase. Infected urine samples were discarded. 
Results. Intravesical application of BoNT-A significant reduced OAB 
symptoms and increased the quality of life (QOL) domain score evaluated in the 
OABq questionnaire. All patients, but one (5.2%), had a positive response to 
treatment with BoNT-A. On average, the urinary ATP concentration decreased 
from 4.82±2.68 nM before to 2.68±2.32 nM (p=0.011) after treatment with BoNT-
A. This finding was inversely correlated with the storage capacity of the bladder 
measured as increases in the voided volumes, which were of 162.6±86.3 ml 
before and 273.4±144.5 ml after injecting BoNT-A. Urinary ATP concentration 
showed no correlation with symptoms severity (r=0.219; p=0.368), however 
higher urinary ATP levels measured before treatment predicted poor 
improvements in patients’ QOL score (r=-0.596; p=0.007) after treatment. 
Conclusions. Data suggests that urinary ATP is a dynamic biomarker of 
bladder overactivity, which may be used to monitor non-invasively, yet accurately, 
treatment responsivness to BoNT-A injections in OAB patients. The results also 
show that urinary ATP may have an outcome predictive value, since patients with 
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higher urinary levels of the nucleotide are more likely to be poor responders to 
BoNT-A treatment in what concerns the QOL score of the OABq. 
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INTRODUCTION 
Nowadays, BoNT-A injections into the bladder wall are commonly used for 
the treatment of overactive bladder syndromes refractory to antimuscarinics. 
Increasing number of studies show that BoNT-A injections enhance bladder 
capacity, increase the threshold volume of first voiding contraction, and reduce 
detrusor tone, resulting in significant decrease in episodes of frequency and 
urgency, thereby significantly improving the quality-of-life (Denys et al., 2012; Nitti 
et al., 2013; Reitz et al., 2004). 
 In neurons, BoNT-A binds with high-affinity to synaptic vesicle protein 2 
(SV2). Following internalization of this complex, BoNT-A cleaves synaptosome-
associated protein of 25 kDa  (SNAP-25), which is one of soluble N-
ethylmaleimide–sensitive factor attachment receptor (SNARE) proteins 
mediating fusion of synaptic vesicles to the plasma membranes, resulting in 
blockage of neurotransmitters exocytosis (Montecucco & Molgo, 2005; Simpson, 
1979). The therapeutic outcome of BoNT-A may also be due to its effects on 
afferent nerves (Apostolidis et al., 2005; Collins et al., 2013). Targeting of BoNT-
A to the urothelium has also been demonstrated (Cruz, 2014; Hanna-Mitchell et 
al., 2015; Khera et al., 2004), although the underlying mechanism of action of 
BoNT-A in uroepithelial cells is still a matter of speculation even considering that 
non-neuronal cells can release vesicular cargo through exocytosis. 
 The urothelium is recognized as an important player on chemical- and 
mechano-sensing transduction pathways of the urinary bladder, particularly in 
cases of OAB syndromes. Urothelial cells release ATP in response to both 
chemical and mechanical stimulations (e.g. bladder distension, increased 
transmural pressure), which undertakes a series of complex autocrine and/or 
paracrine amplification responses culminating in the activation of P2X3 receptors 
in suburothelial afferent nerves that convey sensory information to the central 
nervous system. It has been demonstrated that urothelial cells from patients with 
OAB release higher amounts of ATP than controls, which may contribute to 
urgency and frequency bladder symptoms reported by these patients (Kumar et 
al., 2010). Interestingly, BoNT-A is known to inhibit the vesicular release of 
acetylcholine and ATP from efferent nerves, but it can also inhibit ATP release 
from urothelial cells in animal models of neurogenic and inflammatory bladder 
diseases (Khera et al., 2004; Smith et al., 2005).   
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The mechanisms underlying the release of ATP from urothelial cells seem 
to be complex and are not yet fully elucidated. These may differ depending on 
the stimulus and whether luminal versus abluminal sides of the urothelium is 
being evaluated. Release of ATP via pannexin hemichannels has been identified 
at the apical umbrella cells layer of the urothelium (Beckel et al., 2015; Timóteo 
et al., 2014). Considerable number of studies also support the vesicular ATP 
release from both sides of the uroepithelium; for instance, the release of ATP was 
reduced by incubation with inhibitors of vesicular trafficking and fusion, such as 
brefeldin A (Sui et al., 2014; Wang et al., 2005) and onabotulinum toxin A (Smith 
et al., 2005). The involvement of SNARE-dependent mechanisms has also been 
implicated in the release of ATP from the urothelium (Cruz, 2014).  
 In this context, urodynamic studies using the isolated rat bladder 
demonstrated that instillation with BoNT-A decreases ATP release (Collins et al., 
2013). Application of liposome-encapsulated BoNT-A into bladder lumen can 
effectively reduce frequency and urgency episodes in OAB patients (Kuo et al., 
2010), Apparently, these effects of BoNT-A are due to its actions on the 
urothelium almost exclusively. It is, therefore, plausible that the therapeutic 
effects of BoNT-A injections into the bladder are due not only to their effects on 
the release of neurotransmitters from bladder nerves, but also via the release of 
excitatory signaling messengers from urothelial cells. Consequently, BoNT-A 
injections may decrease ATP release from nerves, both in the detrusor and in the 
suburothelium, as well as from urothelial cells, which might have impact on the 
urinary ATP concentration.  
We have previously shown that women with OAB symptoms due to 
detrusor overactivity have higher urinary ATP concentrations compared to 
healthy controls (Silva-Ramos et al., 2013b). We found a direct correlation 
between urinary ATP levels and the severity of OAB symptoms. Therefore, we 
questioned if intravesical BoNT-A injections to treat OAB syndromes resistant to 
antimuscarinics could effectively reduce urinary ATP concentrations in parallel to 
improvement of lower urinary tract symptoms and whether changes in the 
concentration of the nuceotide can be used as a biomarker to predict the 
therapeutic outcome. 
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PATIENTS AND METHODS 
Patients and procedures. 
 This study and all its procedures were approved by the Ethics Committees 
of Centro Hospitalar do Porto (CHP) and of Instituto de Ciências Biomédicas de 
Abel Salazar of the University of Porto (ICBAS-UP). A total of 25 patients with 
OAB symptoms and urodynamically confirmed detrusor overactivity, who had in 
common failure to antimuscarinic therapy, were enrolled between November 
2011 and November 2015. Exclusion criteria ab initium consist of treatment with 
BoNT-A in the last 12 months, although during that period of time patients could 
have been taken anticholinergics and/or the β3-adrenoceptor agonist, 
mirabegron. Patients with history of malignancy, pelvic radiotherapy, painful 
bladder syndrome, bladder outlet obstruction, current urinary tract infections, 
chronic kidney disease stage > 2, lower urinary tract surgery or any 
instrumentation in the last 4 weeks, with indwelling catheter or intermittent 
catheterization, or with post-void residue >100cc, were excluded.  
 
Figure 23. Flow diagram of patients selection. 
 
 After informed consent, patients completed OABq (overactive bladder 
questionnaire) and were asked to void at normal desire to a sterile measuring 
cup, before and 4 to 8 weeks after BoNT-A injection. Injections were performed 
under sedation with a flexible or rigid cystoscope. A total of 100 U of BoNT-A 
(Botox®, Allergan, Irvine, CA, USA) prepared in 10 ml of saline were administered 
CHAPTER 3 | RESULTS / PUBLICATIONS 
Role of endogenous purines in lower urinary tract dysfunctions 161 
 
in 20 sites (0.5 ml each) distributed evenly throughout the detrusor sparing the 
trigone. Four to eight weeks after the procedure, patients were questioned about 
adverse events, asked to complete the OABq questionnaire and to void at a 
normal desire to a measuring cup after which an evaluation of post-void residual 
volume was estimated by ultrasonography.  
 Urine samples were tested with a rapid reagent dipstick (Combur-10Ò, 
Roche Diagnostics GmbH, Mannheim, Germany ) and if negative for nitrites and 
leucocytes, they were divided into three tubes; one for urine culture, another for 
creatinine measurement and a third one was immediately snap frozen in liquid 
nitrogen and preserved at -80ºC until ATP determination. Patients with positive 
urine cultures were excluded. Nineteen patients (13 women and 6 men) aged 
52.8±16.8 years-old completed the study protocol (Figure 23). Patients with less 
than 25% reduction in bothersome symptomsscore were considered non-
responders. 
 
Measurement of urinary creatinine. 
 The quantitative determination of urinary creatinine was performed in vitro 
on a Cobas Integra 800 analyser using the kinetic colorimetric Creatinine Jaffe ́ 
Gen.2 assay according to the manufacturers’ instructions (Roche Diagnostics 
GmbH, Mann- heim, Germany).  
 
Measurement of Urinary ATP 
 Undiluted urine samples were defrosted till 25ºC and afterwards 
centrifuged at 3000 g at room temperature for 20 seconds to remove cellular 
debris. The supernatant was separated. A mixture of luciferine-luciferase was 
added according to the manufacturer instructions using the ATP 
Bioluminescence Assay Kit HS II (Roche Applied Science Indianapolis, Indiana, 
USA). ATP detection was evaluated using a multi-mode microplate reader 
(Synergy HT, BioTek Instruments Inc., Vermont, USA) controlled via BioTek’s 
Gen5TM Data Analysis Software. Sample bioluminescence was compared to that 
of standard amounts of ATP used in the same concentration range; standard ATP 
samples were prepared daily. All samples were run in duplicate. The minimum 
ATP detection limit in these experimental conditions was 10-12M (10-16moles in 
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100 ml samples) and luminescence correlated linearly to ATP concentration till 
10-6M. Each urine sample remaining was used to quantify the lactate 
dehydrogenase (LDH, EC 1.1.1.27) activity (Keiding, 1974), which is an 
intracellular enzyme that is commonly used as an indicator of cell integrity. 
 
Statistical Analysis. 
 Statistical analyses were performed using IBM SPSS Statistics software 
version 21 (New York, USA). Results are reported as mean values ± standard 
deviation unless stated otherwise. The paired Student’s t-test was used for 
comparisons between groups after Kolmogorov-Smirnov test showed normality 
of data distribution. Correlation between variables was analyzed using Pearson 
test. The correlation between co-variates was performed by multiple regression 
analysis. P<0.05 (two-tailed) values were considered statistically significant.  
 
RESULTS 
Treatment of OAB patients with intravesical applications of BoNT-A 
caused a significant reduction in the bothersome symptoms score and a 
significant increase in all quality of life (QOL) domains of the OABq questionnaire 
(Figures 24 and 25). One patient (5.2%) was considered a non-responder, since 
she reported an increase in the score severity.  
Figure 24. Changes in OABq severity score after intravesical application of BoNT-
A. Higher scores mean higher severity (maximum – 100 points). *P<0.05 represents 
significant differences comparing to the score determined before BoNT-A. 
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On average, the urinary ATP concentration decreased from 4.82±2.68 nM 
before to 2.68±2.32 nM (p=0.011) after treatment with BoNT-A (Table 6). There 
was also an increase in the voided volumes in patients injected with BoNT-A 
(273.4±144.5 ml) compared to the situation immediately before application of the 
toxin (162.6±86.3 ml). Notwithstanding this, reductions of urinary ATP 
concentrations after BoNT-A might not be due to urine dilution.    
 
 
Figure 25. Changes in the QOL domain scores of the OABq before and after 
intravesical application of BoNT-A. Higher scores mean better QOL (maximum – 100 
points). *P<0.05 represents significant differences comparing to the score determined 
before BoNT-A 
 
 
As a matter of fact, we showed in a previous study that bladder distension 
was accompanied by higher urinary ATP amounts (Silva-Ramos et al., 2013b). 
In agreement with this, Figure 26 shows that albeit there is an increase in the 
voided volume following BoNT-A treatment we observed a reduction in the 
absolute ATP amounts (nmol) per volume voided. That is, the slope of the linear 
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relationship between ATP (nmol) and the volume (ml) of the correspondent 
voided sample decreased in patients injected with BoNT-A.  
Even though we consider that these results are preliminary and the 
number of patients of both genders are insufficient to take more positive 
conclusions, it seems that there are differences worth to be reported. Although 
urinary ATP concentrations of OAB patients before treatment with BoNT-A were 
similar in both genders (5.1±2.4 nM in females and 4.2±2.4 nM in males; p>0.05), 
the BoNT-A-induced decrease of urinary ATP levels was more notorious in men 
(Figure 27A). Conversely, the increase in bladder storage capacity apreciated by 
increments in the voided volume was more evident in women (Figure 27B). 
Concurrent changes in these two variables, which are characteristic of OAB 
syndromes, end up in the already mentioned reduction of urinary ATP per voided 
volume occurring in both genders. 
 
Table 6. Measurements before and after BoNT-A injections. 
 
 
Before BoNT-A 
(mean±SD) 
After BoNT-A 
(mean±SD) p 
ATP (nM)  4.82±2.37 2.68±2.32 0.011 
Creatinine (mg/dl) 86.9±58.2 76.2±57.9 0.584 
Voided volume (ml) 162.6±86.3 273.4±144.5 0.003 
Post-void residue (ml) 16.0±15.9 48.5±56.4 0.100 
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Figure 26. Relationship between urinary ATP amounts (nmol) and voided volumes 
before and after BoNT-A injections. The slope of the interpolation line between urinary 
ATP and voided volume is more moderate after treatment with BoNT-A, meaning that for 
the same voided volume de amount of urinary ATP (nmol) decreased significantly.  
 
  
Next, we also explored the relationship between urinary ATP (nM) and 
OAB symptom scores. No significant correlations were detected between 
symptoms severity and/or QOL scores and urinary ATP concentrations before 
treatment with BoNT-A. Nevertheless, the urinary ATP concentrations correlated 
positively with the severity symptoms score (r=0.697; p=0.001) and negatively 
with the total QOL score (r=-0.644; p=0.003) after treatment. Notwithstanding the 
fact that urinary ATP concentration showed no correlation with symptoms severity 
(r=0.219; p=0.368), higher urinary ATP levels measured before treatment with 
BoNT-A is a predictor of poor outcome concenrning patients’ quality-of-life (QOL) 
(r=-0.596; p=0.007).  
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Figure 27. Urinary ATP (nM) (A) and voided volume (B) before and after 
BoNT-A injections in males and females. Although urinary ATP concentrations 
diminished after treatment in both genders, only in males the reduction was 
statistically significant. Conversely, the increase in the voided volume after 
treatment was more pronounced in females. *P<0.05 represents significant 
differences comparing to the values determined before BoNT-A.  
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DISCUSSION 
 Mounting evidences support a role for ATP in the physiology of the lower 
urinary tract and this transmitter has strong implications in the pathophysiology 
of OAB. Although it has been well documented the release of ATP from efferent 
nerve fibres innervating the bladder and that the nucleotide contributes to 
detrusor tone, particularly in pathological conditions, more recent studies 
highlighted its role as mediator of sensory inputs generated by chemical and/or 
mechanical stimulation of the bladder, like for instance the distension-induced 
voiding reflex. Upon stretch, ATP is released by the urothelium to both luminal 
and abluminal sides. Interestingly, the extracellular accumulation of ATP in the 
bladder lumen may be 50-fold higher than the concentration of the nucleotide in 
the abluminal side (Wang et al., 2005) and this may be due to an heterogenous 
distribution and activity of nucleotide release sites and metabolizing ecto-
NTPDases, which are responsible for its extracellular catabolism (see e.g. Silva-
Ramos et al., 2015b). At urothelial and suburothelial layers, ATP may activate 
P2X3 receptors (or P2X2/3 heteromers) on sensory afferent nerves, while luminal 
ATP may have autocrine and/or paracrine actions regulating its own and other 
mediators release, as well as membrane trafficking within umbrella cells. ATP 
released into the bladder lumen may be detected in the urine (Sugaya et al., 
2007). Therefore, measuring urinary ATP concentrations may give insights on the 
purinergic signaling tone under certain clinical conditions affecting the lower 
urinary tract in humans. For instance, our group demonstrated that urinary ATP 
concentrations are significantly higher in women with OAB syndrome and the 
levels of the nucleotide positively correlated with symptoms severity (Silva-
Ramos et al., 2013b). In this study, we show that urinary ATP decreases in OAB 
patients after treatment with BoNT-A, supporting the idea that clinical 
improvements following BoNT-A injections may be mediated, at least partially, by 
decreases in the release of ATP from the urothelium. As a matter offact, at least 
in awake, freely moving rats, ATP instillation into the bladder lumen induces 
detrusor overactivity in a concentration dependent manner (Pandita el al, 2002), 
therefore inhibition of ATP release or blockade of its receptors may contribute to 
ameliorate bladder overactivity. 
 Normalization of urinary biomarkers to urine creatinine is a common 
procedure. In a previous report, we demonstrated that urinary creatinine did not 
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correlate with urinary ATP concentrations and, therefore, this normalization was 
meaningless (Silva-Ramos et al., 2016b). Again, in this series we found no 
significant modifications on urinary creatinine concentrations in samples collected 
before and after treatment of patients with BoNT-A. For this reason, results are 
presented in urinary ATP concentrations without no further correction. 
 Regarding gender differences found in this series of patients, our 
preliminary data show that reduction of urinary ATP concentrations following 
treatment with BoNT-A was clearly more pronounced in males than in females. 
Previously, other groups reported gender differences in urinary ATP 
concentrations, favouring higher baseline values in females (Gill et al., 2015; 
Sugaya et al., 2009). To our knowledge no plausible explanation exists for these 
observations, yet they might have impact on the magnitude of the response to 
BoNT-A. We found no significant differences in the concentration of urinary ATP 
before treatment with BoNT-A among males and females with OAB. However, 
the urinary ATP concentration before BoNT-A treatment in women in this study 
was lower than the one published previously by our group (Silva-Ramos et al., 
2013b). This difference may be explained by the fact that in the previous study 
women with OAB were not undergoing any treatment, whilst in this study all 
women were under pharmacological treatment with antimuscarinics and/or 
mirabegron. This lower than expected urinary ATP found in women may explain 
why return of urinary ATP concentration to basal levels following BoNT-A 
injections was more significant in OAB men than in women, i.e. the gap between 
baseline and disease levels of ATP in men’s urine was higher than that observed 
in women turning the variation of the concentration of the nucleotide after BoNT-
A more evident in men presenting constitutively lower levels of urinary ATP in 
control conditions than women (see above). Another possible explanation may 
be due to the greater increase in voided volumes observed in females compared 
to males after BoNT-A treatment. In women treated with BoNT-A, bladder 
distension to accommodate more urine may partially counteract the expected 
decrease in urothelial ATP release caused by the toxin, because on its own 
mechanical tension and/or bladder stretch are powerful inductors of the 
nucleotide outflow (Ferguson et al., 1997) leading to its accumulation in the urine 
(Silva-Ramos et al., 2013b).  
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 Several studies have shown the efficacy, safety, and tolerability of BoNT-
A for the management of OAB refractory to antimuscarinics (Patel et al., 2006). 
In keeping with this, here we verified an overall improvement on the severity 
symptoms and in the QOL score of OAB patients treated with BoNT-A. Probably 
because the number of patients recruited for this study was limited, we found no 
significant correlation between the improvement of the symptoms score and 
urinary ATP concentrations. The analysis of these parameters may be biased by 
the inclusion of both males and females in the same group of OAB patients. 
Notwithstanding the fact that we could not find a clear correlation between urinary 
ATP concentrations and OAB symptoms severity or the total QOL score just 
before BoNT-A treatment, this gained significance after application of the toxin. 
In patients treated with BoNT-A a significant direct correlation between prevailing 
symptom severity and urinary ATP content was observed. This is in agreement 
with previous studies from our and other groups showing that more symptomatic 
OAB patients exhibit higher urinary ATP (Silva-Ramos et al., 2013b; Sugaya et 
al., 2009). It might happen that highly symptomatic patients refractory to previous 
medications exhibit initial urinary ATP levels beyond a threshold that hardly 
correlates with any clinical findings, but this bias may be overcome when the ATP 
concentration and symptom scores return towards a controlled disease condition. 
 There are other reports showing a reduction of urinary ATP concentraions 
in OAB patients treated with anticholinergics (Sugaya et al., 2009), and the 
decrease of urinary nerve growth factor following BoNT-A injections (Liu et al., 
2009). Nevertheless, in any of these publications the urinary biomarker could 
predict treatment outcome. We attempted to explore this hypothesis in this study. 
Since only one patient was considered a non-responder, it is unreasonable to 
compare urinary ATP between responders to non-responders. Therefore, we 
decided to test correlations between urinary ATP concentrations and the clinical 
outcome determined by the OAB questionaire. No correlation between urinary 
ATP and the severity of symptoms score was verified, yet patients with higher 
urinary ATP concentrations before treatment performed worse in the QOL score 
after BoNT-A injections. This indicates that urinary ATP concentration can predict 
treatment outcome with BoNT-A, at least regarding restoration of QOL. From the 
clinical view point, the possible predictive role of urinary ATP is appealing but 
needs further investigations to access its extent.  
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CONCLUSIONS 
 Data from this study indicate that bladder injections with BoNT-A 
effectively reduce urinary ATP concentrations in patients with OAB, a situation 
that was more pronounced in men than in women. It appears that patients with 
higher urinary ATP levels on admission exhibit poorer outcomes in QOL scores 
after BoNT-A treatment. 
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“To much agreement kills a chat” 
 
   Eldridge Cleaver 
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4.1 OVERALL DISCUSSION  
Last decade assisted to significant changes on the focus of LUTS research 
towards the bladder, as major organ implicated in the pathophysiology of these 
syndromes. Purines (ATP and ADO) are paramount molecules in cell signalling 
in the normal human bladder, yet increasing evidences implicate changes in the 
purinergic cascade as a major source of LUTS associated with bladder 
dysfunction. Data presented in this thesis further support this theory and forecast 
a chief role of purines in the diagnosis, treatment and follow-up of LUTS. 
 The results shown in Section 3.1 fulfil some gaps in our knowledge 
concerning the mechanisms underlying the increase in the purinergic tonus 
commanding detrusor activity in the bladder of BPH patients. We presented direct 
evidences that ATP is released in higher amounts from detrusor strips of the 
bladder of BPH patients stimulated electrically. Moreover, we demonstrated that 
higher extracellular ATP accumulation may result from deficient breakdown of the 
nucleotide due to impairement of NTPDase1/CD39 activity in the detrusor of 
obstructed BPH patients. In addition to this, we also found the the activity of ecto-
5’-nucleotidase/CD73, the rate limiting enzyme for adenosine generation from 
released adenine nucleotides, was hindered in the detrusor of obstructed human 
patients resulting in poor adenosine formation. While ATP accumulation directly 
increases detrusor muscle tension through the activation of ionotropic P2X1 
receptors, the nucleotide indirectly potentiates the release of ACh through an 
action via P2X2/3 receptors on cholinergic nerve terminals, which activity is 
upregulated in the bladder of obstructed BPH patients. The activity of 
prejunctional facilitatory P2X2/3 receptors in obstructed bladders is unrestrained 
because the compensatory A1 inhibitory tonus is hindered in these patients due 
to the lack of adenosine formation. Overall, these features end-up in a situation 
where both cholinergic neurotransmission and purinergic signalling are 
hyperactive leading to detrusor overactivity. All these mechanisms are 
summarized on Figure 28. 
 Using a neurochemical methodology that allows direct measurements of 
radiolabeled ACh, we demonstrated here for the first time that urothelium-
denuded detrusor strips from BPH patients release higher amounts of ACh than 
samples from control organ donors with no evidence of LUTS. This finding is very 
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important, since until now the influence and sensitivity of the human detrusor to 
cholinergic agents in the context of BOO was still a matter of debate in the 
literature. In fact, a lot of conflicting results have been published (Michel & 
Barendrecht, 2008) concerning detrusor function after BOO. In animal models, 
detrusor contractions induced by electrical field stimulation may reflect the closest 
situation to an in vivo myographic recording, yet discrepancies exist in the 
literature where the majority of the studies report either a reduced or an 
unchanged contractile response in BOO (Michel & Barendrecht, 2008). Studies 
reporting contractions induced by muscarinic agonists and KCl in animal models 
of BOO also did not help much because their results were also inconsistent. Data 
concerning human detrusor contractility changes induced by BOO are scarce; the 
existing results suggest no significant changes on EFS- or carbachol-induced 
detrusor contractions observed in detriment of a significantly more powerful 
atropine-resistant purinergic component (Bayliss et al., 1999; Harvey et al., 2002), 
as we showed in this study. These nuances on cholinergic neurotransmission in 
obstructed detrusor samples from animal models and humans (see discussion in 
Section 3.1) probably reflect not only the type of obstruction, but also the time and 
degree of obstruction, making comparisons very difficult to establish and, 
sometimes, anecdotal. We reported here that detrusor strips from obstructed BPH 
patients were less sensitive to exogenous ACh, which may be due (1) to a 
reduction of detrusor contractility associated with bladder stifness and/or (2) to 
muscarinic receptors down-regulation resulting from increased amounts of ACh 
released from cholinergic nerves. Although we have no data measuring KCl-
induced detrusor contractions it is plausible that some structural changes, like the 
smooth muscle hypertrophy and increase in the deposition of extracellular matrix 
proteins, may contribute to this finding. On the other hand, the linkage between 
excessive ACh release from stimulating cholinergic nerve efferents and 
downregulation of muscarinic receptors on detrusor smooth muscle fibres may 
explain the significant number of patients with BPH that fail to respond to 
competitive antimuscarinic agents used to control detrusor overactivity. This 
feature prompts for looking at alternative signalling pathways to tackle with this 
clinical situation, which according to the data presented in this thesis may be the 
purinergic cascade. It is our opinion that the re-equilibrium of the cholinergic nerve 
activity with P2X2/3 receptor antagonists or adenosine A1 receptor activators, with 
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or without blocking P2X1-mediated detrusor contractions, could restore the 
sensitivity of the detrusor to antimuscarinic agents or even control on their own 
detrusor overactivity in BPH patients.   
 
Figure 28. Schematic representation of actions of ATP and ADO on neuromuscular 
transmission in the human detrusor of healthy individuals (A) and of BPH patients 
(B).  In the detrusor of BPH patients there is an increase in the release of ATP and ACh 
from activated cholinergic nerves. ATP is slowly inactivated and ADO formation is 
hampered in these patients resulting in transmitter release facilitation due to activation 
of presynaptic excitatory P2X2/3 receptors and deficient adenosine A1-receptors-
mediated inhibition. At the postjunctional level, surplus ATP accumulation favors 
detrusor overactivity through the activation of P2X1 receptors, whose expression is 
upregulated in BPH patients. 
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 The mechanisms underlying the increase in the purinergic tone in BOO 
patients are far from being completely understood. The extracellular amount of 
purines increase dramatically in ischemic conditions and this has been proven in 
several tissues. Data from experimental animals support the hypothesis that the 
detrusor of obstructed patients experiments periods of ischemia during voiding, 
which tend to be more prolonged with disease severity. These ischemic periods 
cause pH reduction in the detrusor along with oxidative stress and the expression 
of tissue damaging molecules in the bladder wall, which may lead to an 
enhancement of the purinergic tone. The purinergic signalling cascade does not 
depend only on the amount and type of purines released by stressed cells, but 
also on the expression and activity of extracellular metabolizing enymes, ecto-
NTPDases and ecto-5’-nucleotidase, which are very sensitive to environmental 
alterations, including pH and co-factors like Ca2+ and Mg2+. Thus, changes in 
tissue pH may be enough to explain the deficits in the activity of membrane-bound 
NTPDase1/CD39 and ecto-5’-nucleotidase/CD73 observed in obstructed BPH 
patients. As a consequence of these enzymatic changes, ATP tend to 
accumulate in the detrusor and adenosine formation becomes deficient. In this 
study, we showed that these deficits could be reverted by applying exogenously 
apyrase (the homolog of NTPDase1/CD39) or by blocking adenosine cellular 
uptake and/or deamination with dipyridamole and EHNA, respectively. All of 
these compounds contributed to normalize purinergic neuromodulation back to 
control conditions where the excitatory actions of ATP (mediated mainly by 
ionotropic P2X receptors) are balanced by its retaliatory metabolite, adenosine 
(via the activation of inhibitory A1 receptors).  
Even though these effects were all tested in urothelium-denuded detrusor 
strips and, thus, restricted to the detrusor neuromuscular synapse, one may 
speculate that if ATP reaches high enough concentrations it may also target the 
P2X2/3 or P2X3 receptorts located in suburothelial sensory nerve afferents and 
other cell types involved in sensory inputs to the CNS and local reflexes that 
promote detrusor overactivity. Moreover, the lack of endogenous production of 
adenosine in obstructed bladders may unbalance ATP excitation at different 
cellular levels (urothelial cells, suburotelial nerves, myofibroblasts and detrusor 
smooth muscle fibres) besides the main inhibitory action of the nucleoside on 
cholinergic nerve efferents. In reaction to endogenous adenosine deficits, we 
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showed that cholinergic nerves of the bladder of obstructed BPH patients 
exhibited higher amounts of the inhibitory A1 receptor. This opens another window 
of opportunity to control ATP-mediated excitation and attenuate cholinergic 
neurotransmission in patients with detrusor overactivity due to BPH using 
selective adenosine A1 receptor agonists, like the one we have used in this study 
(R-PIA). Within this context, it is tempting to speculate that drugs targeting the 
inhibitory A1 receptor or that bolster endogenous adenosine accumulation (e.g. 
nucleoside uptake blockers and/or ADA inhibitors) might have potential benefits 
in the treatment of LUTS, in parallel to the already identified P2X receptor 
antagonists acting on sensory neurons of the bladder (Gever et al., 2010).  
 Targeting ATP catabolism as not been clinically explored yet in the context 
of urological disorders, but seems a promising endeavor. As mentioned before, 
ATP breakdown is compromized in obstructed bladders of BPH patients and this 
may contribute significantly to the increase in ATP-mediated effects underlying 
LUTS in these patients. This feature explains why the enzymatically-stable ATP 
analogue, a,b-met-ATP, has similar contractile effects on control and obstructed 
detrusor strips, whereas ATP was more powerful in obstructed samples (Harvey 
et al., 2002). According to our enzymatic kinetic data and functional reports in the 
literature (Harvey et al., 2002), NTPDase1/CD39 seems to be the main 
responsible for the extracellular ATP breakdown in the human detrusor. This was 
evidenced because ATP was rapidly converted into AMP, without significant 
accumulation of ADP. Moreover, our results showing that NTPDase1 activity is 
impaired in detrusor strips of BPH patients are in agreement with data from the 
Harvey group demonstrating that the ATP breakdown sensitive to ARL67156, a 
preferential NTPDase1 and NTPDase3 inhibitor without any measurable effect 
on NTPDase 2 and NTPDase8 (Levesque et al., 2007), was significantly less in 
detrusor samples from overactive and obstructed bladders than from control 
individuals (Harvey et al., 2002). Even with this limitation, we were able to 
significantly increase ATP-mediated contractions of detrusor strips from BPH 
patients using ARL67156. Thus, we hypothesize that strenghtening of the 
purinergic tone using NTPDase inhibitors may be therapeutically relevant to 
overcome detrusor underactivity revealed at later stages of bladder obstruction 
due to BPH, particularly in elderly men. This may be a suitable alternative to the 
use of non-suppported cholinomimetic agents, because cholinergic sensitivity of 
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detrusor smooth muscle fibers may be dramatically impaired in these patients, as 
we demonstrated in this study (see below). 
 Interestingly, mucosal ATP is hydrolyzed via a different set of ecto-
NTPDases; ATP breakdown is more pronounced in the abluminal than in the 
luminal side of the urothelium (Figure 29). Using immunofluorescence confocal 
microscopy, our group showed that NTPDase2 is the most abundant enzyme 
being expressed in all layers of the urothelium and in the submucosa. In the case 
of ecto-5´nucleotidase/CD73, this enzyme has a clear assimetric distribution 
staining more abundantly in the basal layer of the urothelium, suburothelial 
connective elements and detrusor smooth muscle fibers (Correia-de-Sá, 2010). 
This distribution pattern is in agreement with HPLC kinetic experiments showing 
that ATP breakdown yields significant amounts of ADP and adenosine in the 
abluminal side of the urothelium (Silva-Ramos et al., 2015b). Taking this into 
consideration, one may hypothesize that the role of adenosine must be more 
prominent in the abluminal side and quite minimal in the luminal side of the 
urothelium.  
Likewise, Ussing chamber experiments using the bladder mucosa of 
rabbits showed that upon stretch the amount of ATP was higher in the luminal 
compartment, whereas adenosine accumulates in higher amounts in the 
abluminal side of the urothelium (Lewis & Lewis, 2006; Wang et al., 2005) . 
Although there are reports indicating that adenosine inhibits ATP release in the 
abluminal side (Dunning-Davies et al., 2013; Yu et al., 2006), less is known about 
its action on suburothelial structures. Anyway, increasing adenosine and 
diminishing ATP concentrations at the mucosal level by favoring ATP breakdown 
may be of therapeutic value in the treatment of LUTS.  
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Figure 29. The catabolism of adenine nucleotides and adenosine formation by 
ecto-5’-nucleotidase is faster in the serosal than in the luminal side of the human 
urothelium. Illustrated is the time course of the extracellular catabolism of adenine 
nucleotides and adenosine formation in the isolated urothelium from organ donors 
(control individuals). ATP and AMP (30 µM) were added at zero time either to the luminal 
or to the serosal side of the human urothelium. Samples (75 µL) were collected from the 
incubation fluid at the indicated times on the abscissa. Each collected sample was 
analyzed by HPLC with UV detection to separate and quantify ATP (black), ADP (red), 
AMP (orange), ADO (green), INO (dark grey) and HX (light grey). Average results 
obtained in 3-5 individuals. The calculated half-life time (t½) for each initial substrate is 
shown for comparison (Silva-Ramos et al., 2015b)  
   
It is also worth noting that in the human bladder the ATP catabolism is 
mimimal at the mucosal side, similarly to what happens in bladder mucosa of 
rabbits (Wang et al., 2005). Although the role of ATP released on the abluminal 
side is better documented, luminal ATP also plays a role in the control of 
micturition. It is, however, not clear if luminal ATP can difuse through the 
urothelial barrier to activate suburothelial targets. Anyway, it has been shown that 
ATP instilled into the bladder induces bladder overactivity in the rat (Pandita & 
Andersson, 2002). Furthermore, intravesical perfusion of apyrase increased the 
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intercontraction interval in the anesthesized rat, whereas the ecto-ATPase 
inhibitor ARL67156 decreased it (Beckel et al., 2015; Timóteo et al., 2014). Given 
the size and hydrophilic nature of these compounds, it is unlikely that they could 
cross the urothelial barrier to act on sub-urothelial targets. It is more plausible 
that luminal ATP activates receptors on umbrella cells, since they express several 
P2X and P2Y receptors, both in rats (Birder et al., 2004; Chopra et al., 2008) and 
in humans (Silva et al., 2015). In agreement with this, our group showed that 
instillation of UDP or its analog PSB0474 into the rat bladder increased the 
voiding frequency through increase of luminal ATP concentrations (Carneiro et 
al., 2014). Thus, luminal ATP may activate receptors in umbrella cells creating a 
vicious cycle ending up to increase the release of ATP and other 
neurotransmitters from the basolateral surface of the urothelium that participate 
in bladder chemical- and mechano-sensations.  
 Another consequence of the slow ATP breakdown in the luminal side of 
the urothelium is the possibility to have direct access of its concentration in voided 
urine, since significant changes in urinary ATP over time due to enzymatic 
metabolism are unlikely. Likewise, differences seen in vitro in the release of ATP 
from the mucosa of patients with LUTS and controls are expected to be reflected 
in the urine, as we show in Section 3.2. In spite of this opportunity, the urinary 
concentrations of ATP have not been studied systematically. As a matter of fact, 
the actual source of the ATP found in urine is uncertain. Some of the ATP may 
come from the kidney, yet most authors agree that the bladder is the major source 
of urinary ATP. Supporting this idea are the following arguments: 
1. Significant amounts of ATP are released upon bladder tissue 
stimulation. Most of this ATP comes from the urothelium directly into the 
luminal side (Ferguson et al., 1997; Wang et al., 2005). 
2. In vitro bladder distension causes ATP release; results from this thesis 
show that the urinary concentration of ATP is directly proportionate to 
the voided volume (i.e. bladder distension). This was evidenced in both 
women and men. 
3. There is no relation between urinary ATP and the concentration of 
creatinine in the urine. 
4. Urinary tract dysfunctions impact on urinary ATP concentrations. 
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5. Treatment of LUTS with antimuscarinics or alpha-blockers (Sugaya et 
al., 2009), as well as with with intravesical BoNT-A injections (this 
thesis), decreases urinary ATP concentrations. 
Within the bladder, efferent nerves and uroepithelium are regarded as the 
most common suppliers of ATP. Mounting evidences point towards the 
urothelium as the main source of urinary ATP, given that evoked release of ATP 
is almost abolished in bladder strips without urothelium (Kumar et al., 2004; 
Munoz et al., 2010). Sun and col. demonstrated for the firt time that ATP could 
be released by stretching cultured urothelial cells from patients with interstitial 
cystitis/painfull bladder syndrome and this could be translated into higher 
concentrations of the nucleotide in the urine (Sun et al., 2001). There are other 
reports proving that ATP can be released in vitro upon stimulating (by EFS or 
stretching) the urothelium of patients with OAB (Kumar et al., 2010) or BPH (Silva 
et al., 2015; Sun et al., 2002). Here, we proved that the urine of patients with OAB 
and BOO collected by voiding at normal desire exhibited higher ATP 
concentrations than that from healthy controls. This lead us to hypothesize that 
urinary ATP could be a highly-sensitive non-invasive biomarker of bladder 
dysfunctions. 
 In fact, there is an unmet clinical need for non-invasive tests designed to 
help the diagnosis of detrusor overactivity and BOO in patients with LUTS. 
Searching for urinary biomakers is becoming a popular endeavour and several of 
them have been attempted for OAB in addition to ATP. These include NGF, 
BDNF, prostaglandins, cytokines and glycosaminoglycans (GAG) (Alkis et al., 
2015; Bhide et al., 2013). Urinary neurothrophins are perhaps the most studied 
urinary markers of OAB (Fry et al., 2014). Both NGF and BDNF have been shown 
to be elevated in patients with OAB, to correlate with disease severity and to be 
sensitive to treatment response (Antunes-Lopes et al., 2013). Although in our 
hands urinary ATP was superior to NGF as a diagnostic marker of OAB, ATP and 
BDNF have ROC AUC´s in the same range (Antunes-Lopes et al., 2011). The 
problem is that the release of BDNF has never been reported in the human 
bladder and urinary levels of this neurotrophin may reflect systemic disease 
conditions. Interestingly, urinary ATP correlates with symptoms severity, it 
significantly decreases with BoNT-A treatment and may predict treatment 
outcome, although larger studies are needed to validate this assumption. Looking 
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at the several urinary biomarkers for OAB published in the literature, it is 
noticeable that they are related to different patophysiologic processes, such as 
nerve growth, inflammation, urothelial signalling or a combination several of these 
mechanisms. So, in accordance to the multifactorial nature of OAB, the 
development of a panel with several urinary biomarkers could be worthwhile, 
mainly if they could give insights onto the etiology of OAB in a given patient and/or 
predict treatment oucomes.  
Another important issue we came across during this research was the 
diference detected in urinary ATP levels between men and women. This has been 
reported before (Gill et al., 2015; Sugaya et al., 2009), although no valuable 
explanation has been advanced. One hypotesis would be the higher death cellular 
content in the urine of females, which is in accordance with higher urinary DHL 
activity and the presence of large desquamative cells in the sediment. It is 
noteworthy the fact that in our studies urine samples were centrifuged to remove 
cellular debris and only aliquots from the supernatant were collected for analysis. 
Anyway, mean urinary ATP concentrations are significantly higher in women 
rendering impossible to compare groups with different genders (Figure 31). 
 
Figure 31. Urinary ATP (nM) distributed by gender. Bars represent mean values ± 
standard deviation.  
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   Men, on the other hand, exhibit less urinary ATP variability and, for this 
reason, urinary ATP accuracy as a biomarker may be greater in men. Here, we 
proposed for the first time that urinary ATP may be a marker of detrusor 
competence in males with BOO due to BPH. The notion that we can diagnose 
obstruction by an simple non-invasive urine test is attractive, particularly 
considering that diagnosing obstruction is a difficult and some times cumbersome 
process. Since the prevalence of detrusor underactivity is increasing (nowadays, 
estimated to range between 11-40%) (Jeong et al., 2012; Thomas et al., 2004) 
and these patients do not benefit from surgical treatment of BPH (Thomas et al., 
2004), there is a urge medical need to correctly identify these individuals. 
Although this issue has not been directly addressed in our studies, assuming that 
ATP found in the urine is related to bladder wall tension, urinary ATP may be able 
to distinguish patients with detrusor underactivity among those with BOO showing 
low urine flow rates and near-control urinary ATP concentrations. Conversely, we 
presume that patients exhibiting higher than normal urinary ATP have detrusor 
overactivity. Confirmation of the discriminative power of urinary ATP in LUTS 
obviously requires integration of this information with standard invasive 
urodynamic tests (e.g. pressure-flow study).  
4.2 CONCLUSION AND FUTURE PERSPECTIVES 
 
Data presented in this thesis highlights the relevance of the bladder 
purinergic system in the pathophysiology of LUTS in patients with BOO and in 
patients with OAB. Additionaly, we gathered information to propose that the 
pharmacological manipulation of the purinergic cascade might be usefull in the 
treatment of detrusor underactivity, but this hypothesis requires further 
investigations in the near future. 
In patients with BOO due to BPH, the enhanced purinergic tone in the 
bladder may be interpreted as a critical response enabling the detrusor to 
generate more pressure to overcome the outflow obstruction. However, on the 
other hand, excessive purinergic signaling may also be regarded as a pathogenic 
factor underlying detrusor overactivity, which might be responsible for storage 
symptoms that have a negative impact in QOL in these patients. In this context, 
any therapeutic strategy designed to correct the unbalance between ATP and 
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ADO mediated actions might be beneficial in patients with bladder overactivity 
due to BOO. These strategies may include (1) the activation of inhibitory A1 
adenosine receptors, either directly with selective agonists or indirectly by 
increasing the availability of the endogenous nucleoside by inhibiting ADA or the 
uptake transport system, or (2) blockade of the excitatory P2X2/3 receptors. 
Taking into consideration that patients with BOO exhibit higher urinary ATP 
concentrations than healthy individuals, data from this thesis strenghten the role 
of urinary ATP as a putative noninvasive biomarker of detrusor competence in 
patients with BOO.  
The enhanced purinergic tone seen in the detrusor of patients with BOO 
due to BPH resembles findings obtained in females with OAB. Moreover, we 
showed here for the first time in a clinical setting that the higher urinary ATP levels 
observed in patients refractory to antimuscarinics fall significantly after their 
successful treatment with BoNT-A, suggesting that there is a close relationship 
between urinary ATP levels and symptoms severety. Our preliminary results also 
revealed that urinary ATP measurements may have a prognostic factor 
concerning the clinical outcome of BoNT-A treatments that is worth to pursuit by 
increasing the number of patients enrolled in the study.   
In summary, this work added novel information highlightening the role of 
purines (ATP and ADO) in the pathophysiology, diagnostic and therapeutic of 
LUTS that may be clinically useful to manage patients afflicted by lower urinary 
tract dysfunctions, which constitute a tremendous burden for a large number of 
aged people and,thus, for health care services. 
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